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ABSTRACT OF THE DISSERTATION
MOLECULAR RISK FACTORS OF PULMONARY ARTERIAL HYPERTENSION
by
Hamza Assaggaf
Florida International University, 2017
Miami, Florida
Professor Quentin Felty, Co-Major Professor
Professor ChangwonYoo, Co-Major Professor
The overall objective of the research presented in this dissertation was to investigate
molecular risk factors of susceptibility to estrogenic chemicals, polychlorinated biphenyls
(PCBs), hormone replacement therapy, and oral contraceptives and how that leads to the
development of pulmonary arterial hypertension (PAH). Environmental and molecular risk
factors for PAH are not clearly understood. This is a major hurdle for the development of
new therapy against PAH as well as understanding individual susceptibility to this disease.
Gender has been shown to impact the prevalence of PAH. Although controversial,
estrogens have been implicated to be a risk factor for PAH. Thus, we hypothesize that
women exposed to estrogenic chemicals are at increased risk of developing PAH when
endocrine disrupting chemicals interact with unopposed estrogen to worsen pulmonary
arterial disease. In support of this hypothesis, we have accomplished the following:
Microarray data on PAH were collected and subsequent meta-analysis was conducted using
genome-wide association and environment-wide association approaches on published
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studies as well as GEO and NHANES data. All PCB geometric mean concentrations found
higher levels in people at risk of PAH than people not at risk of PAH. The sum of nondioxin-like PCBs and the sum of dioxin-like PCBs were significantly higher in people at
risk of PAH than people not at risk of PAH. Also, different levels of LOD (including PCBs
concentration >LOD, > 50th percentile, 50th-75th percentile, and ≥75th percentile) were
significantly higher in people at risk of PAH than people not at risk of PAH. We reported
that females used estrogen pills and oral contraceptive were associated with risk of PAH.
However, females used progestin and estrogen/progestin pills were not at risk of PAH.
Molecular risk factor analysis using machine learning approaches revealed that VAMP2,
LAMA5, POLR2C, VEGFB, and PRKCH genes are causal genes of PAH pathogenesis.
Gene ontology and pathway analysis of PAH showed that genes involved in the apoptosis
pathway, p53 pathway, Ras Pathway, T-cell activation, TGF-beta pathway, VEGF
pathway, and Wnt pathway appear to be significantly associated with PAH. Documenting
the exposure to estrogenic chemicals among the general U.S. population, and identifying
agents and molecular risk factors associated with PAH have the potential to fill research
gaps and facilitate our understanding of the complex role environmental chemicals play in
producing toxicity in the lungs.
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CHAPTER 1
INTRODUCTION
Exposure to toxic environmental chemicals have been known to cause many health
effects over a period of time. Pulmonary arterial hypertension (PAH) is a rare, complex
disease that affects the vascular system and leads to increases in pulmonary artery pressure
and causes thickness of their walls. This thickness has been associated with different
mechanisms including angiogenesis and vasculogenesis (Tofovic, 2010). Pathogenesis of
PAH has been associated with many pathways that interact at different molecular levels
(Tuder, Marecki, Richter, Fijalkowska, & Flores, 2007). Some molecular level interactions
that are involved in PAH pathogenesis include: inflammation, uncontrolled vascular
growth, and formation of obliterative vascular lesion (Irey & Norris, 1973). Females are
associated with PAH and are reported to be at higher risk to the disease than males. This
has been suggested to be a result of the higher exposure to estrogen (Austin et al., 2009).
Moreover, many IPAH registries report such differences between females and males
including REVEAL and French PAH registry with 4.1:1 and 1.9:1, respectively (Badesch
et al., 2010; Humbert et al., 2006). Estrogen causes multiple effects in PAH-associated
pathways such as alveologenesis (through estrogen α and β receptors, ERα, ERβ) (Massaro,
Clerch, & Massaro, 2007; Patrone et al., 2003). Furthermore aromatase and mutation of
BMPR2 are also associated with the exposure to estrogen and the formation of the
plexiform lesion and cause PAH (Cakan, Aldemir, Topcuoglu, & Altuğ, 2009; Machado et
al., 2009).
Vascular changes are known to be associated with the exposure to different
endocrine disrupting chemicals which are available in the environment in different
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products. Also, they can be found in plastic products, pesticides, and flame retardants; and
different routes of exposure were reported for PCB including inhalation, ingestion, and
absorption through skin (Balabanič, Rupnik, & Klemenčič, 2011; J. R. Roy, Chakraborty,
& Chakraborty, 2009). Even though EDCs are presented in small quantities in the
environment, there were reported to accumulate in the body and causing many health and
side effects including cancer, neurological and immunological effect, and reducing fertility.
High exposure in household products was suggested to cause embryonic exposure to EDCs
as well as during breast feeding (Yang, Kim, Weon, & Seo, 2015). Overall, the effect of
these compounds on estrogen activity were suggested through many pathways, which all
lead to increased levels of circulating estrogens; such as the inhibition of sulfotransferase
by PCBs leads to elevation of estradiol in circulation (Kester et al., 2000). The combined
effect of EDCs and estrogen reported to have about 1000 times higher synergic effect than
the individual effect (Kortenkamp & Altenburger, 1998).
Many researchers reported synergic effect either through direct or indirect effect,
starting from ingestion, and exposure to EDC such as PCBs to molecular gene expression
alteration. High exposure levels to PCBs cause lung toxicity and hypertension (Andersson
& Brittebo, 2012). Furthermore pathways-associated with PAH such as inflammation
reported modification of a number of genes due to EDC exposure. For example, PCB 153
modified AHR, IL6, and IL1B; while PCB 126 modified CXCL2, SOD2, and TNF. BPAmodified inflammation genes are PARP1, TNF, and IFNG; and Dibutyl phthalate, diethylhexyl phthalate modified genes are PARP1, MIF, CSF2, MMP9 and HMOX1 (D. Roy,
Cai, Felty, & Narayan, 2007).
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Notably, EDCs showed association with estrogen receptors on disease pathways.
For example, activation of mitogen-activated protein kinase pathway resulted from high
levels of exposure to BPA which activate ERs in breast cancer (Li, Zhang, & Safe, 2006).
Some data suggested that obesity, which is a risk factor of PAH, is linked to EDC exposure
(Grün & Blumberg, 2009). Also, adipogenesis is a known risk factor of obesity, and PCBs
were reported to increase adipogenesis (Arsenescu, Arsenescu, King, Swanson, & Cassis,
2008). BPA exposure showed an association with a high risk of breast cancer, asthma, and
different neurological effects (Rezg, El-Fazaa, Gharbi, & Mornagui, 2014). Phthalates
were associated with an increased risk of cardiovascular disease, through alteration of
PPAR gene expression (Yang et al., 2015).
Pathways associated with PAH induce estrogen activity, and effects of exposure to
EDCs have not been reviewed. However, it is suggested that reviewing common associated
pathways would provide better understanding in disease pathogenesis. Different
expressions of a number of genes were associated with PAH and its multiple pathways and
their associated genes. TGF-β family receptors which cause BMPR2 mutation is known to
be associated with FPAH (Thomson et al., 2000). Also, mutation in Bax, angiopoietin-1,
and Smads are associated with a high risk of PAH (Rajkumar et al., 2010). Moreover, many
pathways are associated with PAH and its pathogenesis including: MAPK signaling
pathway, Apoptosis signaling pathway, VEGF signaling pathway, and Wnt signaling
pathway (Sitbon & Morrell, 2012).
Common PAH associated pathways and genes were collected from literature and
from GEO microarray gene expression datasets. Using this information, we will perform
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Bayesian network analysis and gene ontology search to find common pathways and genes
associated with PAH. This will result in a markov blanket network with a number of genes
could be plausible pathway of PAH.
Using NHANES survey data will help us to better understand the association
between exposure to EDC and how this exposure would affect subjects identified at risk of
PAH. The National Health and Nutrition Examination Survey (NHANES) provide
information about the U.S population in demographic, dietary, physical examination,
laboratory, and questionnaire data (CDC Centers for Disease Control and Prevention,
2017). NHANES reports data in 2-years cycles since 1999 with an average of 5,000
participants each year. We will evaluate the effect of different PCBs including PCB 74, 99,
118, 138, 153, and 180 on population ≥ 20 years old at identified risk of PAH. We will
compare different LODs to evaluate what concentrations of PCB would affect the risk of
PAH. We will evaluate the effect of use of estrogen pills only, use of progestin pills only,
use of estrogen/ progestin combo pills, and use of birth controls on females ≥ 20 years old
at identified risk of PAH. We used REVEAL scoring methods to create new variable “risk
of PAH” to include subjects at risk of PAH since it was not available in NHANES (Benza
et al., 2012). We used available variables hypertension, diabetes, thyroid problems, uric
acid level, and insulin status.
The main objective of this research was to use NHANES data from 1999-2004 and
perform statistical analysis to evaluate the associations between EDCs concentrations,
hormone replacement therapy, and oral contraceptives among subjects identified at risk of
PAH. Also, we will support this finding with the plausible genes resulted from the meta-
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analysis preformed using GEO datasets of microarray gene expressions of PAH. We will
provide an overall evaluation of the effect of EDC on estrogen, effect of different genes
and pathways on risk PAH, and how these different analyses would lead to increased
identified risk of PAH.
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CHAPTER 2
LITERATURE REVIEW
GENDER, ESTROGEN, AND OBLITERATIVE LESIONS IN THE LUNG
Abstract
Gender has been shown to impact the prevalence of several lung diseases such as
cancer, asthma, chronic obstructive pulmonary disease, and pulmonary arterial
hypertension (PAH). Controversy over the protective effects of estrogen on the
cardiopulmonary system should be of no surprise as clinical trials of hormone replacement
therapy have failed to show benefits observed in experimental models. Potential
confounders to explain these inconsistent estrogenic effects include the dose, cellular
context, and systemic versus local tissue levels of estrogen. Idiopathic PAH is
disproportionately found to be up to 4 times more common in females than in males,
however, estrogen levels cannot explain why males develop PAH sooner and have poorer
survival. Since the sex steroid hormone 17β-estradiol is a mitogen, obliterative processes
in the lung such as cell proliferation and migration may impact the growth of pulmonary
tissue or vascular cells. We have reviewed evidence for biological differences of sex
specific lung obliterative lesions and highlighted cell-context specific effects of estrogen
in the formation of vessel lumen-obliterating lesions. Based on this information, we
provide a biological based mechanism to explain the sex difference in PAH severity as well
as propose a mechanism for the formation of obliterative vascular lesions by estrogens.
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CHAPTER 2
LITERATURE REVIEW
GENDER, ESTROGEN, AND OBLITERATIVE LESIONS IN THE LUNG
INTRODUCTION
Lung disease is not only responsible for more than 349,000 deaths per year in the
United States, but also is a chronic condition with more than 35 million Americans living
with chronic lung disease according to the American Lung Association. The increased
prevalence in women of certain lung diseases such as asthma, cystic fibrosis (CF), and
chronic obstructive pulmonary disease (COPD) suggest that sex specific hormones have
detrimental effects on the lung (Tam et al., 2011). The lung is a target tissue of estrogen.
Since the lung expresses estrogen receptor (ER) subtypes, ERα and ERβ, estrogen has been
implicated as a risk factor. The controversy over whether estrogen is protective or
detrimental to the cardiopulmonary system should be of no surprise as clinical trials have
failed to show cardiovascular benefits from hormone therapies. The Women’s Health
Initiative, reported that long-term use of estrogen may have increased, risk of
cardiovascular disease while a significant increase of coronary heart disease was observed
among men receiving estrogens in The Coronary Drug Project (JAMA, 1970, 1973;
Rossouw, 2005). Since the sex hormone 17β-estradiol (E2) is a mitogen, a possible
explanation may be that exposure to E2 contributed to atherosclerotic lesions, which have
been proposed to occur as a result of the monoclonal expansion of a mutated vascular cell
(Benditt & Benditt, 1973).
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The dose of estrogens reportedly used in experimental models and clinically may
offer a potential explanation for the estrogen paradox. On the one hand, estrogen at low
doses acts as a pro-oxidant whereas higher doses act to suppress oxidative stress (Felty,
Xiong, et al., 2005; Felty & Roy, 2005; Felty, Singh, & Roy, 2005; Konings et al., 2017;
Parkash, Felty, & Roy, 2006). In order to understand the actions of estrogen in lung cells,
it is important that we understand estrogen actions which we have summarized in brief.
The classical paradigm of estrogen mechanism of action is through the ER which have
been extensively reviewed; therefore we have limited our discussion in this area. Estrogen
supports cell growth via interaction with estrogen receptors alpha and beta (ERα and ERβ)
by directly binding to estrogen response elements, or through non-genomic pathways. The
non-genomic action of estrogen very often includes ligand-dependent activation of GPR30
at the plasma membrane and leads to the activation of signaling pathways such as
ERK/MAPK, protein kinases A and C, and calcium pathways (Marino, Galluzzo, &
Ascenzi, 2006). Together these genomic and non-genomic pathways can contribute to
obliterative lesions via cell proliferation. Alternatively, reactive oxygen species (ROS)
generated from redox cycling of both stilbene and catechol estrogens can act as signaling
messengers also that are also involved in cell growth (Felty, Xiong, et al., 2005; Liehr &
Roy, 1990; D. Roy & Liehr, 1988). We have shown that physiologically achievable E2
concentrations, corresponding to the estrogenic menstrual peak, induces formation of ROS.
Importantly, the ROS produced as a result of estrogen stimulation does not require estrogen
receptors, as the ER-negative cell line produces a similar amount of ROS as the ER-positive
cell lines (Felty, Xiong, et al., 2005). These studies suggest that estrogen induces oxidative
stress, in part, by both ER-dependent and ER-independent pathways. Therefore, estrogen-
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induced ROS through influencing cell signaling pathways may contribute to the growth of
estrogen exposed lung cells.
Clinically, estrogen is given at a “low dose” to minimize thrombotic risk and
hormone-dependent malignancies. Few in vitro and in vivo studies have studied the adverse
effects of low dose estrogen exposure. For example, high concentrations of E2 (10 μM)
have been shown to act as antioxidants in vitro (Behl et al., 1997), which may explain
certain beneficial effects. Also, the exogenous administration of estrogen may not mimic
the endogenous estrogen response because of differences in pulsatile versus continuous
cell exposure. It has been argued that estrogens perhaps through antioxidant activity
scavenges lipid peroxyl radicals and thus interrupting lipid peroxidation. Estrogen has been
suggested to scavenge hydroxyl radicals at higher doses, and inhibit superoxide radical
generation (Abplanalp et al., 2000). Estrogen can also produce its antioxidant actions
through suppressing inflammatory cytokines or modulating antioxidant enzyme status. For
instance, the apoptotic oxidative effects of cytokine TNF-α which include ROS generation,
lipid peroxidation, antioxidant enzyme consumption, and disruption of mitochondrial
membrane potential may be countered by estrogen (Mok et al., 2006). The chemical
structure of estrogens contain a phenolic ring. In the presence of an oxidant-generating
environment, the phenolic hydroxyl group present at the C3 position of the A ring of
estrogens or catechol estrogens accept electrons, and gets oxidized by either accepting
these electrons or losing a proton (Liehr & Roy, 1990; D. Roy & Liehr, 1988). This may
help explain the antioxidant function of estrogens or estrogenic chemicals. In contrast to
antioxidant effects, estrogens have been described to induce an inflammatory response with
an increase of chemokines such as IL-8 (P. Comeglio et al., 2014). On the contrary,
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androgens have been demonstrated to have potent anti-inflammatory effects, reducing
secretion of cytokines and chemokines which are related to Th1 inflammatory response
(Vignozzi et al., 2013). Testosterone was able to blunt the inflammatory response induced
by potent pro-inflammatory stimuli such as TNFα, LPS, activated CD4 (+) lymphocytes
(Vignozzi et al., 2012). Hence, the counteractive effects of these two sex steroid hormones
might justify the relative increased incidence of pulmonary diseases in females as
compared to males as well as help to explain the paradoxical effects of estrogens.
Besides the dose, the capability of lung tissue to biosynthesize estrogen from
circulatory testosterone by the cytochrome P-450 enzyme aromatase (CYP19) raises the
question of whether a local imbalance between testosterone and E2 levels influences the
development of lung disease. Lastly, cell-context specific effects may also determine
whether physiological or pharmacological concentrations of E2 stimulates cell
proliferation, hypertrophy, or survival of obliterative vascular leisons found in severe
pulmonary arterial hypertension (PAH). Understanding the biological and biochemical
differences of sex specific lung diseases poses a major challenge in clinical research
because of the predominant use of male cell lines and animals models. This has garnered
the attention of NIH which has implemented an initiative to reduce sex bias in research
(Clayton & Collins, 2014). This review will discuss the general state of knowledge of
estrogens in lung disease with a focus on vessel-lumen obliterative lesions that are found
in PAH. This will include a description of estrogens and xenoestrogens in lung tissue and
disease, review of sex bias in obliterative lung disease, explanation for the sex differences
in PAH, and a proposed mechanism for the formation of obliterative vascular lesions by
estrogenic stress.
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Estrogens and the lung
Three major steroidal estrogens in women: estrone (E1), estradiol (E2), and estriol
(E3) are produced by the ovary from cholesterol. The steroidogenesis pathway also
produces ovarian androgens, specifically testosterone and androstenedione, which are
aromatized to E2 by the enzyme aromatase. The cytochrome P-450 enzymes CYP1A1 and
CYP1B1 metabolize E2 into two catechol estrogens, 4-hydroxyestradiol (4-OHE2) and 2hydroxyestraidol (2-OHE2) which are further metabolized to methoxyestrogens via
catechol-O-methyltransferase (Liehr & Roy, 1990; D. Roy & Liehr, 1988). Out of the three
estrogens, E2 has the highest estrogenic activity and is the most abundant in the
bloodstream during reproductive years. Women experience normal fluctuations in estrogen
throughout their lifetime and in their reproductive years. Premenopausal circulating E2
levels range 40-400 pg/ml with a considerable drop after menopause to approximately 1020 pg/ml (DiMarco, 2000). During the menstrual cycle E2 increases in the follicular phase
(days 0-14) in the range of 40-100 pg/ml that ends with a surge of E2 ranging from 100400 pg/ml on day 14. Estradiol levels lower during the luteal phase 40-250 pg/ml and return
to lower levels prior to menstruation. Men also produce estrogen, but at lower levels than
women. The adult testis convert testosterone to E2 by aromatase in Leydig cells and germ
cells (Hess, 2003). Once in the bloodstream estrogen can exist in two forms, bound or
unbound to a protein carrier. Between 20-40% of circulating estradiol is bound to sex
hormone-binding globulin (SHBG) which retains them in the circulation where they are
considered to be inactive (Dunn, Nisula, & Rodbard, 1981). Estradiol that is unbound can
diffuse directly through the cell membrane where it binds to estrogen receptors to regulate
transcriptional processes. In addition, membrane-bound estrogen receptors mediate both
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genomic and non-genomic effects on target cells. Sex differences in fetal lung development
and maturation of adult lung tissue have been attributed to estrogen (Becklake &
Kauffmann, 1999). The formation of alveoli in females depends on estrogens which
modulate alveologeneiss by ERα and ERβ (Massaro, Clerch, & Massaro, 2007; Patrone et
al., 2003). The production of surfactant in the fetal lung can be increased by E2 treatment
(Chu & Rooney, 1985), which may contribute to more rapid lung maturation in female
fetuses than in the male fetus (Torday & Nielsen, 1987). Although alveolar volume and
number of alveoli per unit area do not differ between male and female, males develop larger
lungs with larger conducting airways in adulthood (Martin, Castile, Fredberg, Wohl, &
Mead, 1987).
Several lung diseases are more common in women than in men; and estrogen has
been implicated as a risk factor. Since the most biologically active estrogen is E2; we
reviewed concentrations of E2 reported in pathological conditions of the human lung. In
patients with PAH, it has been recommended to avoid pregnancy. Levels of E2 tend to rise
in the bloodstream up to 7,200 pg/ml during pregnancy which may exacerbate lung
pathology (Carranza-Lira et al., 1998). A recent study reported a significantly higher level
of circulatory E2 [42 pg/ml] and E2/testosterone ratio in men with PAH (Ventetuolo et al.,
2016). Aromatase was shown to be expressed by human pulmonary arterial smooth muscle
cells in both PAH patients and controls(Mair et al., 2014). Since E2/testosterone ratio has
been considered to be correlated with aromatase activity (Cakan, Aldemir, Topcuoglu, &
Altuğ, 2009), it is possible that the localized expression of aromatase may elevate E2 in
the pulmonary artery. With regard to local E2 concentrations, lung tissue concentrations of
20 pg/g in non-small cell lung cancer (NSCLC) have been reported to be 2.2-fold higher
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than those found in corresponding non-neoplastic lung tissues (Niikawa et al., 2008). E2
concentration of 79 pg/g was reported in interstitial pneumonia (IP) which was 2.8-fold
higher than in normal lung (Taniuchi et al., 2014). A significant immunolocalization of
aromatase in IP tissues implicate a role of local metabolism in causing local estrogen
overexposure in the lung. In pre-menopausal women, the major sources of circulatory
estrogens are the ovaries. However, estrogens are produced locally in various reproductive
and non-reproductive tissues in both post-menopausal women and men by enzymatic
conversions of serum androgens and adrenal-cortex steroids. The production of E2, the
most potent estrogen, from the precursor E1 is a major conversion pathway dependent on
the enzyme 17-beta-hydroxysteroid dehydrogenases (17β-HSDs) (Labrie, 2003). The
enzyme CYP19A1 aromatase, mentioned previously, also catalyzes the aromatization of
androstenedione to E1 and testosterone to E2. Evidence from a recent study of COPD
showed that the local production of E2 in the lung had increased levels of enzymes involved
in local estradiol synthesis (Konings et al., 2017). Since chronic inflammation is a major
hall mark of lung diseases such as COPD and pulmonary hypertension we provide a
summary of pro-inflammatory effects as it pertains to estrogen in the following section.
Pro-inflammatory effects of estrogen in the lung:
The function of estrogen in inflammation is complex because on one hand,
suppression of inflammation with increased estrogen occurs in chronic inflammatory
diseases while on the other hand estrogen produces pro-inflammatory effects in some
chronic autoimmune diseases. Estrogen induces pro-inflammatory cytokines, such as
interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α), and a number of other
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inflammation associated genes, which were also associated with exposure to endocrine
disrupting chemicals (EDCs) (Deodutta Roy et al., 2015). How estrogen induced
inflammation may play a role in lung disease is not clear. One of the mechanisms includes
inflammation-mediated oxidative stress. For example, inflammatory genes are associated
among estrogen, EDCs, and several chronic diseases. Polychlorinated biphenyls (PCBs)
congener 126 and congener 153 modify the following inflammation related genes—AHR,
CXCL2, HMOX1, IFNG, IL6, PTGS2, SOD2, and TNF; AHR, CXCL8, HMOX1, IL1B,
IL6, MMP9, NOS2, NOS3, PARP1, PTGS2, and TNF; and AHR, IFNG, IL1B, PARP1,
PTGS2, and TNF, respectively. Dibutyl phthalate, diethyl-hexyl phthalate and BPAmodified inflammation genes are AHR, CXCL8, HMOX1, IL1B, IL6, MIF, MMP9,
PARP1, SOD2, TFRC, and TNF; AHR, CSF2, CXCL8, IFNG, LEP, MMP9, SOD2, and
TNF; and AHR, CSF2, HMOX1, IFNG, IL1B, IL6, LEP, MIF, MMP9, NOS2, NOS3,
PARP1, PTGS2, SOD2, and TNF, respectively. In addition to the direct effect of estrogen
on mitochondria and the redox cycling of catechol estrogen, estrogen-induced proinflammatory cytokines, such as IL-1β, IL-6 and TNF-α can also generate reactive oxygen
and nitrogen species (RO/NS) (Deodutta Roy, Cai, Felty, & Narayan, 2007). In the
pathogenesis of estrogen-dependent lung diseases, the role of IL-6 and IL-1β are implicated
in cell proliferation, angiogenesis and cell adhesion. The concentration of the peptide IL1β seems to determine its stimulatory or inhibitory paracrine and/or autocrine signals that
regulate the growth of estrogen dependent disease (Deodutta Roy, Sarkar, & Felty, 2006).
IL-6 is an important cytokine involved in the pathogenesis of PAH. Clinical data showed
an association between higher levels of IL-6 in PAH patients that also correlated with
patient survival (Groth et al., 2014). Furthermore, IL-6 has been shown to impact the
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development of pulmonary hypertension in COPD patients (Chaouat et al., 2009). In the
transgenic mouse model, overexpression of IL-6 resulted in obliterative neointimal lesions
consisting of endothelial cells (Steiner et al., 2009). It is important to note that estrogen
differentially regulates IL-6 production in various cell types, however, estrogen has been
shown to stimulate IL-6 production in mice and humans (Isse et al., 2010). Taken together
these evidences support the pro-inflammatory contribution of estrogens to obliterative lung
lesions in chronic disease.
Xenoestrogens, endocrine disruptors, and the lung:
Endogenous estrogens are known to strongly regulate angiogenesis and vascular
modeling by influencing the growth of both vascular endothelial and smooth muscle cells.
Exogenous estrogen exposures may also be important factors to consider in sex specific
lung diseases. Pharmacological exposure to hormone replacement therapy (HRT) or oral
contraceptives have been shown to exacerbate PAH (Irey & Norris, 1973; Kleiger, Boxer,
Ingham, & Harrison, 1976; Morse, Horn, & Barst, 1999; Sweeney & Voelkel, 2009), LAM
(Shen, Iseman, Waldron, & King, 1987; Wahedna et al., 1994), and NSCLC (Chlebowski
et al., 2016). There is also a growing body of evidence in support of estrogenic endocrine
disruptors including occupational exposure to chlorinated solvents in PAH (Montani et al.,
2015). High levels of PCBs have been reported in human lung tissue (Rallis et al., 2014).
Inhalation exposure to vapor-phase PCBs was demonstrated to be even more important
than ingestion under some circumstances (Carpenter, 2015). Epidemiological studies have
shown that chronic exposure to PCBs including its estrogenic congeners are associated
with lung toxicity (Hansen et al., 2016) and hypertension (Kreiss et al., 1981). Prenatal
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exposures to PCBs have been associated with decreased lung function in 20-year old
offspring (Hansen et al., 2016). Moreover, population-based studies have provided
evidence that PCBs are damaging to the vascular system (Goncharov et al., 2008;
Gustavsson & Hogstedt, 1997; Sergeev & Carpenter, 2005; Tokunaga & Kataoka, 2003).
In vivo animal studies have shown that PCBs produce placental vascular lesions and
trophoblastic lesions (Bäcklin, Persson, Jones, & Dantzer, 1998). We have reported that
physiological levels of E2 and estrogenic PCB153 [1ng/ml] at a level found in human
serum [0.60 - 1.63 ng/ml] (Charlier, Albert, Zhang, Dubois, & Plomteux, 2004), altered
pulmonary endothelial as well as smooth muscle cell phenotypes (Charlier et al., 2004).
PCB153’s effects on both endothelial cells are even more pronounced than E2 with respect
to vasculosphere formation and vasculogenesis. Another endocrine disrupting chemical,
4,4′-methylenedianiline, used in the synthesis of polyurethanes has been shown to increase
hyperplasia of pulmonary arteries exclusively in female rats (Carroll-Turpin et al., 2015).
In vitro, human pulmonary smooth muscle cells were shown to proliferate when exposed
to 4,4′-methylenedianiline and this was inhibited by treatment with the estrogen receptor
antagonist ICI 182,780. Another well-known xenoestrogen, bisphenol A, has been reported
to enhance development of asthma (Midoro-Horiuti, Tiwari, Watson, & Goldblum, 2010).
Environmentally relevant concentrations of bisphenol A have been shown to elicit
proangiogenic effects in human endothelial cells (Andersson & Brittebo, 2012). Taken
together, these studies suggest that exposure to xenoestrogens and/or endocrine disruptors
as a potential risk factor for obliterative lung lesions.
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Sex bias in lung disease:
Asthma: Gender has been shown to play a role in the diseased lung. We will summarize
sex differences in major lung diseases at times highlighting how estrogens contribute to
obliterative processes in the lung such as cell proliferation and migration. Female hormones
in allergic disease have been extensively studied in asthma. After puberty the prevalence
of asthma is greater in girls than boys (Akinbami, Moorman, & Liu, 2011). The prevalence
of asthma is greater in women than men during early to middle adulthood (Leynaert et al.,
2012). Severity of asthma is also more severe in women with a higher likelihood of death
compared to men (Tam et al., 2011). Modulation of lung inflammation by estrogen may
partly explain this association. In asthma, inflammation enhances airway smooth muscle
cell contractility, proliferation, and extracellular matrix production. Estrogens are known
to modulate immune cells such as macrophages, lymphocyte, and mast cells some of which
express ERs and the estrogen membrane receptor GPR30 (Bonds & Midoro-Horiuti, 2013),
which may contribute to smooth muscle hyperplasia that obliterate the airway.
Chronic obstructive pulmonary disease (COPD): Chronic obstructive pulmonary disease is
a progressive disease that includes emphysema and chronic bronchitis. The incidence of
COPD in women has been reported to be increasing (Han et al., 2007). For example,
smoking is a major risk factor for COPD, but females tend to develop COPD faster than
males even though they smoke less cigarettes (Gold et al., 1996). In nonsmokers, females
make up two-thirds of cases with COPD (Salvi & Barnes, 2009). Cell proliferation has
been shown to contribute to the intimal thickening of pulmonary arteries in both smokers
and patients with mild COPD (Harness-Brumley, Elliott, Rosenbluth, Raghavan, & Jain,

19

2014). The early appearance of obliterative vascular lesions in COPD suggest that the
pathology is not a late complication of pulmonary hypertension. Rather the growth
promoting effects of estrogen on smooth muscle cells may be involved in the early
development of COPD. Besides receptor mediated pathways, oxidative stress from
estrogen metabolism in the lung may contribute to the growth of these cells. Estrogens have
been shown to be hydroxylated to catechol estrogens, and catechol estrogens participate as
a substrate in cytochrome P450 catalyzed redox reactions (Liehr & Roy, 1990; D. Roy &
Liehr, 1988). Thus, estrogen potentiation of oxidative stress may confer susceptibility of
female smokers to COPD. Cystic fibrosis is a rare genetic disorder that affects both men
and women; and is characterized by a buildup of mucus in the lungs. This abnormal level
of mucus leads to repeated, serious lung infections that over time severely damage lungs.
Women have shown a higher prevalence of severe cystic fibrosis and exacerbations
coincide with estrogen peak in the menstrual cycle (Chotirmall et al., 2012; HarnessBrumley et al., 2014). Estrogen has been demonstrated to upregulate the MUC5B gene, a
major mucin in the human airway (Choi et al., 2009). A potential mechanism by which
estrogen may exacerbate cystic fibrosis in women may be by increasing MUC5B
expression.
Lymphangioleiomyomatosis (LAM): Pulmonary lymphangioleiomyomatosis (LAM) is a
progressive and eventually fatal disease that primarily affects premenopausal women and
can be exacerbated by pregnancy (Henske & McCormack, 2012). Estrogen can be
considered a risk factor for LAM because disease severity worsens with estrogen therapy
(Yano, 2002). LAM is associated with abnormal proliferation and invasion of smooth
muscle cells that destroys the lung parenchyma. Small clusters of cells characterize lung
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lesions in LAM which are located along pulmonary bronchioles, blood vessels, and
lymphatics. Clumps of LAM cells in lymph vessels leads to thickening of the vessel wall
and obliteration of the lumen. Immunohistochemical data has also shown higher levels of
estrogen synthesizing enzyme aromatase in LAM cells (Adachi et al., 2015). Lung cancer
is a leading cause of cancer related deaths in women (Jemal, Siegel, Xu, & Ward, 2010).
A greater female predominance of NSCLC in both smokers and nonsmokers suggests that
differences in sex hormones contribute to its pathogenesis (Shim et al., 2013). A worse
prognosis in women with lung cancer has been associated with the expression of aromatase
(Mah et al., 2007). Hence, the pro-proliferative effects of estrogen along with its known
genotoxic effects may explain the sex bias observed in both LAM and NSCLC.
Pulmonary arterial hypertension (PAH): Pulmonary arterial hypertension is clinically
classified as Group 1 in the World Health Organization (WHO) system. Uncontrolled
vascular cell growth has been postulated as the major mechanism involved in PAH
pathogenesis (Rubin M. Tuder, Marecki, Richter, Fijalkowska, & Flores, 2007), which
results in vessel obliteration. Most epidemiological studies have determined the effect of
gender on prevalent PAH cases. Group 1 PAH includes idiopathic PAH, heritable PAH,
drug- and toxin-induced PAH, and PAH associated with conditions such as connective
tissue disease (CTD)-PAH, HIV-PAH, congenital heart disease (CHD)-PAH, and
schistosomiasis. The Registry to Evaluate Early and Long-term PAH Disease Management
(REVEAL) is a database used in an ongoing observational cohort study of PAH designed
to enroll prevalent and/or incident patients in the United States with Group 1 PAH. This
study reported the highest female to male ratio of 4.1:1 in IPAH patients as compared to
the French registry (1.9:1) and the National Institutes of Health registry (1.7:1) (Badesch
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et al., 2010; Humbert et al., 2006; Rich et al., 1987). A female bias was also reported in
other sub-categories of Group 1 PAH which include CHD-PAH (2.8:1), CTD-PAH (9.1:1),
and Drugs/toxins-PAH (5.4:1) (Badesch et al., 2010). We have provided a descriptive table
of female to male ratios reported from these PAH registries (Table 1.).
Table 1: Summary of PAH Registry Female to Male Ratios
Registry

Time

Cohort

No.
Patients
2525

Female : Male
Ratio
4.1:1 IPAH
3.8:1 APAH
5.4:1
Drug/toxin-PAH
1.9:1

REVEAL 2006- Mean age 53 yr
2007 IPAH, HPAH, APAH,
Drug/toxin-induced
PAH
French
2002- Mean age 50 yr
674
2003 IPAH, HPAH,
Drug/toxin-induced
PAH
NIH
1981- Mean age 36 yr
187
1.7:1
1985 IPAH, HPAH
IPAH, idiopathic PAH; HPAH, heritable PAH; APAH, associated PAH

References
(Badesch
et al.,
2010)
(Humbert
et al.,
2006)
(Rich et al.,
1987)

Estrogen as a risk factor in PAH:
In human studies, pulmonary hypertension (Kleiger et al., 1976) and vessel lumenobliterating lesions (Irey & Norris, 1973) have been associated with oral contraceptives.
Hormone replacement therapy has also been associated with severe PAH in postmenopausal women (Taraseviciute & Voelkel, 2006). While these hormone therapies
contain estrogens, the contribution of estrogen to PAH has been debated because of
paradoxical gender effects observed in animal models. The chronic hypoxia-induced
pulmonary hypertension model showed that male rats are more susceptible than females
while estrogen treatment was shown to protect against monocrotaline (MCT)-induced
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pulmonary hypertension [88,89]. In contrast, there are reports of chronic E2-induced
hypoxic pulmonary hypertension in ovariectomized female rats (Artem’eva, Kovaleva,
Medvedev, & Medvedeva, 2015; Kovaleva, Artem’eva, Medvedev, & Medvedeva, 2013a,
2013b). The contradictory effects of E2 in the MCT-induced model may be partly due to
differences in pulsatile versus continuous E2 exposure which cannot fully recapitulate what
occurs in the human body. Another factor that may complicate our understanding comes
from the assumption that exogenous and endogenous E2 act similarly on the pulmonary
vasculature. Recently, a study has shown that reduction of endogenous E2 by ovariectomy
or aromatase inhibitor treatment, decreased vessel muscle thickening or vessel obliterative
lesions (Mair et al., 2014). This study used both the hypoxic mouse and the Sugen 5416
plus chronic hypoxia (SuHx) rat model of PAH. In the SuHx model, rats are given a single
injection of the VEGF receptor blocker Sugen 5416 and exposed to hypoxia for several
weeks (Abe et al., 2010). The protection observed with the anastrazole treatment of the
previous study was corroborated by a study with metformin treatment which reversed PAH
and decreased pulmonary vascular remodeling via aromatase inhibition (Dean, Nilsen,
Loughlin, Salt, & MacLean, 2016). E2 treatment was reported to improve heart function in
the SuHx model (Frump et al., 2015), but its effect on the development of plexiform
lesions, a hallmark of human PAH reproduced in the SuHx rat model, was not reported.
Further studies on the development of obliterative intimal lesions in a chronic E2 treated
SuHx model would be helpful because of the previously mentioned reports of chronic E2induced pulmonary hypertension in ovariectomized female rats.
Other rodent models of PAH have reported a female bias toward PAH. Anorectic
drugs such as dexfenfluramine (Dfen) have been shown to induce PAH in only female mice
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(Dempsie et al., 2013). Treatment of rats with 4, 4'-methylenedianiline (DAPM) induced
female specific smooth muscle hyperplasia of the pulmonary vessels (Carroll-Turpin et al.,
2015). Genetic based mouse models have also shown sex differences in PAH susceptibility.
Female mice overexpressing calcium binding protein S100A4/Mts1 (Mts1) were more
susceptible to develop PAH and developed plexiform-like lesions (Dempsie et al., 2011).
In mice overexpressing the serotonin transporter (SERT), only female SERT+ mice
developed PAH (White et al., 2011). Since E2 treatment increased the severity of PAH in
female SERT+ mice, it is plausible that estrogen is a significant risk factor for the
development of PAH. Furthermore, the inhibition of obliterative vascular lesions by
aromatase inhibitor anastrozole in the SuHx model supports the idea that E2 mediates its
adverse effects by increasing the formation of plexiform lesions in PAH. We have provided
a summary table of the discussed in vivo models that support a role of female sex and/or
estrogen in PAH (Table 2).
Table 2: Models of PAH that support female sex bias and/or detrimental effect of estrogen
Model
Species
Findings
References
Chronic Hx + E2 rat
Female develop hypoxic
(Kovaleva et al.,
pulmonary hypertension; E2
2013a, 2013b)
detrimental
SuHx
rat,
Male and female develop
(Abe et al., 2010;
mouse
PAH
Dean et al., 2016;
Aromatase inhibition
Mair et al., 2014)
protective
Dexfenfluramine
mouse
Female only develop PAH;
(Dempsie et al.,
Ovx protective
2013)
4,4'rat
Female only develop PAH
(Carroll-Turpin et al.,
methylenedianilin
2015)
e
Mts1+
mouse
PAH in female > male
(Dempsie et al.,
Ovx protective
2011)
SERT+
mouse
Female only develop PAH
(White et al., 2011)
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Ovx protective; E2
detrimental
Hx, hypoxia; E2, 17β-estradiol; SuHx, Sugen 5416 plus hypoxia; Mts1+,
overexpression of calcium binding protein S100A4/Mts1; SERT+, overexpression of
serotonin transporter; Ovx, ovariectomized.
Biological based mechanisms for sex differences in PAH
Circulatory levels of E2 cannot explain why males who have lower levels of E2 than
females develop PAH much sooner and have poorer survival. A potential explanation may
lie in different characteristics of the vascular pathology which obliterate the pulmonary
artery. Blood vessels are composed of an outer layer of adventitial fibroblasts, a middle
layer of smooth muscle cells (SMC), and an inner layer of endothelial cells (EC). The
medial thickening of pulmonary arteries is considered the earliest pathological change in
PAH (Rubin, 1997). Chronic hypoxia-induced PAH is characterized by medial thickening
(Meyrick & Reid, 1980; M. Rabinovitch et al., 1986). Experimental data from rodent
models attribute the
thickening

to

pulmonary

arterial

SMC hypertrophy and
extracellular

matrix

deposition in proximal
pulmonary
(Kobs,

arteries
Muvarak,

Eickhoff, & Chesler, 2005; Pak, Aldashev, Welsh, & Peacock, 2007; Stenmark, Fagan, &
Frid, 2006). In contrast, severe IPAH is characterized by clustered proliferation of EC that
results in concentric obliteration of the lumina by vascular structures called plexiform
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lesions, which consist of the monoclonal proliferation of EC and are reported in the late
stages of PAH (R. M. Tuder, Groves, Badesch, & Voelkel, 1994). Three-dimensional
analysis of the plexiform lesion indicated that plexiform lesion is functionally important in
pathogenesis because blood flow is severely obstructed along the entire length of a vessel
affected by a single plexiform lesion (Cool et al., 1999). Although both human pulmonary
arterial SMCs and ECs have been shown to proliferate when exposed to E2 (Tofovic et al.,
2008; White et al., 2011), a difference between these cell types from PAH patients has been
shown with the expression of an estrogen synthesizing enzyme. Pulmonary arterial SMC
were shown to highly express aromatase in PAH patients, but it was absent in human
pulmonary arterial EC (Cakan et al., 2009). Thus, the cell-context specific difference in
aromatase expression can help to explain why men have more severe PAH. Since men are
ill equipped to defend against a higher body burden of E2 when compared to women, we
propose that the local concentration of E2 in pulmonary arteries is higher in men with PAH.
This difference in lung concentration of E2 contributes to the reported faster progression
and severity of PAH in men. Although proliferative changes in pulmonary arteries play a
significant role in the development of PAH, evidence from the SuHx model of PAH suggest
that fibrosis is a determining factor in the poor survival rate of male patients with PAH
(Rafikova et al., 2015). In this study, female rats with PAH primarily showed
vasculoproliferative changes in the pulmonary artery while males showed severe fibrosis
in the adventitia and media of the pulmonary artery. Severe fibrosis observed in male
pulmonary arteries including myocardial fibrosis was associated with impaired heart
function and lower survival rates compared to females.
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Unlike SMCs exposed to the local synthesis of E2 by aromatase, the proximity of
EC to the bloodstream allows these cells to be directly exposed to circulatory E2. The
possibility that estrogen is involved in the growth of EC in the plexiform lesion is suggested
by the increased incidence (2.8-fold) in female PAH patients of plexiform lesions
compared to their male counterparts (Stacher et al., 2012). A plausible mechanism for
estrogen’s involvement in plexiform lesion growth comes from evidence that infantile
hemangiomas, a different type of vascular lesion, are reported with increased incidence in
females with elevated levels of circulating E2 (Sasaki, Pang, & Wittliff, 1984). The
combination of hypoxia and estrogen has been demonstrated in vitro to synergistically
enhance EC proliferation (Kleinman et al., 2007), which we postulate also contribute to the
growth of plexiform lesions. Higher circulatory E2 may therefore explain the
predominance of plexiform lesions in women with PAH because it acts directly on EC
prolfieration. Plexiform lesions are considered to be a late pathological event compared to
the much earlier pathology of pulmonary arterial SMC hypertrophy. This suggests that the
plexiform lesions in women PAH patients can take more time to obstruct the pulmonary
artery unlike the more rapid hypertrophy of SMCs that occurs in men, which can help to
explain sex differences in disease severity. A summary scheme of the sex difference in
vessel obliteration is shown in Fig. 1.
Estrogen-induced obliterative vascular lesions:
Vessel obliterating lesions have been reported in female biased lung diseases
including idiopathic interstitial pneumonia (Hallowell, Reed, Fraig, Horton, & Girgis,
2012), COPD (Santos et al., 2002), and IPAH (R. M. Tuder et al., 1994). Eearly appearance
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of obliterative vascular lesions observed in mild cases of COPD, mentioned previously,
suggests that the growth of vascular lesions occurs much earlier than at the end stage of
PAH. Uncontrolled vascular cell growth has been postulated as the major mechanism
involved in PAH pathogenesis (Rubin M. Tuder et al., 2007). More specifically, the
hypertrophic growth of SMC is responsible for progressive thickening of blood vessels of
the lung that ends in obstruction (Marlene Rabinovitch, 2008). Proliferative endothelial
lesions that result from a focal budding of EC are also reported to be an aggressive cell
phenotype associated with a poor prognosis in NSCLC and severe IPAH (Rojiani &
Dorovini-Zis, 1996; Tanaka et al., 2003; R. M. Tuder et al., 1994). Despite progress in
understanding IPAH, current therapy (epoprostenol and derivatives, endothelin receptor
antagonists, and phosphodiesterase type 5 inhibitors) has become a major clinical barrier
for the treatment of patients with end-stage IPAH. Median survival for IPAH patients in
the United States was reported to be only 2.8 years without treatment (D’Alonzo et al.,
1991). Although these drugs allow clinical, functional, and hemodynamic improvements,
the prognosis of patients remains poor because a critical aspect of end-stage IPAH is the
continual growth of vascular lesion cells which eventually obliterate the lumen. Antiproliferative agents such as tyrosine kinase inhibitors have been investigated in IPAH,
however, safety concerns have restricted the clinical application of these drugs and
therefore the need to identify new therapeutic targets has remained.
The molecular pathogenesis of vessel-lumen obliterating lesions in humans remains
unknown. Largely the focus has been on loss-of-function mutations in the BMPR2 gene
observed in approximately 80% of familial PAH and in 20% of patients with sporadic PAH
(Machado et al., 2009). In addition to BMPR2, estrogen receptor signaling has been
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implicated to be involved in the pathogenesis of obliterative vascular lesions. However,
these studies have not been consistently focused on investigating target cells (vascular
lesion “initiating” cells) that are susceptible to genetic and epigenetic instability and
ultimately progress into the plexiform lesion. Investigators have conveniently used either
adult EC or SMC without considering the in vivo plexiform lesion histopathology.
Histopathology of both human and animal model obliterative vascular lesions suggests they
are multicellular and just like solid tumors contain stem cells that may be involved in the
pathogenesis of IPAH (Hanahan & Weinberg, 2011). Surprisingly, there are numerous
clinical and experimental data of vessel stem cells in the blood and the lungs of various
forms of PAH (Felty, Sakao, & Voelkel, 2015). Although several different cell types,
including vascular SMCs, inflammatory cells, and fibroblasts are involved in the
vasculoproliferative process; we recognize EC to be the initial site of injury. Previously we
showed that E2 treatment leads to an increase in macrophage cell proliferation and
secretion of TNF- (Felty & Roy, 2002; D. Roy & Cai, 2002) which could contribute to
vascular lesion formation via paracrine effects with other cell types in the vessel wall.
Estrogen involvement in immune responses in lung diseases described previously support
an inflammatory role in PAH.
Endothelial and smooth muscle cells are directly involved in the pathology of
plexiform lesions. Pulmonary arterial SMC express aromatase which allows for the local
production of E2 whereas human pulmonary arterial microvascular EC do not possess this
enzyme (Mair et al., 2014). Higher aromatase activity in pulmonary arterial SMCs may
lead to locally produced estrogen that acts in an autocrine or paracrine manner, with
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possible cross talk between SMC and EC. Besides estrogen synthesis, the metabolism of
E2 by another enzyme CYP1B1 may contribute to the formation of lumen obliterating
vascular lesions. CYP1B1
expression is increased in
pulmonary arterial SMCs
from patients with IPAH
(White

et

al.,

2012).

Cytochrome P450 family
member CYP1B1 is a key
enzyme involved in the metabolism of E2 to catechol estrogens and expressed in the lung.
Oxidation of E2 produces 2 catechol estrogens that, in turn, are further oxidized to the
quinones, which can react with DNA resulting in depurinating adducts that can lead to
mutagenesis. Genetic instability usually associated with pathological disorders and
referring to a range of genetic alterations from mutations to chromosome rearrangements
may contribute to the quasi-malignant vascular lesions observed in PAH patients. In
support of this concept, chromosomal abnormalities and increased DNA damage have been
observed in vessel-lumen obliterating lesions from PAH patients (Federici et al., 2015) and
we have shown a positive correlation of oxidative DNA damage (8-OHdG) in benign and
malignant vascular tissues (Das & Felty, 2014). In vivo experimental evidence in support
of genotoxic damage in PAH was shown in the SERT+ model of PAH, female SERT+
mice showed increased levels of 8-OHdG (Johansen et al., 2016). We have provided a
hypothetical mechanism by which chronic estrogenic stress-induces genetic instability in
stem cells that progresses to form the obliterative vascular lesion (Fig. 2).
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Conclusion:
Mitogenic and genotoxic effects of estrogen may be a common pathogenic
mechanism to explain the presence of obliterative lesions in lung tissue and vessels.
Estrogen has been shown to promote lung disease in experimental models of PAH, lung
cancer, LAM, and benign metastasizing leiomyoma (BML) (Mair et al., 2014; MárquezGarbán, Chen, Goodglick, Fishbein, & Pietras, 2009; Shim et al., 2013; Yu, Astrinidis,
Howard, & Henske, 2004). Studies have reported associations between estrogen
concentrations in lung disease. Lung tissues from interstitial pneumonia are reported with
2.8-fold higher levels of E2 (Taniuchi et al., 2014), NSCLC has high intratumoral E2
concentration associated with aromatase expression (Márquez-Garbán et al., 2009); and
more recently, higher concentrations of E2 have been associated with the risk of PAH in
men (Ventetuolo et al., 2016). Furthermore, higher aromatase activity and circulatory E2
have been reported to increase the risk of PAH in patients with portopulmonary
hypertension (Roberts et al., 2009). Based on the evidences discussed in this review, female
gender bias towards obliterative lung disease may be attributed to the hormone estrogen.
Even though women have a 3-4 times higher prevalence than men of PAH,
circulatory E2 levels cannot explain why men develop PAH much sooner and have poorer
survival. Pulmonary arterial SMC hypertrophy that contributes to medial thickening is
considered one of the earliest pathological changes observed in chronic hypoxia-induced
PAH. We postulate that the severity of PAH in males is due to high local concentration of
E2 produced by pulmonary arterial SMC, which leads to hypertrophy, vasoconstriction,
and vessel obstruction. Since males cannot defend against a higher body burden of E2
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unlike females, males succumb to a rapid and more severe progression of vascular
obliteration in PAH. Females are more susceptible to develop pulmonary vascular disease
characterized by obliterative hyper-proliferative vascular lesions because EC are directly
exposed to circulatory E2 from the bloodstream. Higher circulatory E2 found in women
can therefore explain the predominance of plexiform lesions in female PAH patients. The
molecular mechanisms that underlie sex differences in vessel-lumen obliterating lesions
remain largely unknown and this is a major hurdle to identifying novel sex-dependent
molecular targets to treat obliterative vascular lesions. Understanding the molecular basis
of this gender disparity in PAH may offer a new treatment paradigm in this devastating
disease that currently has a high unmet clinical need.
Emerging evidence suggest that a local imbalance between testosterone and E2
levels influences the development of lung disease in COPD and PAH. In light of this
information, we propose that novel therapies targeted against local tissue production of
estrogen may be of clinical benefit and lead to novel therapeutic strategies in treating
estrogen dependent lung diseases. The activation of the farnesoid X receptor (FXR) has
been reported to inhibit aromatase at the level of mRNA, protein, and enzymatic activity
(Catalano et al., 2010) and represents a novel therapeutic mechanism to reduce local tissue
estrogen production in the lung. The potential inhibitory effect of FXR on aromatase is
significant because a new class of drugs (FXR agonist, such as obeticholic acid, OCA) was
recently shown to prevent monocrotaline-induced PAH (Vignozzi et al., 2017). Similar
cardiopulmonary protective effects of OCA treatment have been demonstrated also in
blemycin-induced pulmonary fibrosis (Paolo Comeglio et al., 2017). FXR activation by
treatment with OCA was shown to protect against bleomycin-induced lung damage by
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suppressing epithelial-to-mesenchymal transition (EMT), inflammation, and collagen
deposition. This may be of major benefit in the treatment of PAH. Endothelial-tomesenchymal transition (EndMT) a process similar to EMT has been implicated to
contribute to obliterative vascular remodeling in idiopathic PAH (Hopper et al., 2016).
Furthermore, the release of cytokines IL-1β, IL-6, TNF-alpha, and IL-10 by macrophages
present in pulmonary lesions are suggested to play an important role in the pathogenesis of
PAH [41]. Since FXR activation was shown to suppress EMT as well as cause a dosedependent reduction of proinflammatory cytokines, the FXR class of drugs are highly
innovative therapeutic agents for the treatment of estrogen dependent obliterative lung
diseases including PAH.
Hypothesis
Estrogenic chemicals influencing ID3 target genes contribute to susceptibility of PAH
Specific Aims
Specific Aim 1: Collect retrospective environmental exposure data from NHANES
database and gene expression data from the GEO database.
Specific Aim 2: Investigate the association between exposure to estrogenic chemicals
and subjects at risk for PAH.
Specific Aim 3: Identify ID3 regulated molecular gene networks within PAH pathways.
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CHAPTER 3
MANUSCRIPT 1
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND RISK OF
PULMONARY ARTERIAL HYPERTENSION IN THE UNITED STATES
POPULATION: ANALYSES OF NHANES DATA 1999-2004
ABSTRACT
Background:
Pulmonary arterial hypertension (PAH) is a disease with higher risk in women. Endocrine
disrupting chemicals (EDC) are associated with increase of estrogen activity and
metabolism which leads to increase the risk of PAH. Polychlorinated biphenyls (PCBs)
are known to be endocrine disrupters and to alter estrogenic activity in human.
Objectives:
The objective of this study was to evaluate the association between exposure to PCBs and
risk of PAH among U.S. population.
Methods:
Using Centers for Disease Control and Prevention’s National Health and Nutrition
Examination Survey (NHANES) data from 1999-2004, we selected subjects identified at
risk of PAH and ≥ 20 years old with available blood samples data. We used lipid adjusted
serum levels of six PCBs congeners (including PCB 74, 99, 118, 138, 153, and 180), the
sum of non-dioxin-like PCBs (PCB 099 + 138 + 153+187), and the sum of dioxin-like
PCBs (PCB 074 + 118) along with other variables provided from different health
examinations. We included gender, age, BMI, and race and confounders in our analysis.
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PCB concentration geometric means were analyzed in subjects identified ≥ 20 years old
at risk of PAH and not at risk of PAH.
Results:
Different analysis showed that all PCBs congeners were significantly higher in subjects
identified at risk of PAH than subjects identified not at risk of PAH. Multiple limit of
detections (LODs) were used to evaluate PCBs associations with the risk of PAH. All
LOD showed higher association of PCBs congeners concentrations in subjects identified
at risk of PAH including (PCBs concentrations >LOD, > 50th percentile, 50th-75th
percentile, and ≥75th percentile).
Conclusions:
Using NHANES data from 1999-2004, we found that exposure to PCBs increases the risk
of PAH in the U.S. population ≥ 20 years old. However, epidemiological studies need to
be conducted to provide better explanation of PCBs association and other diseases.
Keywords: PCBs, NHANES, pulmonary arterial hypertension, PAH
MANUSCRIPT 1
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND risk of
PULMONARY ARTERIAL HYPERTENSION IN THE UNITED STATES
POPULATION: ANALYSES OF NHANES DATA 1999-2004
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a vascular disease that affects
pulmonary arteries and causes increase in the mean arterial pressure (Rich et al., 1987).
PAH has poor prognosis with duration time of 2.8 years, from the beginning of the
symptoms (D’Alonzo et al., 1991). PH surveillance reported that prevalence of 5.4
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/100,000 population which was reported for the year 2002 in the U.S. and the same report
showed that the rate of death was decreased among men while increased among women,
which reflect the higher incidence of PAH among women. Data from NCHS reported
5.3% of deaths because of cardiopulmonary diseases in 2008 (NHLBI, 2012). However,
women reported higher cases than men during the same period. Also, black race reported
the highest death rates comparing with other race groups with 7.3 /100,000 population.
Elderly, > 85 years was the highest age group with number of death with 63.2 /100,000
population (CDC, 2005b).
Besides gender, many risk factors were reported to be associated with increased
risk of PAH including: hypertension, abnormal lung function, diabetes, uric acid level,
age, insulin status, obesity, thyroid problems, and female sex hormones. Insulin
resistance (IR) was reported to be associated with PAH and poor survival rate in females
(Zamanian et al., 2009). Registry to Evaluate Early and Long-term PAH Disease
Management (REVEAL) showed significant association between obesity (BMI > 30, Pvalue=0.004) and PAH comparing with normal and underweight patients (Burger et al.,
2011). Zhang and colleagues showed that serum uric acid levels in PAH patients
(405±130 μmol/L) were higher than control subjects (344±96 μmol/L; P<0.05).
Reference values were 360 μmol/L and 420 μmol/L for females and males, respectively
(Zhang, Ma, & Wang, 2013). Older age was reported to be a risk factor of PAH
comparing with younger patients. Schachna reported that elderly > 60 years old had 2
times higher risk of PAH than patients < 60 years old (OR, 2.30; 95% CI, 1.32 to 3.99)
(Schachna et al., 2003). This also supports the finding of the age specific death rate for
elderly by CDC in 2005 (CDC, 2005b). Many studies showed high prevalence of thyroid
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problems and risk of PAH. In 2007, Li and colleagues reported that risk of PAH was 2
times higher in people who had thyroid diseases than others (OR, 2.53; 95% confidence
interval, 1.55 to 4.08; p < 0.001) (J. H. Li et al., 2007). Diabetes showed high prevalence
in patients with PAH than control (OR, 1.53; 95% CI, 1.45 to 1.60; p < 0.001). Gender
difference was reported in France national registry that females had higher risk of PAH
than males (OR 1.9; P <0.035) (Marc Humbert et al., 2006). Also, REVEAL study
reported the highest female to male ratio of 4.1:1 in IPAH (Badesch et al., 2010).
Moreover, oral contraceptives and hormone replacement therapies were reported to be
associated with severity of PAH and formation of obliterative lesions in idiopathic-PAH
(IPAH) (Irey & Norris, 1973; Taraseviciute & Voelkel, 2006).
Polychlorinated biphenyls (PCBs) are group of complex chemical contaminants in
the environment that have different effects on the human body including
neurodevelopmental effects (Ribas-Fito, Sala, Kogevinas, & Sunyer, 2001). They were
widespread into the industries by 1920’s as transformers of many products. PCBs were
known to have high resistant of degradation by chemical and biological factors (Jensen,
1987). Even though they were banned during the 1970’s, their exposure remained in the
environment by many ways. Exposure to PCBs was reported in wildlife tissues, animal fat,
and even in human serum with small amounts (Dewailly et al., 1999). PCBs are known to
be endocrine disrupting chemicals (EDCs) which have different effects on health by
altering cellular activity, pathways and metabolism. They can be found in plastic products,
pesticides, and flame retardants (J. R. Roy et al., 2009).
Estrogen and EDCs were associated with inducing many molecular level
processes such as inflammation. Estrogen reported to have direct effect on inflammatory
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cytokines such as TNF-α, IL-6, and IL-1β (D. Roy et al., 2007). Various EDCs such as
PCB126 congener are associated with modifications of many induced-inflammation
genes including IL6, TNF, and CXCL8; while PCB 153 is associated with modifications
of SOD2, AHR, and IL6. Bisphenol A is shown to be associated with inflammatory
induced genes including PARP1, MMP9, HMOX1, and IL1B. Nevertheless, PCB153
was also reported to alter smooth muscle cell phenotypes and pulmonary endothelial
(Charlier, Albert, Zhang, Dubois, & Plomteux, 2004).
In this study, we evaluated the association between 6 PCB congeners, the sum of
dioxin-like PCBs, and the sum of non-dioxin-like PCBs in subjects at risk of PAH in the
National Health and Nutrition Examination Survey (NHANES) between the years 19992004. We aimed to 1) describe the mean of PCB concentration in population ≥ 20 years
of age who were identified at risk of PAH compared with subjects identified not at risk of
PAH; and 2) use different LOD levels of PCBs’ to evaluate the higher concentration of
PCBs and the risk of PAH.
METHODS
Study Design
The main objective of this study was to investigate the association between
exposure to EDCs such as PCB and risk of PAH and pulmonary diseases in the U.S.
general population. To clarify and confirm the suggested role of EDCs, we used
NHANES data from 1999-2004 provided by Centers for Disease Control and Prevention
(CDC) to conduct a secondary statistical analysis. National Health and Nutrition
Examination Survey (NHANES) is a program developed by National Center for Health
Statistics (NCHS) to assess the nutritional and health status for children and adults in the
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United States. NHANES started in the early 1960s producing different surveys for many
health issues as well as many age groups. Since 1999, NHANES started producing
annually continuous interviews and surveys targeting different health and nutritional
measurements for evaluation purposes including demographic, dietary, health-related
questions, socioeconomic, dental, medical, physiological measurements, and laboratory
tests. An average of 5,000 participants enrolled every year and 15 counties across the
nation are visited every year. To acquire a representative sampling of the population,
many parameters needed to be taken into consideration for oversampling. Oversampling
would be sub-grouped, stratified in strata’s and then divided into different locations.
Oversampling includes age (adolescents (12-19 years), adults (≥ 60 years)) and
ethnicity/race (non-Hispanic black and Mexican Americans). After being eligible, the
participants undergo series of interviews and examinations in a specially equipped mobile
evaluation clinic (MEC). MEC examination consist of collections of urine and blood
samples, personal interviews, and dental and physical examinations. Urine is collected
from participant if ≥ 6 years, and blood samples collected from participant if ≥ 1 year.
CDC institutional board approved the study protocol and all participants signed a consent
before joining the NHANES. All data are strictly confident and coded in different
identification factors to keep privacy. Transportation, personal care (baby/ elderly) and
cash payment for participating are included (CDC, 2012).
Laboratory Methods
Exposure to environmental chemicals can be through different routes including
dermal, ingestion, or inhalation. Thus, measurements of these chemicals or their
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metabolites in blood and urine can reflects the amount enters the body. About 2,500
subsamples participated in each 2-years cycle for blood serum and urine samples. CDC
used many procedures to measure environmental chemical exposure including isotope
dilution mass spectrometry, graphite furnace atomic absorption spectrometry, or
inductively coupled plasma mass spectrometry. These procedures or protocols are
provided by Division of Laboratory Sciences, National Center for Environmental Health,
and CDC’s Environmental Health Laboratory. Serum blood samples are measured per
whole weight or per gram of total lipid to reflect the amount of PCBs stored in body fat.
During the MEC exam and transit location, both urine and blood serum samples are
stored in 4 ◦C or froze at -20 ◦C before shipping to the Division of Laboratory Sciences,
National Center for Environmental Health, CDC’s Environmental Health Laboratory
(CDC, 2013b).
Serum PCB
One-third sampling procedure was used to measure PCB levels in blood serum
samples of participant’s ≥ 12 years old in 1999-2000 and 2003-2004 survey cycles. In
2001-2002 survey cycle, NHANES used age inclusion to be ≥ 20 years old. PCBs were
analytically reported on a lipid-adjusted basis (ng/g or ppb) and a whole weight (ng/g or
ppb).
Questionnaire Methods
Multiple time points included collection of demographic, reproductive health, and
medical health data. Intensive two weeks training program including exercises, training
interview, and training on personal audio computer interview was conducted and
supervised by NCHS and accompanied staff. Also, multiple quality control monitoring
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procedure were conducted through full pilot test before starting questionnaire. During a
household interview, people ≥ 16 years old provided demographic data. During the
personal interview in Mobile Examination Center (MEC), females ≥ 12 years old
provided reproductive health data. For both males and female (constriction by age and
gender), medical health data was provided during the MEC interview (CDC, 2012).
Selection of Participants
Inclusion criteria used for the study included people during MEC were ≥ 20 years
old who completed and provided, personal interview and urine and blood samples,
respectively. A participant will be included in the study population if PCB measurements
were available. In addition, people at risk of PAH were selected based on an inclusion
criteria specifically for this variable. We created the Risk of PAH variable based on any
risk factors that reported individually to be associated with PAH in literature. As
mentioned earlier in introduction, these risk factors included hypertension, diabetes,
thyroid problems, uric acid level, insulin status, and female hormone (only for female
participants). Risk of PAH variable was created after sum of all risk factor scoring to be
at risk of PAH if > 2 for male participants and to be 3 for female participants (CDC,
2012). Participant will be deleted from the dataset if any of these risk factors answer or
level were missing.
Sample Weights and Limits of Detection
Sample weight is required when merging NHANES complex survey data to avoid
bias from non-response selection. As mentioned earlier PCB measurements were
collected in one third selection procedure, so weighting these environmental chemical is
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also required. The weight variable was provided in each 2-year cycle from 1999-2004
“for all variables; and it was created for the environmental chemical based on NHANES
analytic guidelines (CDC, 2013b). Detection limit for each of the environmental
chemicals was divided into 0 if below detection limit and 1 if above detection limit for
PCB. However, if PCB serum level was below the detection limit, it is required to be
divided by the square root of 2. CDC improved their procedure and techniques yearly,
which resulted in changing in the detection limit of the environmental chemicals (CDC,
2013). Individual PCB congener has their own LOD because they have different sample
volumes. Thus, calculations for each of the environmental chemicals is required based on
sample volume for each serum and urine sample to be analytically sensitive. Serum
samples environmental chemical LOD was calculated per amount of lipid and urine
samples environmental chemical LOD was calculated per volume of urine (CDC, 2013b).
EDC Exposure Assessment
PCB Variables.
Number of available PCB data was varied in different NHANES cycles (19992000, 2001-2002, and 2003-2004) and to avoid bias of low detection limit samples, we
selected 6 PCB congeners which had measurements above 60% of the population
samples. Based on this inclusion criteria, the selected PCB congeners to find the
association with the risk of PAH were: 2,4,4’,5-tetrachlorobiphenly (PCB 74), 2,2’4,4’,5pentachlorobiphenyl (PCB 99), 2,3’,4,4’,5-pentachlorobiphenyl (PCB 118),
2,2’,3,4,4’,5-hexachlorobiphenyl (PCB 138), 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB
153), and 2,2’,3,4,4,5,5’-heptachlorobiphenyl (PCB 180). We also analyzed the sum of
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dioxin-like PCBs (PCB 74 and PCB 118) and of non-dioxin-like PCBs (PCB 99, PCB
138, PCB 153, PCB 180). Using complex survey NHANES data for 1999-2004 merged
year cycles, we analyzed the association of these PCBs and the risk of PAH in ≥ 20 years
old.
Reproductive and Medical Health Variables
Data was collected from medical health questionnaire, reproductive health
questionnaire, and laboratory data to analyze the association between serum PCB and the
risk of PAH.
Medical Health Questionnaire.
Using medical health questionnaire, the participant > 20 years old had to provide
a response to risk factors of PAH including “have you ever been told by a doctor or
health professional that you have diabetes?”, “Has a doctor or other health professional
ever told that you had a thyroid disease?” Diabetes risk factor was scored 0 if answer was
NO, and scored 1 if answer was YES. Thyroid problem risk factor was scored 0 if answer
was NO, and scored 1 if answer was YES. Each of these variables was transformed into 0
if no risk of PAH and 1 if at risk of PAH.
Reproductive Health Questionnaire.
Using reproductive health questionnaire, female participants > 20 years old had to
provide a response to risk factor of PAH “have you ever used female hormones such as
estrogen and progesterone?” Female hormone risk factors (female participants only) was
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scored 0 in the female participant answered No, and scored 1 if the female participant
answered YES.
Laboratory data.
Using laboratory data measurements, uric acid level should be available for the
included participant, as well as measurements of both (triglycerides and HDLCholesterol) to calculate insulin status (insulin sensitive or insulin resistance). Uric acid
risk factor is a continuous variable, so males and females have different references. Males
participants scored 0 if any had uric acid level < 419 mmol/L, and scored 1 if any male
participant had uric acid level > 420 mmol/L. Females participants scored 0 if any had
uric acid level < 359 mmol/L, and scored 1 if any male participant had uric acid level >
360 mmol/L. Insulin status was calculated by dividing triglycerides level by HDLcholesterol level to be < 1.99 “insulin sensitive (IS)” or > 2.00 “insulin resistance (IR)”.
Insulin status scored 0 if IS and scored 1 if IR. Risk of PAH variable was created after
sum of all risk factor scoring to be at risk of PAH if > 2 for male participants and to be 3
for female participants (CDC, 2012). Participant will be deleted from the dataset if any of
these risk factors answer or level were missing.
Statistical Analysis
We selected people > 20 years old and had available data for PCBs, medical
health, and reproductive health to be included in the analysis to find the association with
the risk of PAH. Because non-normal distribution of the PCBs measurements, they were
log transformed before the analysis. Also, data was weighted using the required weight
by the National Center for Health Statistics guidelines to be representative to the whole
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population. We used stratum and PSA to estimate variance of the demographic data. We
calculated geometric means (GM), geometric standard errors (GSE), and proportions for
all PCBs and their associated with the risk of PAH. We used Student’s t-test GM to
compare PCBs level’s mean and the association with the risk of PAH. To find the
associated risk of PAH with each of the PCBs’, we used logistic regression models to
calculate the odds ratios (ORs) and their 95 % confidence intervals (CI).
Because of small number of participants who had risk of PAH, we used NCHS guidelines
to categorize the limit of detection (LOD) into many levels to perform different analysis
based on the LOD (51). These LOD including 1) < LOD vs. ≥ LOD; 2) < LOD to 50th
percentile (reference) vs. ≥ 50th percentile, and 3). < LOD to 50th percentile vs. 50th
percentile to 75th percentile vs. ≥ 75th percentile. Statistical analysis were performed
using SPSS software (release 20) for windows and SAS software for windows (release
9.4; SAS Institute Inc. Cary, N.C.). We used 5% (P ≤0.05) as significance level for all
analysis.
Potential Confounding Variables.
We included many potential confounding variables as categorical variables which
are gender, age, body mass index (BMI, kg/m2), annual family income, smoking status,
alcohol consumption, race, and education level. Gender were categorized into male (1)
and female (2), age was categorized into three age groups including 20-59 years (1), 6074 years (2) and ≥ 75 years (3). BMI was categorized into > 25 kg/m2 (1), 25-30 kg/m2
(2), and ≥ 30 kg/m2 (3). Annual family income was categorized into 0-$24,999 (1),
$25,000-$54,999 (2), $55,000-$74,999 (3), and ≥ $75,000 (4). Smoking status was
categorized into smokers (1) and non-smokers (2), and alcohol consumption was
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categorized into consumers (1) non-consumers (2). Race was categorized into nonHispanic White (1) and others (2), and education level was categorized into three
categories < 12th grade (1), 12th grade (2), and > 12th grade (3). All confounding variable
data included in the analysis to find the association of PCB and risk of PAH was used
from the demographic file. Categorization of age and race into specific ranges was to
avoid bias in the results due to low number of people at risk of PAH in younger ages and
other races.
RESULTS
Descriptive Statistics.
The study population who completed medical health questionnaire, reproductive
health questionnaire; and had available laboratory data to analyze the association between
serum PCB and the risk of PAH were 4,495 participants ≥ 20 years old. Among the
included population, 166 (3.7%) of them identified at risk to PAH and 4,329 (96.3) of
them were not at risk of PAH (Table 3). Males reported 25 (0.41%) of them identified at
risk to PAH, while 141 (2.96%) females were identified at risk to PAH. However, 2092
(47.78%) males and 2237 (48.86%) females were not at risk of PAH, respectively (Table
3). Race distribution reported 94 (2.72%) of people at risk of PAH to be non-Hispanic
white and 69 (0.65%) were others. However, people not at risk of PAH were 2197
(69.13%) non-Hispanic white and 2132 (27.5%) were others (Table 3). Age was
categorized into 3 group; where 47 (1.45%) of people at risk of PAH and 2888 (76.09%)
of people not at risk of PAH were in 20-59 years old group. Most participants at risk of
PAH among all age groups were in 60-74 years old group with 78 (1.28%), while same
age group reported 906 (13.67%) participant not to be at risk of PAH. Elderly > 75 years
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old were the smallest number among all age groups with 41 (0.63%) at risk of PAH and
535 (6.86%) not at risk of PAH (Table 3). Obese participant reported the highest number
among people at risk of PAH with 83 (2.32%), followed by 54 (1.39%) and 19 (0.58%)
for overweight and normal weight, respectively. However, people not at risk of PAH
were 1079 (35%), 1149 (33.35%), and 970 (27.35%) for normal weight, overweight, and
obese, respectively (Table 3). Annual family income reported 0-$24,999 group to
represent the highest number of population in both risk of PAH 81 (1.29%) and 1692
(28.12%) not at risk of PAH. In the group of $25,000-$54,999, there were 47 (1.17%) at
risk of PAH and 1242 (28.66%). However, $55,000-74,999 group reported the lowest
number of people at risk of PAH and people not at risk of PAH with 10 (0.39%) and 390
(11.01%), respectively (Table 3). No significant difference in distribution of people at
risk of PAH in education variable, however, people with high education level ≥ 12th
grade reported to be the highest not at risk of PAH with 1943 (53.28%) (Table 3). Most
subjects at risk of PAH were not smokers with 62 (3.24%), while 29 (1.52%) were
smokers. Subjects not at risk pf PAH reported 711 (46.64%) to be smokers and 899
(48.59%) were not smokers (Table 3). Alcohol users, 20 (0.77%) were not at risk of
PAH, while no cases reported to be at risk of PAH. Non-alcohol users were 165 (4.41%)
at risk of PAH and 3258 (94.82%) were not at risk of PAH (Table 3).
Individual PCB geometric mean (GM) for people at risk of PAH and not at risk of PAH
was represented in (Table 4) with their geometric standard error (GSE). An average
number of people at risk of PAH was 153 in all PCB included in the analysis which were
above LOD concentration (Table 4). Generally, people at risk of PAH reported
significant higher GM for all PCBs than people not at risk. Among GM of all PCB for
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people at risk of PAH, GM of PCB 153 was the highest concentration with 51.28 ng/g,
while PCB 99 reported the lowest GM concentration among all PCB in people at risk of
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PAH with 8.79 ng/g (Table 4). As well, people not at risk of PAH reported lowest GM in
PCB 99 with 6.06 ng/g and the highest GM was in PCB 153 with 33.02 ng/g (Table 4).

We analyzed the association between our study population by different age groups and all
PCBs GM > LOD. All GM PCBs, in people at risk of PAH and with no risk of PAH,
were markedly increased with age with some exceptions in PCBs 99, 153, and 180 in age
group 60-74 years, and PCB 180 an age group of ≥ 75 (Table 5). However, people at risk
of PAH reported that PCB 153 had the highest GM while PCB 99 reported the lowest
GM among all PCBs in the age group of 20-59 years old with 36.89 ng/g and 6.90 ng/g,
respectively (Table 5). No significant difference was reported within GM of PCB in the
study population in the other age groups 60-74 years old and ≥ 75 years old (Table 5).

We analyzed the association between age adjusted PCB concentrations in study
population race groups. Using lipid adjusted PCB concentration, participants categorized
as “non-Hispanic white” had higher GM concentrations of all PCBs than people
categorized as “other” for not at risk of PAH population (Table 6). However, population
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at risk of PAH reported that people categorized as “other” had higher concentrations of
PCB 99, 138, 153, and 180, while non-Hispanic white category had higher PCB 74 and
118 (Table 6).

For all 6 PCB congeners, there were 150 participants at risk of PAH, 154
participants at risk of PAH in dioxin-like PCBs (74+ 118) (Table 7), and non-dioxin-like
PCBs (99+138+153+180) (Table 8). We analyzed the Dioxin-like PCBs (74+118) serum
concentration to evaluate their association with the risk of PAH in our study population
(Table 7). Dioxin-like PCB concentration in serum was significantly higher in people at
risk of PAH with 3.58 ng/g, than people not at risk of PAH with 2.81 ng/g (Table 7). We
categorized limit of detection of dioxin –like PCBs into < LOD to 50 % and > 50%.
People not at risk of PAH reported mean of dioxin-like PCB < LOD to be 2.59 ng/g,
while LOD ≥ 50% with 3.53 ng/g (Table 7). However, people at risk of PAH reported
mean of dioxin-like PCB < LOD to be 2.61 ng/g, while LOD ≥ 50% with 3.81 ng/g
(Table 7).
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All covariates reported higher mean dioxin-like PCBs in population at risk of PAH than
population not at risk of PAH except in race covariate, people categorized as “other”
reported higher dioxin-like PCB mean to be lower in people at risk of PAH (Table 7).
Overall, the highest mean of dioxin-like PCB was reported in people ≥ 75 with risk of
PAH, while the lowest mean of dioxin-like PCBs was in race categorized as “others” in
people at risk of PAH (Table 7).
Non-dioxin-like PCB included the sum of PCBs (99+138+153+180) was analyzed
to evaluate the association with the risk of PAH by mean of concentration and 95% CI
(Table 8). People at risk of PAH reported higher mean of non-dioxin-like PCBs that
people not at risk of PAH with 4.87 ng/g and 4.41 ng/g, respectively (Table 8). We also
evaluated the association of covariates with risk of PAH and their association with mean
concentration of non-dioxin-like PCBs including gender, race, age, BMI, annual family
income, education level, smoking, and alcohol use. Most covariates reported higher mean
of non-dioxin-like PCBs in people at risk of PAH than people not at risk of PAH.
However, concentration < LOD to 50% of non-dioxin-like PCBs was higher in people
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not at risk of PAH (Table 8). Nevertheless, concentration of non-dioxin-like PCBs
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remained the same in age groups 60-74 and > 75 with 5.10 ng/g and 5.33, respectively,
for both risk of PAH groups of non-dioxin-like PCBs. Overall, the highest concentration
of non-dioxin-like PCBs was reported in age group > 75 years with 5.33 ng/g, while the
lowest concentration was reported in people at risk of PAH at < LOD to 50% with 4.16
ng/g (Table 8).
We analyzed the LOD for all PCBs concentrations with the study population to evaluate
their association with the risk of PAH with different LOD. Small number of people at risk
of PAH was reported with all PCBs concentration < LOD comparing to number of people
not at risk of PAH (Table 9). We reported GM with 95% CI for LOD level of each PCB
and all PCB concentrations > LOD were higher in people at risk of PAH than people not
at risk of PAH (Table 9). However, PCB concentration < LOD remained the same among
people at risk and not at risk of PAH (Table 9).
People at risk of PAH reported PCB > LOD concentration GM at 16.94 ng/ng for PCB
74, 11.5 ng/ng for PCB99, 22.87 ng/ng for PCB118, 40.56 ng/ng for PCB138, 54.02
ng/ng for PCB153, and 42.66 ng/ng for PCB180 (Table 9). However, people not at risk of
PAH reported PCB > LOD concentration GM at 11.54 ng/ng for PCB 74, 8.41 ng/ng for
PCB99, 15.36 ng/ng for PCB118, 33.89 ng/ng for PCB138, 47.33 ng/ng for PCB153, and
38.31 ng/ng for PCB180 (Table 9).
We also analyzed all PCBs concentration with another division of LOD because
small number of people at risk in table 1.7, and we used < LOD to 50% and > 50%
percentiles to be reported in (Table 10). Also, small number of people at risk of PAH was
reported for all PCB with concentration < LOD to 50 % with 4, 11, 11, 15, 22, and 21 for
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PCBs 74, 99, 118, 138, 153, and 180, respectively (Table 10). All GM for different levels
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of PCB LOD concentrations were higher in people at risk of PAH than people not at risk
of PAH, except PCB118 > 50% and PCB180 (Table 10).
People at risk of PAH reported PCB > 50% concentration GM at 18.03 ng/ng for
PCB 74, 12.74 ng/ng for PCB99, 25.69 ng/ng for PCB118, 47.49 ng/ng for PCB138,
64.89 ng/ng for PCB153, and 48.37 ng/ng for PCB180 (Table 10). However, people not
at risk of PAH reported PCB > LOD to 50% concentration GM at 15.22 ng/ng for PCB
74, 10.58 ng/ng for PCB99, 7.22 ng/ng for PCB118, 43.87 ng/ng for PCB138, 63.86
ng/ng for PCB153, and 49.90 ng/ng for PCB180 (Table 10).
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Overall, no significance difference was reported between GM PCB concentrations of
people at risk of PAH and people not at risk of PAH (Table 10).
To get more accurate LOD, we performed another analysis with more divided
LOD for PCB concentrations using < LOD to 50th percentile, 50th percentile to 75th
percentile, and ≥ 75th percentile (Table 11). Higher number of people at risk of PAH were
reported among LOD ≥ 75th percentile than < LOD to 50th percentile and 50th percentile
to 75th percentile (Table 11). All LOD of PCB concentration were higher in people at risk
of PAH than people not at risk of PAH, except GM of PCB 138 < LOD to 50th percentile,
GM of PCB180 50th percentile to 75th percentile, and ≥ 75 % percentile (Table 11).
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The most significant GM was reported in PCB 118 of LOD ≥ 75 % percentile with 33.89
for people not at risk of PAH and 39.02 for people at risk of PAH (Table 11).
We calculated estimated odds ratio (OR) and 95% confidence intervals to
evaluated all PCBs concentration association with risk of PAH (Table 12). Because of
low number of subjects at risk of PAH, we used < LOD to 50th percentile (reference

group) and ≥ 50th percentile. We calculated unadjusted OR; gender adjusted OR; age,
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race, and BMI adjusted OR; and age, race, BMI, and gender adjusted OR. In Unadjusted
OR, all PCBs were significantly associated with identified risk of PAH in (≥ 50th
percentile) when we compare it to the reference group (< LOD to 50th percentile) (Table
12). After gender adjusting, all PCB concentration were significantly associated with risk
of PAH. The highest OR was found in PCB 74 with [OR of 4.00; 95% CI: 3.98-4.01]
(Table 12).
We calculated estimated OR and 95% confidence intervals for PAH with PCB
concentrations divided into < LOD to 50th percentile (reference group), 50th to 75th
percentile, and ≥ 75th percentile (Table 13). In unadjusted calculated OR, all PCB

concentrations were significantly associated with identified risk of PAH. The highest OR
was reported with PCB 74 with [OR of 4.32; 95% CI: (4.31-4.34)]. In gender adjusted
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OR model, all PCB concentrations were higher than un adjusted model except for PCB
180 reported lower OR than in unadjusted model (Table 13). In age, race, and BMI
adjusted OR; and age, race, BMI, and gender adjusted OR, all PCB concentration were
associated with identified risk of PAH. However, no significant difference was reported
within the two models (Table 13).

We calculated estimated OR and 95% confidence intervals for PAH and dioxinlike and non-dioxin-like PCBs < LOD to 50th percentile (reference group) and ≥ 50th
percentile (Table 14). In unadjusted calculated OR, dioxin-like and non-dioxin-like PCBs
were significantly associated with identified risk of PAH [OR of 2.64; 95% CI: (2.63-
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2.66)] and 1.58 (1.79-1.59), respectively. In the age, race, and BMI adjusted model; and

age, race, BMI, and gender adjusted OR, non-dioxin-like PCBs at levels ≥ 50th percentile
and levels ≥ 75th percentile were not associated with identified risk of PAH (Table 14).
DISCUSSION
The fact that EDCs can affect estrogen activity in different tissue in human body,
encouraged us to evaluate PCBs and their effect on the risk of PAH. It is known that
estrogen, oral contraceptive, and female bias has been suggested to be risk factors in the
pathogenesis of PAH. This is the first cross-sectional study that evaluate the exposure of
PCBs and their association with the risk of PAH. We represented the significant
association of exposure to 6 PCB 74, 99, 118, 138, 153, and 180 congeners individually
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and high risk of PAH in the U.S. population > 20 years old using NHANES data 19992004. Furthermore, we demonstrated the sum of dioxin-like PCBs (PCB 74 and 118), and
non-dioxin-like PCBs (PCB 118, 138, 153, and 180) and their association with high risk
of PAH.
Our results are supported with the known association between PAH and its risk
factors which is high estrogen activity, as well the bias in female gender (Badesch et al.,
2010). Females were six times significantly higher in population at risk of PAH than
males. We found that PRKCH is a gene resulted from the meta-analysis of gene
expression of PAH might have plausible role in pathogenesis of PAH. Also it was
reported that PRKCH induce ERs transcriptional activity resulted from exposure to high
levels of EDCs (Cho & Katzenellenbogen, 1993). Also, adipogenesis is known risk factor
of obesity, and EDCs were reported to increase the PPAR and promote adipogenesis
(Charlier et al., 2004). Obese people were at higher risk of PAH than normal and
overweight people. This result is also supported by REVEAL results that reported
significant association between obese people and PAH (BMI > 30, P-value=0.004
(Burger et al., 2011). GM of all individual PCB levels was significantly increased in
people at risk of PAH than people not at risk of PAH. Another NHANES study of PCBs
association with hypertension reported 11 PCBs to risk factor including PCBs (PCBs
126, 74, 118, 99, 138/158, 170, and 187) (Everett, Mainous, Frithsen, Player, &
Matheson, 2008). Nevertheless, PCBs reported to promote vascular endothelial cell
activity and increase the risk of cardiovascular diseases (Ha, Lee, & Jacobs, 2007; Lim,
Smart, Toborek, & Hennig, 2007).

74

GM of all PCBs concentration in people at risk of PAH was higher in different
age groups than people not at risk of PAH with some exception such as GM of PCB 180
was lower in people at risk of PAH in age groups 60-74 years old and > 75 years old.
Also, GM of all PCBs at people at risk of PAH was significantly higher in both races
(non-Hispanic white and other) than people not at risk. However, there is no significant
difference in GM of PCBs concentration within non-Hispanic white and others. Sum of
Dioxin-like PCBs (74+118) and non-Dioxin-like PCBs (99+138+153+180) concentration
were higher in people at risk of PAH than people not at risk of PAH. All confounders
including gender, age, BMI, annual family income, educational level, smoking, and
alcohol use reported higher concentration of Dioxin-like PCBs and non-Dioxin-like PCBs
in people at risk of PAH than people not at risk of PAH, except race. GM of PCBs >
LOD were significantly higher in people at risk of PAH than people not at risk of PAH.
Also, GM of all PCBs LOD > 50%, 50-75%, and > 75% were higher in people at risk of
PAH than people not at risk of PAH, except PCB 180. Risk of PAH appeared to be the
highest in subjects identified at risk of PAH with the highest PCB concentrations in
unadjusted models. PCB 74 reported the highest association among all PCBs in all
models. However, some exception for higher concentrations of dioxin like PCBs and
non-dioxin like PCBs were found no associated risk with PAH age, race, and BMI
adjusted model; and age, race, BMI, and gender adjusted model.
There is limited on data of PCB and its association with PAH. However, estrogen
has high affinity to the lung because of high ER receptors activity. Although, sex
hormone 17β-estradiol (E2) is associated with the formation of atherosclerotic lesions
and vascularization (Benditt & Benditt, 1973). As well, estrogen toxicity is significantly
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associated with high levels of inflammatory cytokine, which indeed lead to PAH (D. Roy
et al., 2007). High levels pf PCB were reported in the human lung (Rallis et al., 2014).
Although, lung toxicity and hypertension are associated with high levels of PCBs and
their estrogenic congeners (Hansen et al., 2016; Kreiss et al., 1981). Moreover, PCBs are
associated with damaging of cardiovascular system (Goncharov et al., 2008; Sergeev &
Carpenter, 2005). Given that pulmonary smooth muscle and endothelial cells reported
human serum level of E2 was found at [0.60 - 1.63 ng/ml] of estrogenic PCB 153
[1ng/ml] (Charlier et al., 2004).
There are some limitations in our study including that we created a variable
named risk of PAH because there was no PAH variable included in the NHANES survey
data. This increases the risk of misclassification to people at risk and not at risk of PAH.
Also, a low number of people at risk of PAH in the study population resulted in low
significance comparison within different analysis. Given that limited data on PCBs
exposure and their association with PAH affected our comparison and analysis of the
results. However, using NHANES cross-sectional survey data including representative
sample size, medical health data, reproductive health data, and laboratory data of the U.S.
population provided us with strength in our study.
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CHAPTER 4
MANUSCRIPT 2
HORMONE REPLACEMENT THERAPY AND ORAL CONTRACEPTIVES
AND RISK OF PULMONARY ARTERIAL HYPERTENSION IN THE UNITED
STATES FEMALES: ANALYSES OF NHANES 1999-2004
ABSTRACT
Background: Females are known to be predominant of pulmonary arterial hypertension
(PAH). Estrogens and oral contraceptives were reported to be associated with PAH. In
this study, we will evaluate the association between hormone replacement therapy and
oral contraceptives with risk of PAH.
Objectives: The objective of this study was to evaluate the association between hormone
replacement therapy and oral contraceptives and risk of PAH among females ≥ 20 years
old in U.S. population.
Methods: We used Centers for Disease Control and Prevention’s National Health and
Nutrition Examination Survey (NHANES) data from 1999-2004 for females ≥ 20 years
old. We selected females identified at risk of PAH with available data on hormones and
birth control. We used data on use of estrogen pills only, progestin pills only,
estrogen/progestin pills combined, and birth control pills. We included age, race, and
BMI as confounders in our analysis. We calculated odds ratios (OR) for the association
between each variable and the risk of PAH.
Results: We found 97 (3.7%) females at risk of PAH and 2,280 (96.295) not at risk of
PAH. Females used hormone pill with estrogen reported [OR of 1.24; 95% CI 1.23-1.25].
Females used hormone pills with progestin and estrogen/progestin pills reported no risk
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of PAH with [OR of 0.57; 95% CI 0.56-0.58] and [OR of 0.59; 95%CI 0.59-0.60],
respectively. However, all variables (estrogen, progestin, and estrogen/ progestin)
reported significant OR with risk of PAH in elderly and obese females. Also, females
used birth control pills reported significant association with risk of PAH [OR of 2.47;
95%CI 2.46-2.48], elderly [OR 5.84; 95% CI 5.81-5.88], and obese [OR 7.43; 95% CI
7.38-7.48].
Conclusions:
Using NHANES data from 1999-2004, we found that use of estrogen pills and birth
controls have a significant association with risk of PAH in females ≥ 20 years old.
However, progestin only pills and estrogen/progestin combo pills did not show any
association with risk of PAH.
Keywords: Hormone replacement therapy, Oral Contraceptives, NHANES,
pulmonary arterial hypertension, PAH

MANUSCRIPT 2
HORMONE REPLACEMENT THERAPY AND ORAL CONTRACEPTIVES
AND RISK OF PULMONARY ARTERIAL HYPERTENSION IN THE UNITED
STATES FEMALES: ANALYSES OF NHANES 1999-2004
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive disease and is frequently
fatal (Yuan & Rubin, 2005). PAH is known by an increase in pulmonary arterial pressure,
proliferation and remodeling of vascular cells; which leads to right heart failure (Price et
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al., 2012). PAH was known to be more dominant in females with ration of 1.9:1 to 4.1:1
in various studies with no clear understanding of gender bias (Badesch et al., 2010; Rich
et al., 1987). Thus, PAH patients were encouraged to avoid pregnancy. Multiple
interactions are involved in the pathogenesis of PAH including environmental exposure
(hypoxia and drugs), genetics, cellular interaction, and sex hormones (Pugh & Hemnes,
2010). Although it was suggested that gender bias in PAH could be explained with
testosterone acts as protective factor of pulmonary vasculature, estrogens acts as
destroying factor. Estrogen is known to promote growth of smooth muscle cells and
vascular endothelial cells by regulating vascular remodeling and angiogenesis. As well,
estrogen is known to induce inflammatory chemokines such as IL-8 (Comeglio et al.,
2014). However, as we explained in our review, estrogen could have an antioxidant effect
and be a protective factor for superoxide radical generation (Assaggaf & Felty, 2017).
Hormonal changes usually comes with pregnancy and PAH pregnant reported high
mortality rates as 50% (Weiss, Zemp, Seifert, & Hess, 1998). Usually, contraceptives are
recommended for PAH females at childbearing age, but estrogen containing
contraceptives are not recommended (Bonnin et al., 2005; Humbert et al., 2001).
Progestin is known to prevent estrogen activity and expression. This was found in uterine
cells and prevented their proliferation (Slayden, Hirst, & Brenner, 1993). Progestin was
added to hormone replacement therapy (HRT) to mimic estrogen activity in breast cancer
(Hirvonen, 1996). However, the mechanistic association between estrogen and progestin
is not fully understood.
Animal models with induced hypoxia and monocrotaline reported that estrogen
acutely increased vasorelaxation of pulmonary artery (Lahm et al., 2007). Another PH
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animal model showed that females have less vascular remodeling than males
(Rabinovitch, Gamble, Miettinen, & Reid, 1981). Mutation in bone morphogenetic
protein receptor type 2 (BMPR2) gene, is known as familial PAH. This type of PAH is
significantly associated with females and specifically young females (35.8 ± 15.4, p <
0.0001) (Eric D Austin et al., 2009). In BMPR2 mutation, females reported 2.4 higher
risk than males and it was suggested to be because of estrogen metabolism (E. D. Austin
et al., 2009). Many studies reported that oral contraceptives and HRT worsen PAH
(Morse, Horn, & Barst, 1999; Sweeney & Voelkel, 2009). Conversely, cohort HRT study
reported that patients developed PAH at low rates (Beretta et al., 2006). Thus, oral
contraceptives are contradicted with PAH and extensive research is recommended. Taken
together, estrogen and sex hormones are suggested to play an unknown important role
with risk of PAH. Thus, we hypothesized that estrogen to be risk factor of high risk of
PAH in females.
In this study, we evaluated the association between use of hormone pills with
estrogen, use of hormone pills with progestin, use of hormone pills with
estrogen/progestin, and use of birth control pills in females at risk of PAH in the National
Health and Nutrition Examination Survey (NHANES) between the years 1999-2004. We
calculated Odd Ratio (OR) of each variable to evaluate its association with risk of PAH.
METHODS
Study Design. The main objective of this study was to investigate the association
between hormone replacement therapy (estrogen, progestin, estrogen/progestin) and oral
contraceptives and risk for PAH and pulmonary diseases in females > 20 years old in the
U.S. To clarify and confirm the suggested role of hormone replacement therapy and oral
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contraceptives, we used NHANES data from 1999-2004 provided by Centers for Disease
Control and Prevention (CDC) to conduct a secondary statistical analysis. National
Health and Nutrition Examination Survey (NHANES) is a program was developed by
National Center for Health Statistics (NCHS) to assess the nutritional and health status
for children and adults in the United States. NHANES started in the early 1960s
producing different surveys for many health issues as well as many age groups. Since
1999, NHANES started producing annually continuous interviews and surveys targeting
different health and nutritional measurements for evaluation purposes including
demographic, dietary, health-related questions, socioeconomic, dental, medical,
physiological measurements, and laboratory tests. An average of 5,000 participants
enrolled every year and 15 counties across the nation are visited every year. To acquire a
representative sampling of the population, many parameters needed to be taken into
consideration for oversampling. Oversampling would be sub-grouped, stratified in
strata’s and then divided into different locations. Oversampling includes age (adolescents
(12-19 years), adults (≥ 60 years)) and ethnicity/ race (non-Hispanics black and Mexican
Americans). After being eligible, the participants undergo series of interviews and
examinations in a specially equipped mobile evaluation clinic (MEC). MEC examination
consist of collections of urine and blood samples, personal interviews, and dental and
physical examinations. Urine is collected from participant if ≥ 6 years, and blood samples
collected from participant if ≥ 1 year. CDC institutional board approved the study
protocol and all participants signed a consent before joining the NHANES. All data are
strictly confident and coded in different identification factors to keep privacy.
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Transportation, personal care (baby/ elderly) and cash payment for participating are
included (CDC, 2012).
Questionnaire Methods. Multiple time points included collection of demographic,
reproductive health, and medical health data. Intensive two weeks training program
including exercises, training interview, and training on personal audio computer
interview was conducted and supervised by NCHS and accompanied staff. Also,
multiple quality control monitoring procedure were conducted through full pilot test
before starting questionnaire. During a household interview, people ≥ 16 years old
provided demographic data. During the personal interview in Mobile Examination Center
(MEC), females ≥ 12 years old provided reproductive health data. For both males and
female (constriction by age and gender), medical health data was provided during the
MEC interview (CDC, 2012).
Selection of Participants. Inclusion criteria used for the study included females during
MEC were ≥ 20 years old who completed and provided personal interview. Subjects with
defined risk of PAH were selected based on an inclusion criteria. We created the Risk of
PAH variable based on any risk factors that reported individually to be associated with
PAH in literature. As mentioned earlier in introduction, these risk factors included
hypertension, abnormal lung function, diabetes, thyroid problems, uric acid level, insulin
status, and female hormone. Risk of PAH variable was created after sum of all risk
factors scoring to be at risk of PAH if > 3 for female participants (CDC, 2012).
Participant will be deleted from the dataset if any of these risk factors answer or level
were missing.
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Sample Weights. Sample weight is required when merging NHANES complex survey
data to avoid bias from non-response selection. The weight variable was provided in each
2-year cycle from 1999-2004 “for all variables (CDC, 2013b).
Reproductive and Medical Health Variables. Data was collected from medical health
questionnaire and reproductive health questionnaire to analyze the association between
hormone replacement therapy and oral contraceptives and the risk of PAH.
Medical Health Questionnaire. Using medical health questionnaire, females > 20 years
old had to provide a response to risk factors of PAH including “have you ever been told by
a doctor or health professional that you have diabetes?”, “Has a doctor or other health
professional ever told that you had a thyroid disease?” Diabetes risk factor was scored 0 if
answer was NO, and scored 1 if answer was YES. Thyroid problem risk factor was scored
0 if answer was NO, and scored 1 if answer was YES. Each of these variables was
transformed into 0 if no risk of PAH and 1 if at risk of PAH.
Reproductive Health Questionnaire. Using reproductive health questionnaire, female
participants > 20 years old had to provide a response to risk factor of PAH “have you ever
used female hormones such as estrogen and progesterone?” Female hormone risk factor
was scored 0 in the female participant answered NO, and scored 1 if the female participant
answered YES.
Hormone replacement therapy and Oral Contraceptives. We used 4 questions to
evaluate the association between hormone replacement therapy and oral contraceptive and
PAH. For hormone therapy, we used questions “{Have you/Has SP} ever taken female
hormone pills containing estrogen only?”, “{Have you/Has SP} taken female hormone pills
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containing progestin only?”, “{Have you/Has SP} taken female hormone pills containing
both estrogen and progestin?”, and “Now I am going to ask you about {your/SP's} birth
control history. {Have you/Has SP} ever taken birth control pills for any reason?” Use
hormone pills w/estrogen only scored 1 if YES, and 2 if NO. Used hormone pills
w/progestin only scored 1 if YES, and 2 if NO. Used estrogen/progestin combo pills scored
1 if YES, and 2 if NO. Ever taken birth control pills scored 1 if YES, and 2 if NO.
Laboratory data. Using laboratory data measurements of uric acid level should be
available for the included participant, as well as measurements of both (triglycerides and
HDL-Cholesterol) to calculate insulin status (insulin sensitive or insulin resistance). Uric
acid risk factor is a continuous variable, so males and females should have different
references. Thus, female participants scored 0 if any had uric acid level < 359 mmol/L, and
scored 1 if any male participant had uric acid level > 360 mmol/L. Insulin status was
calculated by dividing triglycerides level by HDL-cholesterol level to be < 1.99 “insulin
sensitive (IS)” or > 2.00 “insulin resistance (IR)”. Insulin status scored 0 if IS and scored
1 if IR. “Subjects at risk of PAH” variable was created after sum of all risk factor scoring
to be “Subjects at risk of PAH” if > 3 for female participants (CDC, 2012). Participant will
be deleted from the dataset if any of these risk factors answer or level were missing.
Statistical Analysis. We selected females ≥ 20 years old and had available data for
hormones and reproductive health to be included in the analysis to find the association with
the risk of PAH. Data was weighted using the required weight by the National Center for
Health Statistics guidelines to be representative to the whole population. We used stratum
and PSA to estimate variance of the demographic data. To find the associated risk of PAH
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with hormone therapy and oral contraceptives, we used logistic regression models to
calculate the odds ratios (ORs) and their 95 % confidence intervals (CI). Statistical analysis
was performed using SPSS software (release 20) for windows and SAS software for
windows (release 9.4; SAS Institute Inc. Cary, N.C.). We used 5% (P ≤1.05) as significance
level for all analysis.
Potential Confounding Variables. We included many potential confounding variables as
categorical variables which are age, body mass index (BMI, kg/m2), annual family income,
smoking status, alcohol consumption, race, and education level. Age was categorized into
three age groups including 20-59 years (1), 60-74 years (2) and ≥ 75 years (3). BMI was
categorized into > 25 kg/m2 (1), 25-30 kg/m2 (2), and ≥ 30 kg/m2 (3). Annual family income
was categorized into 0-$24,999 (1), $25,000-$54,999 (2), $55,000-$74,999 (3), and ≥
$75,000 (4). Smoking status was categorized into smokers (1) and non-smokers (2), and
alcohol consumption was categorized into consumers (1) non-consumers (2). Race was
categorized into non-Hispanic White (1) and others (2), and education level was
categorized into three categories < 12th grade (1), 12th grade (2), and > 12th grade (3). All
confounding variable data included in the analysis to find the association of hormones and
oral contraceptives and subjects at risk of PAH was used from the demographic file.
Categorization of age and race into specific ranges was to avoid bias in the results due to
low number of people at risk of PAH in younger ages and other races.
RESULTS
Descriptive Statistics. The study population who completed medical health questionnaire,
reproductive health questionnaire; and had available laboratory data to analyze the
association between hormones and oral contraceptives and subjects at risk of PAH were
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2,377 participants ≥ 20 years old. Among the included population, 97 (3.7%) of them
identified at risk to PAH and 2,280 (96.3) of them were not at risk of PAH (Table 15). Race
distribution reported 58 (2.97%) of people at risk of PAH to be non-Hispanic white and 39
(0.73%) were others. However, people not at risk of PAH were 1129 (68.16%) nonHispanic white and 1151 (28.13%) were others. Age was categorized into 3 group; where
26 (1.39%) of people at risk of PAH and 1550 (37.89%) of people not at risk of PAH were
in 20-59 years old group. Most participants at risk of PAH among all age groups were in
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60-74 years old group with 43 (1.48%), while same age group reported 467 (14.78%)
participant not to be at risk of PAH. Elderly > 75 years old were 28 (0.82%) at risk of PAH
and 263 (7.62%) not at risk of PAH. Obese participant reported the highest number among
people at risk of PAH with 53 (2.83%), followed by 29 (1.37%) and 10 (0.54%) for
overweight and normal weight, respectively. However, people not at risk of PAH were 608
(40.28%), 519 (26.91%), and 577 (28.07%) for normal weight, overweight, and obese,
respectively. Annual family income reported 0-$24,999 group to represent the highest
number of population in both risk of PAH 48 (1.47%) and 944 (32.78%) not at risk of PAH.
In the group of $25,000-$54,999, there were 24 (1.14%) at risk of PAH and 627 (27.98%).
However, $55,000-74,999 group reported the lowest number of people at risk of PAH and
people not at risk of PAH with 6 (0.42%) 198 (10.03%), respectively. No significant
difference in distribution of people at risk of PAH in education variable, however, people
with high education level ≥ 12th grade reported to be the highest not at risk of PAH with
1018 (52.31%). Most Subjects at risk of PAH were not smokers with 37 (4.02%), while 17
(2.16%) were smokers. Subjects not at risk of PAH reported 316 (47.02%) to be smokers
and 372 (46.79%) were not smokers (Table 15). Alcohol users, 97 (4.81%) were not at risk
of PAH, while no cases reported to be at risk of PAH. Non-alcohol users were 97 (4.81%)
at risk of PAH and 1744 (94.54%) were not at risk of PAH (Table 15).
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of
hormone pills with estrogen are shown in (Table 16). Results are presented for five logistic
regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI,
and race adjusted. In unadjusted model, use of hormone pills with estrogen was associated
with higher risk of PAH [OR of 1.24; 95%CI 1.23-1.25]. After adjusting age, it remained
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associated with risk of PAH but with less significant [OR 1.04; 95% CI 1.03-1.05].

However, when we adjusted for BMI, it was significantly associated with higher risk of
PAH [OR 2.42; 95% CI 2.41-2.43]. After adjusting all variable (age, race, and BMI), use
of hormone pills with estrogen was associated with higher risk of PAH [OR of 1.10; 95%CI
1.09-1.11]. We further investigated the association between use of hormone pills with
estrogen and risk of PAH within each group of adjusted variables age, race, and BMI. Age
reported gradual increase in OR risk of PAH with older age. Age group 20-59 years old
OR was [1.02; 95% CI 1.01-1.03], 60-74 years old {OR 2.15; 95% CI 1.14-2.16], and age
group > 75 reported [OR 4.48; 95% CI 4.45-4.51]. Race was not associated with risk of
PAH in Non-Hispanic white [OR 0.91; 95% CI 0.91-0.92]; however, race group “other”
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was associated with high risk of PAH [OR 1.22; 95%CI 1.21-1.23]. All BMI groups were
associated with risk of PAH. Normal BMI was [OR 1.28; 95% CI 1.28-1.30]; obese was
[OR 6.25; 95% CI 6.21-6.29]; and overweight was [OR 3.01; 95% CI 2.99-3.04].
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of
hormone pills with progestin are shown in (Table 17). Results are presented for five logistic
regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI,
and race adjusted. All models, unadjusted and adjusted were not associated with risk of
PAH. In unadjusted model, use of hormone pills with progestin was not associated with

93

risk of PAH [OR of 0.57; 95%CI 0.56-0.58]. After adjusting age, it remained not associated
with risk of PAH [OR 0.74; 95% CI 0.74-0.75].
We further investigated the association between use of hormone pills with progestin
and risk of PAH within each group of the adjusted variables age, race, and BMI. Age was
associated with age groups 60-74 and > 75 years old with [OR 2.04; 95% CI 2.03-2.05]
and [OR 4.11; 95% CI 4.08-4.14], respectively. Race was not associated with risk of PAH
in both groups Non-Hispanic white and other wit [OR 0.57; 95% CI 0.56-0.57] and [OR
0.91; 95%CI 0.90-0.92], respectively. Subjects used hormone pills with progestin and had
normal BMI were not associated with risk of PAH. However, subjects with obese and
overweight BMI were associated with higher risk of PAH [OR 6.33; 95% CI 6.29-6.38]
and [OR 2.92; 95% CI 2.89-2.94], respectively.
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of
hormone pills with estrogen/progestin are shown in (Table 18). Results are presented for
five logistic regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted;
and age, BMI, and race adjusted.
All models, unadjusted and adjusted were not associated with risk of PAH. In unadjusted
model, use of hormone pills with estrogen/progestin were not associated with risk of PAH
[OR of 0.59; 95%CI 0.59-0.60]. After adjusting age, it remained not associated with risk
of PAH [OR 0.65; 95% CI 0.65-0.66]. We further investigated the association between use
of hormone pills with estrogen/progestin and risk of PAH within each group of the adjusted
variables age, race, and BMI. Age was associated with age groups 60-74 and > 75 years
old with [OR 2.05; 95% CI 2.04-2.06] and [OR 4.38; 95% CI 4.35-4.41], respectively.
Race was not associated with risk of PAH in both groups Non-Hispanic white and other
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white [OR 0.90; 95% CI 0.90-0.91] and [OR 0.60; 95%CI 0.60-0.61], respectively.
Subjects used of hormone pills with estrogen/ progestin and had normal BMI were not
associated with risk of PAH. However, subjects with obese and overweight BMI were
associated with higher risk of PAH [OR 6.73; 95% CI 6.69-6.78] and [OR 3.17; 95% CI
3.15-3.19], respectively.
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of
birth control pills are shown in (Table 19). Results are presented for five logistic regression
models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI, and race
adjusted. All models, unadjusted and adjusted were associated with risk of PAH. In
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unadjusted model, use of birth control pills was associated with higher risk of PAH [OR of

2.47; 95%CI 2.46-2.48]. After adjusting age, it remained associated with risk of PAH [OR
1.24; 95% CI 1.23-1.25]. However, when we adjusted for BMI, it was significantly
associated with higher risk of PAH [OR 2.46; 95% CI 2.45-2.47]. The highest OR was
reported after adjusting race [OR 2.56; 95% CI 2.55-2.57]. After adjusting all variable (age,
race, and BMI), use of birth control pills was associated with higher risk of PAH [OR of
1.23; 95%CI 1.22-1.24]. We further investigated the association between use of birth
control pills and risk of PAH within each group of the adjusted variables age, race, and
BMI. All age groups were associated with higher risk of PAH 20-59, 60-74 and > 75 years
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old with [OR 1.18; 95% CI 1.18-1.19], [OR 5.14; 95% CI 5.12-5.17], and [OR 5.84; 95%
CI 5.81-5.88], respectively.
Race was associated with higher risk of PAH in both groups Non-Hispanic white
and other wit [OR 1.86; 95% CI 1.86-1.87] and [OR 2.55; 95%CI 2.54-2.56], respectively.
All BMI groups were associated with higher risk of PAH when use birth control pills.
Subjects with normal and overweight BMI were associated with higher risk of PAH [OR
2.44; 95% CI 2.43-2.45] and [OR 3.72; 95% CI 3.69-3.75], respectively. However, obese
reported the highest [OR 7.43; 95% CI 7.38-7.48].
DISCUSSION
This is the first study to date that used NHANES data to evaluate hormone and oral
contraceptive in subject with risk of PAH. Our results support the known high risk of PAH
with estrogen exposure. We showed estrogen to be associated with OR of 1.24 in subjects
at risk of PAH. This result support the hypothesis and confirm the known risk of estrogen
in PAH. In fact, many studies reported high risk of PAH with high estrogen in circulation
(Roberts et al., 2009). Also, it was suggested that estrogen induce pathogenesis of PAH (E.
D. Austin et al., 2009; West et al., 2008). Proliferation of pulmonary artery smooth muscle
cells is known in PAH; and Estrogen metabolites 16α-hydroxyestrone showed to increase
PASMC proliferation (White et al., 2012). Estrogen is associated with higher risk of
thromboembolism (Humbert et al., 2001). Moreover, this association was linked with up
regulation of estrogen metabolizing enzyme cytochrome P450 1B1 (CYP1B1) (White et
al., 2011).
However, with BMI adjusting, the OR risk of PAH and estrogen exposure increase
to 2.41, which reflect a key role of BMI in PAH. This finding support the significant
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association between obesity and PAH (BMI > 30, P-value=0.004) in REVEAL (Burger et
al., 2011). We found elderly to be at higher risk of PAH with OD up to 4.48 when exposed
to estrogen. Schachna reported that elderly > 60 years old had 2 times higher risk of PAH
than patients < 60 years old (OR, 2.30; 95% CI, 1.32 to 3.99) (Schachna et al., 2003). This
also supports the finding of the age specific death rate for elderly by CDC in 2005 (CDC,
2005).
Progestin is found in birth control and it have been recommended as a safe
medication to prevent pregnancy for PAH females (Santiago-Munoz, 2011; Thorne et al.,
2006). Our result showed no risk of PAH in females used progestin pills only with OR of
0.75. Thorne and colleagues found no association of progestin only use with PAH and it
was recommended to use for risk of venous thrombotic (Thorne et al., 2006). However,
age and BMI showed contradicted high OR of up to 4.11 and 6.33, respectively, in females
used progestin pills only. This might explain the contradicted effect of progestin reported
to increase thromboembolism in some PAH cases (Thorne et al., 2006).
Combined estrogen/ progestin contraceptives are known to have contradicted effect
on PAH (Montani et al., 2013). Our results showed OR of 0.59 for estrogen/ progestin pills
use and risk of PAH. Combined therapy has been used for PAH, with some side effects of
high risk of cardiovascular diseases (Lara et al., 2012). In MCT-induced PAH, combined
estrogen/ progestin was reported to prevent development of PAH and right ventricular
hypertrophy (Jones, Zhang, Jackson, & Tofovic, 2006). However, randomized clinical trial
reported estrogen/ progestin may increase risk of coronary heart disease (CHD) in
postmenopausal females (Manson et al., 2003). We reported OR of 4.38 for elderly using
estrogen/ progestin pills. The same association of age was reported with estrogen/ progestin
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use and risk of CHD. Also, we showed obese females using estrogen/ progestin pills to
have the highest risk of PAH with OR of 6.73.
Our results showed that use of birth control increase risk of PAH in females with
OR of 2.47. PAH association with oral contraceptive been reported in pre- and
postmenopausal females (Kleiger, Boxer, Ingham, & Harrison, 1976). We also showed
birth control female users have high risk of PAH in all age groups, race, and BMI. No
reports found for race and its association with PAH. Taken together, our study is the first
cross-sectional study that use NHANES data to evaluate the association between hormone
therapy and oral contraceptive. Our results support the known findings that females using
estrogen and oral contraceptive are at higher risk of PAH.
There are some limitations in our study including that we used scoring method for
PAH risk factors such as REVEAL scoring methods (Benza et al., 2012). Because of
limited data in NHANES, we used available variables hypertension, diabetes, thyroid
problems, uric acid level, and insulin status. Thus, we created a variable named risk of
PAH because there was not PAH variable included in the NHANES survey data. This may
increase the risk of misclassification to people at risk and not at risk of PAH. However,
using NHANES cross-sectional surveys including representative sample size, medical
health data, and reproductive health data of the U.S. population provided us with strength
in our study.
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CHAPTER 5
MANUSCRIPT 3
Meta-analysis of Pulmonary Arterial Hypertension Microarray Expression Data
Reveals Significant Aberrations of Gene Networks Involved in PAH Associated
Pathways
ABSTRACT
Pulmonary arterial hypertension (PAH) causes many vascular changes including
smooth-muscle cell and endothelial-cell proliferation, vasoconstriction, and thrombosis.
PAH reported to associated with many genes such as BMPR2 and ALK1. It is important
to understand the mechanism behind the onset of PAH to find an effective treatment and
early diagnosis of the disease. Many disrupted pathways represented the complexity of
PAH and difference in gene expression could prove the effect of how important to
understand pathways elements. Thus, we performed meta-analysis on a published gene
expression microarray datasets comparing gene expression in PAH samples and control
samples. Six microarray datasets were included in our meta-analysis. Bioinformatics and
Bayesian network analysis statistically identifies genes that are associated with PAH from
our meta-analysis results, gene ontology databases, and literature. The most significant
pathways associated with PAH were Apoptosis signaling pathway, p53 pathway, Ras
Pathway, T-cell activation, TGF-beta signaling pathway, VEGF signaling pathway, Wnt
signaling pathway. Using BN analysis, we found VAMP2, LAMA5, POLR2C, VEGFB,
and PRKCH to be a plausible pathway of PAH.
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MANUSCRIPT 3
Meta-analysis of Pulmonary Arterial Hypertension Microarray Expression Data
Reveals Significant Aberrations of Gene Networks Involved in PAH Associated
Pathways
Introduction
Pulmonary arterial hypertension (PAH) is a disease that affects pulmonary arteries
leading to increase in mean pulmonary arterial pressure. This increase in arterial pressure
cause many vascular changes including smooth-muscle cell and endothelial-cell
proliferation, vasoconstriction, and thrombosis (Rubin M. Tuder et al., 2007). Although,
neointimal lesion formation cause intraluminal block which characterized by abnormal
proliferation of smooth muscle cells (SMCs) (Marc Humbert et al., 2004). Human studies
suggested that only women especially young women were more susceptible of developing
PAH (Tofovic, 2010). Notably, familial PAH with mutated bone morphogenic protein
receptor type 2 (BMPR2) had a higher penetration of disease in women because of the
alteration in E2 metabolism (E. D. Austin et al., 2009). Recently, REVEAL reported that
female-to-male ratio for IPAH is 4.1:1 (Badesch et al., 2010). In France, data were
collected from 674 adults with PAH and followed up for 3 years from 2003-2006. This
registry has confirmed that female are predominant in most PAH subtypes with a sex ratio
(SR) female/ male of 1.9 for all PAH.
Pulmonary hypertension can be caused by different medical conditions, majority of
these conditions are demonstrated histopathologically by hypertrophy of the pulmonary
arterioles (Rubin M. Tuder et al., 2009). Explanation of this high susceptibility remains
unclear; however sex hormones and estrogen were reported to play a role in pathogenesis
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of pulmonary hypertension. Indeed, females’ longer survival was referred to estrogen
activity in PAH. On the other hand, mutations in Bone Morphogenic Protein (BMP)
receptor type II (BMPR2) were reported in about 23% of all PAH cases (Newman, Phillips,
& Loyd, 2008). Mutations in BMPR2 were associated with the increase vascular smooth
muscle cells proliferation by downregulating of BMP signaling (Morrell et al., 2001).
Genomic and non-genomic pathways were reported to have an effect on estrogen
receptors α and β. For example, prostacyclin release and nitric oxidelo production were
reported to be higher by rapid non-genomic mechanisms, which increase endothelial nitric
oxide synthase activity and endothelial nitric oxide synthase messenger RNA (mRNA)
levels and (Sherman et al., 2002). Notably, HIF-1α regulate several genes that have
significant role in angiogenesis, vascular reactivity and remodeling, and cell proliferation
(Tofovic, 2010). The importance of HIF-1α was linked to many human and experimental
models including severe PAH in humans where HIF-1α was up regulated in obliterative
endothelial lesions; and high levels of HIF-1α were associated with vascular remodeling
and development of PAH.
Murine models were studied by Mair and colleagues and they have reported
overexpression of MTS1 and serotonin transporter gene (SERT1) in mice (Dempsie et al.,
2011). Pulmonary shunting, is the less oxygen in alveoli, was reported to cause alterations
of the endothelin pathway in piglets and young lambs. These alterations resulted in high
expression of endothelin-1 and endothelin-A receptor; and with chronic shunting, increase
endothelial nitric oxide synthesis (eNOS). Indeed, these alterations were associated with
increased blood flow in pulmonary arteries (Rondelet et al., 2012). Sugen/hypoxia rat
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model showed that pulmonary shunts were associated with high expression of VEGF in
IPAH (Geiger et al., 2000).
Hypoxia and oxidative stress have a significant role in PAH, human and
experimental. By down regulating expression of CYPIA, which control E2 metabolism,
hypoxia and oxidative stress cause proliferation of pulmonary ECs and VSMCs, as well as
pulmonary vascular remodeling (Kleinman et al., 2007). Hypoxia has been associated to
decrease VEGF protein and gene expression, however, the down-regulation cause VEGFR
blockade and endothelial cell injuries followed by plexiform lesion formation (Voelkel,
Vandivier, & Tuder, 2006). Vascular endothelial growth factor (VEGF) has proliferative
and high levels of VEGF and VEGF receptor-2 expressions have been reported in IPAH
patients’ lung samples. VEGF and VEGFR2 are expressed by ECs within the plexiform
lesions in lungs from patients with PAH (Malenfant et al., 2013). However, mutations in
these molecules were linked with PAH pathogenesis and lesion formation. Plexiform lesion
in IPAH showed up regulation in some genes including TGF-1, HIF1a, THBS1, MMP9,
and cKIT (Jonigk et al., 2011). Jonigk and colleagues found a significant up regulation
mediators in plexiform lesion such as THBS1, HIF1a, Ang-1, VEGF and its receptors
(VEGFR1 and VEGFR2), and Tie-2 (Jonigk et al., 2011).
Genetic mutation and risk of PAH have been reported with many genes and
pathways. Transforming growth factor β (TGF-β) family receptors are the most known
pathway to cause gene mutation in PAH. From the TGF-β, two genes were reported to
cause PAH including BMPR2 and activin-receptor–like kinase 1 (ALK1) (Foletta et al.,
2003). More than 45 mutations have been identified in familial type of PAH patients
because the inheritance role of BMPR2. However, BMPR2 mutation cannot express the
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disease alone. Mutation in ALK1 is rare, however it was reported to cause IPAH (Farber
& Loscalzo, 2004).
Other somatic gene mutations linked to PAH development including prostacyclin,
Bax, thromboxane, serotonin transporter, angiopoietin-1, plasminogen activator inhibitor,
Smads, and Von Willebrand factor (Rajkumar et al., 2010). Moreover, molecular studies
reported that down regulation of the voltage-gated K_ 1.5 potassium channel and up
regulation of the transient receptor potential channel calcium channels were associated with
PAH. These abnormal regulations cause pulmonary artery smooth muscle cells to
proliferate, contract and resist to apoptosis (Bonnet et al., 2007). On the other hand,
abnormal expression of NADPH oxidase 4 (NOX4) and interleukin-6, were reported to
cause vasoconstriction and remodeling in PASMCs. In chronic hypoxia mice, 2.5-fold up
regulation of NOX4 were reported to be associated with IPAH than controls (Mittal et al.,
2007). Moreover, supporting the role of vascular remodeling, NOX2 was reported to be as
3.5-fold up regulated in human lung PAH (Rajkumar et al., 2010). Abnormal proliferation
and growth of vascular smooth muscle cells in PAH were also associated with abnormal
expression of PPP2CA and MYBL1 genes (Rajkumar et al., 2010). Although, Shelat and
colleagues reported that overexpression of E2F1 (a transcription factor which control cell
cycle) and NCOA2 were associated with PAH (Shelat et al., 2001).
Serotonin is a vasoconstrictor which stimulate smooth muscle cell hyperplasia and
hypertrophy (Farber & Loscalzo, 2004). High levels of serotonin have been associated to
increase the proliferation of cultured pulmonary vascular smooth-muscle cells in IPAH
patients (S. Eddahibi et al., 2001). Furthermore anorexigens (appetite suppressants) such
as aminorex, dexfenfluramine, and the fenfluramine and phentermine (fen/phen) have role
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in plexiform lesions and serotonin pathogenesis (Wideman & Hamal, 2011). High
incidence of IPAH was reported among patients who took dexfenfluramine elevate the
secretion of serotonin from platelets and prevent its reuptake. Serotonin promotes cell
growth and vasoconstriction; and in plexiform lesion formation, serotonin high levels
affect signaling pathways downregulation of mutated BMPR2; which was observed in mice
as well (X. Yang et al., 2005). Anorexigens trigger IPAH by: increasing serotonin release
from cellular stores which stimulate plasma serotonin levels and serotonin receptors and
trigger the formation of plexiform lesions (Saadia Eddahibi & Adnot, 2002)(Launay et al.,
2002). In up to 80% of IPAH patients, serotonin role cause rapid increase in PVR that lead
to vasoconstriction followed remodeling in smooth muscle cell proliferation. This acute
pulmonary vasoconstriction usually mediated by the expression of receptors on vascular
smooth muscle cells including 5-HT2A, 5-HT2B, and 5- HT1B/1D (Rodat-Despoix,
Crevel, Marthan, Savineau, & Guibert, 2008).
It was reported that lack in expression of TGF-β receptor 1, TGF-β receptor 2, and
their signaling smad(s) 1-4, including the phosphorylated smad 1/5/8 and 2 had a central
role in plexiform lesions formation (Rubin M. Tuder et al., 2007). The lack of expression
of these smads indicated the absence of their signaling through TGF-β or BMP as well,
which allowed plexiform cells to abnormally proliferate (Richter et al., 2004). In general
many signaling pathways when interrupted cause proliferation and angiogenesis, which are
the leading cause of lesion formation. Many cellular and molecular mechanisms and
pathways involve in the initiation and progression of IPAH. Different factors and
molecules can cause plexiform lesion formation, either by increase proliferation or by
decreasing apoptosis. Most of these mechanisms and pathways were applied on laboratory
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experiments as animal models. Plexiform lesions have been defined as active angiogenic
lesion caused by irregular or neoplastic-like endothelial proliferation and myofibroblast
infiltration (Berger, Geiger, Hess, Bogers, & Mooi, 2001)(R. M. Tuder et al., 2001).
Even though TGF-β signaling molecules are not expressed in the central core of
plexiform lesion, they are actively expressed outside of the plexiform lesion (Abe et al.,
2010). Moreover, other pathways inducing vasoconstrictor production are over-expressed
within the lesion including thromboxane, leukotrienes, and endothelin (Budhiraja, Tuder,
& Hassoun, 2004); and vasodilator production by prostacyclin and nitric oxide (Berger et
al., 2001).
Plexiform lesion growth was reported to be caused by mononuclear inflammatory
cells surround vascular sites (P. Dorfmüller, Perros, Balabanian, & Humbert, 2003).
Moreover, high levels of pro-inflammatory cytokines were reported around plexifonn
lesions in PAH including macrophages and B and T lymphocytes. Inflammatory processes
on pulmonary endothelial cells can cause proliferative pulmonary vasculopathy. Proinflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha (TNF-a), as
well as macrophages and lymphocytes were reported to increase aromatase activities and
peripheral E2 synthesis (Tofovic, 2010). This linkage was associated with high levels of
E2 as well as pulmonary vascular remodeling and progression of PAH (Peter Dorfmüller
et al., 2011).
It is important to understand the mechanism behind the onset of PAH to find an
effective treatment and early diagnosis of the disease. Many disrupted pathways represent
the complexity of PAH and difference in gene expression could prove the effect of how
important to understand pathways elements. This study aims to show what is the effect of
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the difference in gene expression on PAH using microarray expression data of PAH and
non-PAH from published studies. We further extend our aim to investigate what genes
make this difference and what pathways are associated with the disease and these genes.
Moreover, to know how this combination of significant associated genes with PAH would
lead us to discover new pathway of PAH. This will be applied using BN modeling of gene
networks.
Materials and Methods
Microarray dataset
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO) was searched for gene expression profiles and datasets of Pulmonary Arterial
Hypertension. Synonyms combination key terms were used for this comprehensive
systematic search including: Pulmonary Arterial Hypertension (PAH), Idiopathic, case
control, study. No language, subject, and/or period restriction were applied. All age period
were included (pediatric, children, and adults); and both gender (males and females) were
included. All types of pulmonary hypertension (pulmonary arterial hypertension (PAH),
congenital heart disease (CHD-PAH), connective tissue disease (CTD-PAH), chronic
thromboembolic pulmonary hypertension (CTEPH), idiopathic pulmonary arterial
hypertension (IPAH), systemic sclerosis (Ssc-PAH), limited systemic sclerosis-PAH (lssPAH), portopulmonary hypertension (PoPH), and ventricular septal defect (VSD-PAH).
Data extracted included study title, year of publication, disease of interest, study
population, if the study included healthy controls, gender of participants (if available),
mean age, age of each participant (if available). Sixteen datasets were found with different
types of PAH (IPAH, Ssc-PAH, and Lss-PAH) and control subjects. The inclusion criteria
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we used were: article to be published, PAH subjects, all datasets files available to download
from GEO, clear information attached to submitted files, less than 50% missing gene
expressions. All datasets were normalized and discretized using z-score normalization
method (the value – mean / standard deviation), and (z<-1=0; -1<z<1=1; z=>1, 2),
respectively.
Datasets were tested for random distribution using 10% of genes in SPSS. Because
we have different biological material locations, datasets were separated into blood and
tissue samples. We combined all dataset to find out how many genes are common among
all six datasets. We checked that ID1-4 gene expression are available, and we calculated
their fold change as well. Statistical t-test was performed to identify genes that significantly
expressed in PAH blood and tissue samples from GEO datasets, and we selected the first
quartile of significant p-value of 0.05. Statistical correlation analysis was performed on
ID3 correlated genes in blood and tissue from GEO datasets, and we selected the first
quartile of correlated genes. We matched the common genes that were significantly
expressed in PAH blood and tissue samples and ID3 correlated genes in blood and tissue
from GEO datasets; and target gene list were created for blood and tissue.
Gene ontology and pathway analysis
We used (PANTHER, Protein ANalysis THrough Evolutionary Relationships,
Classification System DataBase) for gene ontology analysis to understand the functions of
the gene list. PANTHER provides comprehensive function information about genes, and
was designed to also facilitate analysis of large numbers of gene associations
(http://pantherdb.org/). Statistical enrichment test for each of biological process, molecular
function, protein class, cellular component, and pathway were evaluated according to the
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likelihood that their numerical values were drawn randomly from the overall distribution
of values. The Mann-Whitney U Test (Wilcoxon Rank-Sum Test) was used to determine
the P-value (the chromatin packaging and remodeling genes have random values relative
to overall list of values that were input).
Protein-protein interaction network construction
We used STRING database (http:// string-db.org), which provides functional
profile of each gene, to identify the association in the gene list. Also, to demonstrate
functional and canonical pathway analysis associated with the list of genes provided in
network maps. STRING provided data from published identified functions and
interactions.
Bayesian network analysis (Bene):
The idea behind BN is to record how many times that different values of the variable (X)
occur together with different vectors (V) in the data. In our analysis, X = variable (genes,
disease, age, gender,...etc.), V= sample (patient or control) (Silander & Myllymaki, 2012).
BN are directed acyclic graphs (DAGs) which represent an association among different
variables, and variable can have more than one state (Heckerman, 1998). The association
between these variables, which represented by the best BN, resulted through Bene software
are based on five logical steps which (Silander and Myllynaki) explained in their published
article (Silander & Myllymaki, 2012). “These five steps are: 1) Calculate the local scores
for all n2n−1 different (variable, variable set)-pairs, 2) Using the local scores, find best
parents for all n2n−1 (variable, parent candidate set)-pairs, 3) Find the best sink for all 2n
variable sets, 4) Using the results from Step 3, find a best ordering of the variables, and 5)
Find a best network using results computed in Steps 2 and 4”. Using discretized data, Bene
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first constructed a best net using BDe score (with equivalent sample size 1.0) and a best
net using the BIC score (Silander & Myllymaki, 2012) and (Yoo, 2012). The aim of using
BN analysis is to develop a model which examine the association of gene expression levels
in PAH samples and control samples. This might determine the risk of PAH with different
expression of genes.
Genie
GeNIe 2.1 is a software used to validate and manipulate BN structure resulted from Bene.
It helped us to find out what genes and expression affect PAH or control samples.
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Figure 3 Flow chart summarizing the steps was carried out through this study
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RESULTS
Six PAH microarray datasets met our inclusion criteria and were included in the
analysis (Table 20). Samples and controls were divided into two groups based on the
biological material location, blood and tissue (Table 21). Common genes were matched
among six datasets and 10,716 genes found to be common in all datasets (supplement1).
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Table 21. Distribution of GEO samples included in the analysis (PAH, control, and
gender), based on 2 biological material location (Tissue and Blood).
PAH
Control
Total
Tissue
38
24
62
Blood
84
54
138
Total
122
78
200
Male/ Female
29/ 82
17/ 49
46/ 131

Statistical analysis t-test of the 10,716 common genes showed that 2,598 genes in
blood samples and 2,542 genes in tissue samples were significantly expressed in PAH
samples (P-value < 0.05). Correlation analysis of ID3 correlated genes showed that 2,679
gene in blood samples and 2,699 genes in tissue samples, were in the first quartile of ID3
correlated genes (Supplement 2).
We matched the results of significant genes from the two statistical analysis tests,
t-test and ID3 correlation. Matching results showed that 701 genes in blood and 573 genes
in tissue, were common in t-test and ID3 correlation test (Table 22 and Table 23) (Figure
1 and 2). Only 28 genes were common significantly expressed among blood and tissue
samples (Table 24) (Figure 3 diagram). All Common genes represented in blood samples,
tissue samples, t-test significant with PAH, and ID3 correlated genes showed in (Figure 4).

Figure 4 Venn diagram represent number of ID3 correlated genes (2,679) and number of
significantly expressed genes in PAH tissue samples from GEO datasets (2,679), in Blood
samples. 700 genes are common between ID3 correlated genes and significantly
expressed genes in PAH tissue samples from GEO datasets.
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Figure 5 Venn diagram represent number of ID3 correlated genes (2,699) and number of
significantly expressed genes in PAH tissue samples from GEO datasets (2,700), in
Tissue samples. 572 genes are common between ID3 correlated genes and significantly
expressed genes in PAH tissue samples from GEO datasets.

Figure 6 Venn diagram represent number genes (27) are common between ID3
correlated genes and number of significantly expressed genes in PAH from GEO
datasets, blood samples (700) genes and tissue samples (572) genes.
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Figure 7 Venn diagram represent overall number of genes are common between different
list of correlate with ID3 and number of genes are significantly expressed in PAH blood
and tissue samples from GEO datasets. Yellow represent number of genes are
significantly expressed in PAH blood samples from GEO datasets (2,679). Green
represent number of genes are ID3 correlated in PAH tissue samples from GEO datasets
(2,699). Blue represent number of genes are ID3 correlated in PAH blood samples from
GEO datasets (2,679). Red represent number of genes are significantly expressed in PAH
tissue samples from GEO datasets (2,700).

119

Table 22. Genes that are significantly expressed in PAH samples; and significantly correlated with ID3 in blood samples (701
genes) from the significant gene list provided from GEO PAH datasets
Gene
Gene Name
FAU
Finkel-Biskis-Reilly murine sarcoma virus
Symbol
(FBR-MuSV) ubiquitously expressed
KIFC2
kinesin family member C2
STAG3
stromal antigen 3
LDHB
lactate dehydrogenase B
LSM4
LSM4 homolog, U6 small nuclear RNA
associated (S. cerevisiae)
FHIT
fragile histidine triad gene
ZNF395
zinc finger protein 395
OXA1L
oxidase (cytochrome c) assembly 1-like
DHX35
DEAH (Asp-Glu-Ala-His) box polypeptide
SLC2A4RG SLC2A4 regulator
35
RPL19
ribosomal protein L19; ribosomal protein L19
RPL12
ribosomal protein L12 pseudogene 2
pseudogene 12
ADAM7
ADAM metallopeptidase domain 7
TUBB2A
tubulin, beta 2A
CDCA4
cell division cycle associated 4
H1FX
H1 histone family, member X
GNG7
guanine nucleotide binding protein (G
CLK1
CDC-like kinase 1
protein), gamma 7
MYLIP
myosin regulatory light chain interacting
STAG1
stromal antigen 1
protein
KLRB1
killer cell lectin-like receptor subfamily B,
ACBD6
acyl-Coenzyme A binding domain containing
member 1
6
CGRRF1
cell growth regulator with ring finger domain
WDR74
WD repeat domain 74
1
BRPF1
bromodomain and PHD finger containing, 1
LIG1
ligase I, DNA, ATP-dependent
SH3YL1
SH3 domain containing, Ysc84-like 1 (S.
ESPL1
extra spindle pole bodies homolog 1 (S.
cerevisiae)
cerevisiae)
WDR73
WD repeat domain 73
RAD1
RAD1 homolog (S. pombe)
MALL
mal, T-cell differentiation protein-like
UXT
ubiquitously-expressed transcript
MC1R
tubulin, beta 3; melanocortin 1 receptor (alpha
NME3
non-metastatic cells 3, protein expressed in
melanocyte stimulating hormone receptor)
MAGEE1
melanoma antigen family E, 1
RPLP0
ribosomal protein, large
CD320
CD320 molecule
CCR10
chemokine (C-C motif) receptor 10
MAPK6
mitogen-activated protein kinase 6
SH3BGR
SH3 domain binding glutamic acid-rich
RPS17
ribosomal protein S17
protein
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RPS14
SURF2
RPS11
HSPBAP1
CRTC2
RAD23B
WDR60
DUSP12
ACP1
PPP1R3D
ARIH1
IL17D
SLC29A2
DUSP16
PABPC1

TCF3
KIAA1683
SSSCA1
ZNF622
MGAT4A
ZNF529

ribosomal protein S14
surfeit 2
ribosomal protein S11
HSPB (heat shock 27kDa) associated protein
1
CREB regulated transcription coactivator 2
RAD23 homolog B (S. cerevisiae)
WD repeat domain 60
dual specificity phosphatase 12
acid phosphatase 1, soluble
protein phosphatase 1, regulatory (inhibitor)
subunit 3D
ariadne homolog, ubiquitin-conjugating
enzyme E2 binding protein, 1 (Drosophila)
interleukin 17D
solute carrier family 29 (nucleoside
transporters), member 2
dual specificity phosphatase 16
poly(A) binding protein, cytoplasmic
pseudogene 5; poly(A) binding protein,
cytoplasmic 1
transcription factor 3 (E2A immunoglobulin
enhancer binding factors E12/E47)
KIAA1683
Sjogren syndrome/scleroderma autoantigen 1
zinc finger protein 622
mannosyl (alpha-1,3-)-glycoprotein beta-1,4N-acetylglucosaminyltransferase, isozyme A
zinc finger protein 529

TCF7
ZC3H15
KLF12
KLF13
NXF1
RPS5
RPS7
C1ORF64
PKP2
RGS3
HEBP2
PPRC1
TGFBR3
DHX40

SYTL1
SGSH
ELF2
BACH2
ZNF18
KCNAB2
UBE2G1
UFC1
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transcription factor 7 (T-cell specific, HMGbox)
zinc finger CCCH-type containing 15
Kruppel-like factor 12
Kruppel-like factor 13
nuclear RNA export factor 1
ribosomal protein S5
ribosomal protein S7
chromosome 1 open reading frame 64
plakophilin 2
regulator of G-protein signaling 3
heme binding protein 2
peroxisome proliferator-activated receptor
gamma, coactivator-related 1
transforming growth factor, beta receptor III
similar to DEAH (Asp-Glu-Ala-His) box
polypeptide 40; DEAH (Asp-Glu-Ala-His)
box polypeptide 40
synaptotagmin-like 1
N-sulfoglucosamine sulfohydrolase
E74-like factor 2 (ets domain transcription
factor)
BTB and CNC homology 1, basic leucine
zipper transcription factor 2
zinc finger protein 18
potassium voltage-gated channel, shakerrelated subfamily, beta member 2
ubiquitin-conjugating enzyme E2G 1 (UBC7
homolog, yeast)
ubiquitin-fold modifier conjugating enzyme 1

EIF2A
KCNK12
LSM14A
HSF2
USP12
USP11
GKAP1
CLDND1
MASTL
DPP9
TWISTNB
ERRFI1
SERTAD1
FGF3

SERTAD2
TTC32
ZNF548
EXOSC9
ARHGEF1
BRF1

EXOSC6
BRF2

eukaryotic translation initiation factor 2A,
65kDa
potassium channel, subfamily K, member 12
LSM14A, SCD6 homolog A (S. cerevisiae)
heat shock transcription factor 2
ubiquitin specific peptidase 12
ubiquitin specific peptidase 11
G kinase anchoring protein 1
claudin domain containing 1
microtubule associated serine/threonine
kinase-like
dipeptidyl-peptidase 9
TWIST neighbor
ERBB receptor feedback inhibitor 1
SERTA domain containing 1
fibroblast growth factor 3 (murine mammary
tumor virus integration site (v-int-2) oncogene
homolog)
SERTA domain containing 2
tetratricopeptide repeat domain 32
zinc finger protein 548
exosome component 9
Rho guanine nucleotide exchange factor
(GEF) 1
BRF1 homolog, subunit of RNA polymerase
III transcription initiation factor IIIB (S.
cerevisiae)
exosome component 6
BRF2, subunit of RNA polymerase III
transcription initiation factor, BRF1-like
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GMEB2
SDK2
SLC3A2
MRPL9
PAPD5
GLCCI1
ZNF335
LRPAP1
CARD11
PFDN1
BRWD1
ZNF134
BNIP1
BNIP2
EIF4A2

IL12A
CAND2
OSBPL10
KCNH8

glucocorticoid modulatory element binding
protein 2
sidekick homolog 2 (chicken)
solute carrier family 3 (activators of dibasic
and neutral amino acid transport), member 2
mitochondrial ribosomal protein L9
PAP associated domain containing 5
glucocorticoid induced transcript 1
zinc finger protein 335
low density lipoprotein receptor-related
protein associated protein 1
caspase recruitment domain family, member
11
prefoldin subunit 1
bromodomain and WD repeat domain
containing 1
zinc finger protein 134
BCL2/adenovirus E1B 19kDa interacting
protein 1
BCL2/adenovirus E1B 19kDa interacting
protein 2
similar to eukaryotic translation initiation
factor 4A2; eukaryotic translation initiation
factor 4A, isoform 2
interleukin 12A
cullin-associated and neddylation-dissociated
2 (putative)
oxysterol binding protein-like 10
potassium voltage-gated channel, subfamily H
(eag-related), member 8

ZNF551
ARL4C
ZNF484
ASTE1
GRASP
KIAA1429
ARL4A
ZNF276
MIDN
EXOC8
CREM
MKNK2
RPL36
EEA1
CBLL1
CCL28
ZNF653
ZNF34
ITM2A
PLEKHG4
WDR19
SNRK
RPL32

zinc finger protein 551
ADP-ribosylation factor-like 4C
zinc finger protein 484
asteroid homolog 1 (Drosophila)
GRP1 (general receptor for phosphoinositides
1)-associated scaffold protein
KIAA1429
ADP-ribosylation factor-like 4A
zinc finger protein 276
midnolin
exocyst complex component 8
cAMP responsive element modulator
MAP kinase interacting serine/threonine
kinase 2
ribosomal protein L36
early endosome antigen 1
Cas-Br-M (murine) ecotropic retroviral
transforming sequence-like 1
chemokine (C-C motif) ligand 28
zinc finger protein 653
zinc finger protein 34
integral membrane protein 2A
pleckstrin homology domain containing,
family G (with RhoGef domain) member 4
WD repeat domain 19
SNF related kinase
small nucleolar RNA, H/ACA box 7A; small
nucleolar RNA, H/ACA box 7B; ribosomal
protein L32
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PPP3CC

protein phosphatase 3 (formerly 2B), catalytic
subunit, gamma isoform
ARMCX2
armadillo repeat containing, X-linked 2
TCEA2
transcription elongation factor A (SII), 2
PCSK6
proprotein convertase subtilisin/kexin type 6
GALNT11
UDP-N-acetyl-alpha-Dgalactosamine:polypeptide Nacetylgalactosaminyltransferase 11 (GalNAcT11)
GALNT12
UDP-N-acetyl-alpha-Dgalactosamine:polypeptide Nacetylgalactosaminyltransferase 12 (GalNAcT12)
EXOC2
exocyst complex component 2
IL6
interleukin 6 (interferon, beta 2)
SPTY2D1
SPT2, Suppressor of Ty, domain containing 1
(S. cerevisiae)
ZNF160
zinc finger protein 160
EXPH5
exophilin 5
ZNF24
zinc finger protein 24
RPL24
ribosomal protein L24; ribosomal protein L24
pseudogene 6
ZNF668
zinc finger protein 668
ETF1
eukaryotic translation termination factor 1
5-Mar membrane-associated ring finger (C3HC4) 5
PHYH
phytanoyl-CoA 2-hydroxylase
ZNF165
zinc finger protein 165
FEM1C
fem-1 homolog c (C. elegans)
DUSP5
dual specificity phosphatase 5
RLF
rearranged L-myc fusion

MEF2D
P2RY10
RASSF5
ZNF671
DUSP2
TFRC
WDR26
DUSP1
C21ORF2
RPL22
PTP4A1
PTP4A2
WHSC1L1
SLFN13
ZBTB5
GAMT
ZBTB3
ZNF256
WNT7A
WDR20
SRP14

myocyte enhancer factor 2D
purinergic receptor P2Y, G-protein coupled,
10
Ras association (RalGDS/AF-6) domain
family member 5
zinc finger protein 671
dual specificity phosphatase 2
transferrin receptor (p90, CD71)
WD repeat domain 26
dual specificity phosphatase 1
chromosome 21 open reading frame 2
ribosomal protein L22 pseudogene 11;
ribosomal protein L22
protein tyrosine phosphatase type IVA,
member 1
protein tyrosine phosphatase type IVA,
member 2
Wolf-Hirschhorn syndrome candidate 1-like 1
schlafen family member 13
zinc finger and BTB domain containing 5
guanidinoacetate N-methyltransferase
zinc finger and BTB domain containing 3
zinc finger protein 256
wingless-type MMTV integration site family,
member 7A
WD repeat domain 20
signal recognition particle 14kDa
(homologous Alu RNA binding protein)
pseudogene 1; signal recognition particle
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ZNF581
PRC1
RBM3
PASK
TGFB3
LNX2
KIAA1328
SLC7A5
SLC7A6
TCEAL3
IDH3G
LRRC57
MFHAS1
AAK1
SLC2A1
PDE4B

DDX24
EIF1

14kDa (homologous Alu RNA binding
protein)
zinc finger protein 581
protein regulator of cytokinesis 1
RNA binding motif (RNP1, RRM) protein 3
PAS domain containing serine/threonine
kinase
transforming growth factor, beta 3
ligand of numb-protein X 2
KIAA1328
solute carrier family 7 (cationic amino acid
transporter, y+ system), member 5
solute carrier family 7 (cationic amino acid
transporter, y+ system), member 6
transcription elongation factor A (SII)-like 3
isocitrate dehydrogenase 3 (NAD+) gamma
leucine rich repeat containing 57
malignant fibrous histiocytoma amplified
sequence 1
AP2 associated kinase 1
solute carrier family 2 (facilitated glucose
transporter), member 1
phosphodiesterase 4B, cAMP-specific
(phosphodiesterase E4 dunce homolog,
Drosophila)
DEAD (Asp-Glu-Ala-Asp) box polypeptide
24
similar to eukaryotic translation initiation
factor 1; eukaryotic translation initiation
factor 1

PITPNC1
DDX20
ZNF446
LONRF1
IMP4
IDUA
NET1
RPL35A
SPTLC1
RELA
RELB
ENC1
PDE4D

YTHDF3
TATDN2
WEE1
CCDC6
RCL1
PODXL2

phosphatidylinositol transfer protein,
cytoplasmic 1
DEAD (Asp-Glu-Ala-Asp) box polypeptide
20
zinc finger protein 446
LON peptidase N-terminal domain and ring
finger 1
IMP4, U3 small nucleolar ribonucleoprotein,
homolog (yeast)
iduronidase, alpha-Lneuroepithelial cell transforming 1
ribosomal protein L35a
serine palmitoyltransferase, long chain base
subunit 1
v-rel reticuloendotheliosis viral oncogene
homolog A (avian)
v-rel reticuloendotheliosis viral oncogene
homolog B
ectodermal-neural cortex (with BTB-like
domain)
phosphodiesterase 4D, cAMP-specific
(phosphodiesterase E3 dunce homolog,
Drosophila)
YTH domain family, member 3
TatD DNase domain containing 2
WEE1 homolog (S. pombe)
coiled-coil domain containing 6
RNA terminal phosphate cyclase-like 1
podocalyxin-like 2

IGBP1
VSNL1
RNF138
TESK2
MFAP3
VAMP2
MFAP4
ZNF586
ARFGAP3
HDLBP
EID3
ADAMTSL
2
MAPKAPK
5
SETD1A
LRIG1
BEX2
LRIG2
SESN1
RABGGTB
ATF2
ISYNA1
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chromosome 14 open reading frame 19;
immunoglobulin (CD79A) binding protein 1
visinin-like 1
ring finger protein 138
testis-specific kinase 2
microfibrillar-associated protein 3
vesicle-associated membrane protein 2
(synaptobrevin 2)
microfibrillar-associated protein 4
zinc finger protein 586
ADP-ribosylation factor GTPase activating
protein 3
high density lipoprotein binding protein
EP300 interacting inhibitor of differentiation
3
similar to ADAMTS-like 2; ADAMTS-like 2
mitogen-activated protein kinase-activated
protein kinase 5
SET domain containing 1A
leucine-rich repeats and immunoglobulin-like
domains 1
brain expressed X-linked 2
leucine-rich repeats and immunoglobulin-like
domains 2
sestrin 1
Rab geranylgeranyltransferase, beta subunit
activating transcription factor 2
inositol-3-phosphate synthase 1

TUBB

ZNF324
ZNF326
POLE3
ICOS
SYAP1
JUND
RPL3
ZNF329
RPL10A

TRAF3
B4GALT1
PRAF2
OVGP1
HERPUD1

TAF6

DOCK9
TNFRSF13
C

tubulin, beta; similar to tubulin, beta 5;
tubulin, beta pseudogene 2; tubulin, beta
pseudogene 1
zinc finger protein 324
zinc finger protein 326
polymerase (DNA directed), epsilon 3 (p17
subunit)
inducible T-cell co-stimulator
synapse associated protein 1, SAP47 homolog
(Drosophila)
jun D proto-oncogene
ribosomal protein L3; similar to 60S
ribosomal protein L3 (L4)
zinc finger protein 329
ribosomal protein L10a pseudogene 6;
ribosomal protein L10a; ribosomal protein
L10a pseudogene 9
TNF receptor-associated factor 3
UDP-Gal:betaGlcNAc beta 1,4galactosyltransferase, polypeptide 1
PRA1 domain family, member 2
oviductal glycoprotein 1, 120kDa
homocysteine-inducible, endoplasmic
reticulum stress-inducible, ubiquitin-like
domain member 1
TAF6 RNA polymerase II, TATA box
binding protein (TBP)-associated factor,
80kDa
dedicator of cytokinesis 9
tumor necrosis factor receptor superfamily,
member 13C
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NR4A1

nuclear receptor subfamily 4, group A,
member 1
DNHD1
dynein heavy chain domain 1
RPL23A
ribosomal protein L23a
THUMPD2 THUMP domain containing 2
CACNA2D2 calcium channel, voltage-dependent, alpha
2/delta subunit 2
MMAA
methylmalonic aciduria (cobalamin
deficiency) cblA type
ATF4
activating transcription factor 4 (taxresponsive enhancer element B67); activating
transcription factor 4C
CDKN1B
cyclin-dependent kinase inhibitor 1B (p27,
Kip1)
DNAJB9
DnaJ (Hsp40) homolog, subfamily B,
member 9
PLK3
polo-like kinase 3 (Drosophila)
ZNF419
zinc finger protein 419
EAF1
ELL associated factor 1
ARMC8
armadillo repeat containing 8
CDC42SE2 CDC42 small effector 2
GTF2F1
general transcription factor IIF, polypeptide 1,
74kDa
NDUFV1
NADH dehydrogenase (ubiquinone)
flavoprotein 1, 51kDa
GTF2F2
general transcription factor IIF, polypeptide 2,
30kDa
HIST1H3A histone cluster 1, H3a
TUBD1
tubulin, delta 1
FBXO30
F-box protein 30

RHBDL1
HIVEP1
ZNF414
DNAJB1
IER2
USPL1
IER5
LRRC8A
HP1BP3
DPH5
WWC2
DPH3
ALG9
RPS3
SPRY1
PAX7
PTDSS1
PPP2R1B
ANKS1A
SIT1

rhomboid, veinlet-like 1 (Drosophila)
human immunodeficiency virus type I
enhancer binding protein 1
zinc finger protein 414
DnaJ (Hsp40) homolog, subfamily B,
member 1
immediate early response 2
ubiquitin specific peptidase like 1
immediate early response 5
leucine rich repeat containing 8 family,
member A
heterochromatin protein 1, binding protein 3
DPH5 homolog (S. cerevisiae)
WW and C2 domain containing 2
DPH3, KTI11 homolog (S. cerevisiae);
DPH3B, KTI11 homolog B (S. cerevisiae)
asparagine-linked glycosylation 9, alpha-1,2mannosyltransferase homolog (S. cerevisiae)
ribosomal protein S3 pseudogene 3;
ribosomal protein S3
sprouty homolog 1, antagonist of FGF
signaling (Drosophila)
paired box 7
phosphatidylserine synthase 1
protein phosphatase 2 (formerly 2A),
regulatory subunit A, beta isoform
ankyrin repeat and sterile alpha motif domain
containing 1A
signaling threshold regulating transmembrane
adaptor 1
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PTGER4
ARID5A
CCNL1
CDK9
MID1IP1
RPS4X

NCL
PMM1
SIGLEC6
ZFAND2A
RRAS2

CA6
UBC
SLC41A1
INPP4B
UBAP1
OTUD4
BCLAF1

CABP1
NR3C2
BTN2A2

prostaglandin E receptor 4 (subtype EP4)
AT rich interactive domain 5A (MRF1-like)
cyclin L1
cyclin-dependent kinase 9
MID1 interacting protein 1 (gastrulation
specific G12 homolog (zebrafish))
ribosomal protein S4X pseudogene 6;
ribosomal protein S4X pseudogene 13;
ribosomal protein S4, X-linked
nucleolin
phosphomannomutase 1
sialic acid binding Ig-like lectin 6
zinc finger, AN1-type domain 2A
related RAS viral (r-ras) oncogene homolog
2; similar to related RAS viral (r-ras)
oncogene homolog 2
carbonic anhydrase VI
ubiquitin C
solute carrier family 41, member 1
inositol polyphosphate-4-phosphatase, type II,
105kDa
ubiquitin associated protein 1
OTU domain containing 4
similar to Bcl-2-associated transcription
factor 1 (Btf); BCL2-associated transcription
factor 1
calcium binding protein 1
nuclear receptor subfamily 3, group C,
member 2
butyrophilin, subfamily 2, member A2

PPM1B
TSPYL5
RNF125
RNF126
TFAM
HIC2
TSC22D2
TSPYL2
AP3M2
ECD
CD6
SCNN1D
GCHFR
CD7
CNNM2
MAF
EBP
VHL
SNX25
GDPD5
MAL
DRG2
FBL
PWP1

protein phosphatase 1B (formerly 2C),
magnesium-dependent, beta isoform
TSPY-like 5
ring finger protein 125
ring finger protein 126
transcription factor A, mitochondrial
hypermethylated in cancer 2
TSC22 domain family, member 2
TSPY-like 2
adaptor-related protein complex 3, mu 2
subunit
ecdysoneless homolog (Drosophila)
CD6 molecule
sodium channel, nonvoltage-gated 1, delta
GTP cyclohydrolase I feedback regulator
CD7 molecule
cyclin M2
v-maf musculoaponeurotic fibrosarcoma
oncogene homolog (avian)
emopamil binding protein (sterol isomerase)
von Hippel-Lindau tumor suppressor
sorting nexin 25
glycerophosphodiester phosphodiesterase
domain containing 5
mal, T-cell differentiation protein
developmentally regulated GTP binding
protein 2
fibrillarin
PWP1 homolog (S. cerevisiae)

ID2
ZBED4
SDF2L1
BAX
JAK1
UCKL1
ID3
GGA1
SCAND1
NELL2
SNIP1
BBX
RNASEH1
LUZP1
CRY2
H2AFV
CD44
WWP2
TRAK1
INSIG1
COL12A1
FAM53C
STAM
FAM103A1
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inhibitor of DNA binding 2, dominant
negative helix-loop-helix protein
zinc finger, BED-type containing 4
stromal cell-derived factor 2-like 1
BCL2-associated X protein
Janus kinase 1
uridine-cytidine kinase 1-like 1
inhibitor of DNA binding 3, dominant
negative helix-loop-helix protein
golgi associated, gamma adaptin ear
containing, ARF binding protein 1
SCAN domain containing 1
NEL-like 2 (chicken)
Smad nuclear interacting protein 1
bobby sox homolog (Drosophila)
ribonuclease H1
leucine zipper protein 1
cryptochrome 2 (photolyase-like)
H2A histone family, member V
CD44 molecule (Indian blood group)
WW domain containing E3 ubiquitin protein
ligase 2
trafficking protein, kinesin binding 1
insulin induced gene 1
collagen, type XII, alpha 1
family with sequence similarity 53, member C
signal transducing adaptor molecule (SH3
domain and ITAM motif) 1
family with sequence similarity 103, member
A1

FAM53B
DDX10
SUPT5H
CRY1
BCL7B
CD3G
CD3E
STRN3
TBRG4
KRT10
PIM3
GCC1
DEPDC5
VEGFB
CHRAC1
CCR7
PRDM4
ABT1
MLLT10

MNT
TGFBRAP1
RAB12
BIN1
MRPL46
CDV3

family with sequence similarity 53, member B
DEAD (Asp-Glu-Ala-Asp) box polypeptide
10
suppressor of Ty 5 homolog (S. cerevisiae)
cryptochrome 1 (photolyase-like)
B-cell CLL/lymphoma 7B
CD3g molecule, gamma (CD3-TCR complex)
CD3e molecule, epsilon (CD3-TCR complex)
striatin, calmodulin binding protein 3
transforming growth factor beta regulator 4
keratin 10
pim-3 oncogene
GRIP and coiled-coil domain containing 1
DEP domain containing 5
vascular endothelial growth factor B
chromatin accessibility complex 1
chemokine (C-C motif) receptor 7
PR domain containing 4
activator of basal transcription 1
myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila); translocated
to, 10
MAX binding protein
transforming growth factor, beta receptor
associated protein 1
RAB12, member RAS oncogene family
bridging integrator 1
mitochondrial ribosomal protein L46
CDV3 homolog (mouse)
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ELL
GPBP1L1
PFKFB3
AFAP1L2
ANGEL2
COIL
TIPRL
TJAP1
SLC11A2
EPHB6
STX18
NGRN
MRPL54
SUPV3L1
FBXO8
TSEN54
TP53BP2
SMAD7
CRIP2
CREBBP
ANKMY1
SMYD3
CELSR1
ZBTB44

elongation factor RNA polymerase II
GC-rich promoter binding protein 1-like 1
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3
actin filament associated protein 1-like 2
angel homolog 2 (Drosophila)
coilin
TIP41, TOR signaling pathway regulator-like
(S. cerevisiae)
tight junction associated protein 1 (peripheral)
solute carrier family 11 (proton-coupled
divalent metal ion transporters), member 2
EPH receptor B6
syntaxin 18
neugrin, neurite outgrowth associated
mitochondrial ribosomal protein L54
suppressor of var1, 3-like 1 (S. cerevisiae)
F-box protein 8
tRNA splicing endonuclease 54 homolog (S.
cerevisiae)
tumor protein p53 binding protein, 2
SMAD family member 7
cysteine-rich protein 2
CREB binding protein
ankyrin repeat and MYND domain containing
1
SET and MYND domain containing 3
cadherin, EGF LAG seven-pass G-type
receptor 1 (flamingo homolog, Drosophila)
zinc finger and BTB domain containing 44

U2AF1L4
OCIAD2
DLX3
EPHA4
CBLB
TEX13A
LAMA5
DCP1A
NIPSNAP1
ZIK1
COPS2
HIP1R
CCNT1
SPINK2
UVRAG
VPS37B
TERF2IP
SPINK7
FLT3LG
BAG4
C4ORF36

U2 small nuclear RNA auxiliary factor 1-like
4
OCIA domain containing 2
distal-less homeobox 3
EPH receptor A4
Cas-Br-M (murine) ecotropic retroviral
transforming sequence b
testis expressed 13A
laminin, alpha 5
DCP1 decapping enzyme homolog A (S.
cerevisiae)
nipsnap homolog 1 (C. elegans)
zinc finger protein interacting with K protein
1 homolog (mouse)
COP9 constitutive photomorphogenic
homolog subunit 2 (Arabidopsis)
huntingtin interacting protein 1 related
cyclin T1
serine peptidase inhibitor, Kazal type 2
(acrosin-trypsin inhibitor)
UV radiation resistance associated gene
vacuolar protein sorting 37 homolog B (S.
cerevisiae)
telomeric repeat binding factor 2, interacting
protein
serine peptidase inhibitor, Kazal type 7
(putative)
fms-related tyrosine kinase 3 ligand
BCL2-associated athanogene 4
chromosome 4 open reading frame 36
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ACTR6
BAG3
SEMA3E
ATP5L
COL11A2
NT5E
TFIP11
ZFP36
PRPF31
ZBTB20
ZCCHC10
POLR1E
POGZ
SLC25A5

FAM35A
POLR1C
HERC2
ARRDC2
ZBTB24
ZBTB25
RHBDD2

ARP6 actin-related protein 6 homolog (yeast)
BCL2-associated athanogene 3
sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin) 3E
ATP synthase, H+ transporting, mitochondrial
F0 complex, subunit G
collagen, type XI, alpha 2
5'-nucleotidase, ecto (CD73)
tuftelin interacting protein 11
zinc finger protein 36, C3H type, homolog
(mouse)
PRP31 pre-mRNA processing factor 31
homolog (S. cerevisiae)
zinc finger and BTB domain containing 20
zinc finger, CCHC domain containing 10
polymerase (RNA) I polypeptide E, 53kDa
pogo transposable element with ZNF domain
solute carrier family 25 (mitochondrial
carrier; adenine nucleotide translocator),
member 5; solute carrier family 25
(mitochondrial carrier; adenine nucleotide
translocator), member 5 pseudogene 8
family with sequence similarity 35, member
A
polymerase (RNA) I polypeptide C, 30kDa
hect domain and RLD 2
arrestin domain containing 2
zinc finger and BTB domain containing 24
zinc finger and BTB domain containing 25
rhomboid domain containing 2

RAB11FIP4
GZMM
CTNNBIP1
RAB11FIP2
GZMK
C6ORF106
CHMP1B
AVEN
RBM38
SUSD3
GADD45B
FKBP11
SLC27A5
NXT1
BCAT2
YPEL5
POLR2J
STARD10
POLR2D
ZBTB17
POLR2C
SUMO3

RAB11 family interacting protein 4 (class II)
granzyme M (lymphocyte met-ase 1)
catenin, beta interacting protein 1
RAB11 family interacting protein 2 (class I)
granzyme K (granzyme 3; tryptase II)
chromosome 6 open reading frame 106
chromatin modifying protein 1B
apoptosis, caspase activation inhibitor
RNA binding motif protein 38
sushi domain containing 3
growth arrest and DNA-damage-inducible,
beta
FK506 binding protein 11, 19 kDa
solute carrier family 27 (fatty acid
transporter), member 5
NTF2-like export factor 1
branched chain aminotransferase 2,
mitochondrial
yippee-like 5 (Drosophila)
polymerase (RNA) II (DNA directed)
polypeptide J, 13.3kDa
StAR-related lipid transfer (START) domain
containing 10
polymerase (RNA) II (DNA directed)
polypeptide D
zinc finger and BTB domain containing 17
polymerase (RNA) II (DNA directed)
polypeptide C, 33kDa
SMT3 suppressor of mif two 3 homolog 2 (S.
cerevisiae) pseudogene; SMT3 suppressor of
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ZFP36L2
C12ORF45
PLCL1
ZDHHC23
TOE1
NR1D2
ANKRD39
BCL11B
BCL11A
APBA2
BCL9L
BCAS2
CSNK1A1
JARID2
C10ORF35
BCKDHB
CD1C
BIRC6
ILF3
ITPR3
APRT
KHK

mif two 3 homolog 2 (S. cerevisiae); SMT3
suppressor of mif two 3 homolog 3 (S.
cerevisiae)
zinc finger protein 36, C3H type-like 2
chromosome 12 open reading frame 45
phospholipase C-like 1
zinc finger, DHHC-type containing 23
target of EGR1, member 1 (nuclear)
nuclear receptor subfamily 1, group D,
member 2
ankyrin repeat domain 39
B-cell CLL/lymphoma 11B (zinc finger
protein)
B-cell CLL/lymphoma 11A (zinc finger
protein)
amyloid beta (A4) precursor protein-binding,
family A, member 2
B-cell CLL/lymphoma 9-like
breast carcinoma amplified sequence 2
casein kinase 1, alpha 1
jumonji, AT rich interactive domain 2
chromosome 10 open reading frame 35
branched chain keto acid dehydrogenase E1,
beta polypeptide
CD1c molecule
baculoviral IAP repeat-containing 6
interleukin enhancer binding factor 3, 90kDa
inositol 1,4,5-triphosphate receptor, type 3
adenine phosphoribosyltransferase
ketohexokinase (fructokinase)

MRPL22
ILF2
HELB
IFT57
RBM15
TOB1
PBX4
CBX4
SAE1
MMP3
VIPR1
KLHL3
MRPS30
DMPK
KLHL7
DMXL1
GATA3
SRRM2
TARDBP
TFB2M
ROBO3
GABPB2
SATB1
CA11

mitochondrial ribosomal protein L22
interleukin enhancer binding factor 2, 45kDa
helicase (DNA) B
intraflagellar transport 57 homolog
(Chlamydomonas)
RNA binding motif protein 15
transducer of ERBB2, 1
pre-B-cell leukemia homeobox 4
chromobox homolog 4 (Pc class homolog,
Drosophila)
SUMO1 activating enzyme subunit 1
matrix metallopeptidase 3 (stromelysin 1,
progelatinase)
vasoactive intestinal peptide receptor 1
kelch-like 3 (Drosophila)
mitochondrial ribosomal protein S30
dystrophia myotonica-protein kinase
kelch-like 7 (Drosophila)
Dmx-like 1
GATA binding protein 3
serine/arginine repetitive matrix 2;
hypothetical LOC100132779
TAR DNA binding protein
transcription factor B2, mitochondrial
roundabout, axon guidance receptor, homolog
3 (Drosophila)
GA binding protein transcription factor, beta
subunit 2
SATB homeobox 1
carbonic anhydrase XI
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ERP29
SOCS6
MFGE8
SLC25A36
C8ORF58
CLPP
SNRPA
RNF26
SLC38A1
AKAP8
EMP2
PRPS1

PACS1
DERL2
MYL5
BLM
ITGAE

COX7C
GIPC1
ZMYND8
LLGL1
KARS

endoplasmic reticulum protein 29
suppressor of cytokine signaling 6
milk fat globule-EGF factor 8 protein
solute carrier family 25, member 36
chromosome 8 open reading frame 58
ClpP caseinolytic peptidase, ATP-dependent,
proteolytic subunit homolog (E. coli)
small nuclear ribonucleoprotein polypeptide
A
ring finger protein 26
solute carrier family 38, member 1
A kinase (PRKA) anchor protein 8
epithelial membrane protein 2
phosphoribosyl pyrophosphate synthetase 1;
phosphoribosyl pyrophosphate synthetase 1like 1
phosphofurin acidic cluster sorting protein 1
Der1-like domain family, member 2
myosin, light chain 5, regulatory
Bloom syndrome, RecQ helicase-like
integrin, alpha E (antigen CD103, human
mucosal lymphocyte antigen 1; alpha
polypeptide)
cytochrome c oxidase subunit VIIc
GIPC PDZ domain containing family,
member 1
zinc finger, MYND-type containing 8
lethal giant larvae homolog 1 (Drosophila)
lysyl-tRNA synthetase

FXYD7
RRAGC
DAZAP1
PRR7
PPP1R16B
LAPTM5
UBE2D2
BLOC1S2
MTCH1
HARS2

LMTK3
BTF3
NPM3
GLO1
RNF10
UBAP2L
STRBP
AXIN2
CTRL
PARD6A
REEP6

FXYD domain containing ion transport
regulator 7
Ras-related GTP binding C
DAZ associated protein 1
proline rich 7 (synaptic)
protein phosphatase 1, regulatory (inhibitor)
subunit 16B
lysosomal multispanning membrane protein 5
ubiquitin-conjugating enzyme E2D 2
(UBC4/5 homolog, yeast)
biogenesis of lysosomal organelles complex1, subunit 2
mitochondrial carrier homolog 1 (C. elegans)
histidyl-tRNA synthetase 2, mitochondrial
(putative); D-tyrosyl-tRNA deacylase 1
homolog (S. cerevisiae)
lemur tyrosine kinase 3
basic transcription factor 3; basic transcription
factor 3, like 1 pseudogene
nucleophosmin/nucleoplasmin, 3
glyoxalase I
ring finger protein 10
ubiquitin associated protein 2-like
spermatid perinuclear RNA binding protein
axin 2
chymotrypsin-like
par-6 partitioning defective 6 homolog alpha
(C. elegans)
receptor accessory protein 6
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OBSCN
GABARAP
L1
GNRH1
AK1
PTPN4
ZMYM5
GALT
EPHX2
AK2
TOMM40
ABHD14B
EVL
TSN
FOXP4
C8ORF33
ATF7IP2
EIF4B

PHF3
TXNDC11
PHF1
FCAR

obscurin, cytoskeletal calmodulin and titininteracting RhoGEF
GABA(A) receptors associated protein like 3
(pseudogene); GABA(A) receptor-associated
protein like 1
gonadotropin-releasing hormone 1
(luteinizing-releasing hormone)
adenylate kinase 1
protein tyrosine phosphatase, non-receptor
type 4 (megakaryocyte)
zinc finger, MYM-type 5
galactose-1-phosphate uridylyltransferase
epoxide hydrolase 2, cytoplasmic
adenylate kinase 2
translocase of outer mitochondrial membrane
40 homolog (yeast)
abhydrolase domain containing 14B
Enah/Vasp-like
translin
forkhead box P4
chromosome 8 open reading frame 33
activating transcription factor 7 interacting
protein 2
similar to eukaryotic translation initiation
factor 4H; eukaryotic translation initiation
factor 4B
PHD finger protein 3
thioredoxin domain containing 11
PHD finger protein 1
Fc fragment of IgA, receptor for

EIF4H
CYFIP2
GLMN
SPTBN1
CIRBP
COQ10A
KIAA0355
PTPN1
CD79A
SCMH1
HSP90AB1
HPS1
ECHDC2
HUS1B
CXCR3
UQCRFS1

RSRC2
PDCD2
PHC3
CD96
FOS
PCGF2

eukaryotic translation initiation factor 4H
cytoplasmic FMR1 interacting protein 2
glomulin, FKBP associated protein
spectrin, beta, non-erythrocytic 1
cold inducible RNA binding protein
coenzyme Q10 homolog A (S. cerevisiae)
KIAA0355
protein tyrosine phosphatase, non-receptor
type 1
CD79a molecule, immunoglobulin-associated
alpha
sex comb on midleg homolog 1 (Drosophila)
heat shock protein 90kDa alpha (cytosolic),
class B member 1
Hermansky-Pudlak syndrome 1
enoyl Coenzyme A hydratase domain
containing 2
HUS1 checkpoint homolog b (S. pombe)
chemokine (C-X-C motif) receptor 3
ubiquinol-cytochrome c reductase, Rieske
iron-sulfur polypeptide-like 1; ubiquinolcytochrome c reductase, Rieske iron-sulfur
polypeptide 1
arginine/serine-rich coiled-coil 2
programmed cell death 2
polyhomeotic homolog 3 (Drosophila)
CD96 molecule
v-fos FBJ murine osteosarcoma viral
oncogene homolog
polycomb group ring finger 2
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PLEKHB1
KLHL26
PCBP2
NECAP2
NUDT16L1
NECAP1
CNTNAP1
CDK10
LTB
DUS1L
PHC1
PSMD8
PIGA
PSMD9
NRIP3
UBE2A
ALDH5A1
ZNF92
MPP6
PRKCH

pleckstrin homology domain containing,
family B (evectins) member 1
kelch-like 26 (Drosophila)
poly(rC) binding protein 2
NECAP endocytosis associated 2
nudix (nucleoside diphosphate linked moiety
X)-type motif 16-like 1
NECAP endocytosis associated 1
contactin associated protein 1
cyclin-dependent kinase 10
lymphotoxin beta (TNF superfamily, member
3)
dihydrouridine synthase 1-like (S. cerevisiae)
polyhomeotic homolog 1B (Drosophila);
polyhomeotic homolog 1 (Drosophila)
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 8
phosphatidylinositol glycan anchor
biosynthesis, class A
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 9
nuclear receptor interacting protein 3
ubiquitin-conjugating enzyme E2A (RAD6
homolog)
aldehyde dehydrogenase 5 family, member
A1
zinc finger protein 92
membrane protein, palmitoylated 6 (MAGUK
p55 subfamily member 6)
protein kinase C, eta

PIGT

phosphatidylinositol glycan anchor
biosynthesis, class T
LAS1L
LAS1-like (S. cerevisiae)
ARHGAP25 Rho GTPase activating protein 25
NCR3
natural cytotoxicity triggering receptor 3
MCM6
minichromosome maintenance complex
component 6
CCDC51
coiled-coil domain containing 51
IFNAR2
interferon (alpha, beta and omega) receptor 2
JOSD1
Josephin domain containing 1
CTSK
cathepsin K
BTG2
BTG family, member 2
BTG1
B-cell translocation gene 1, anti-proliferative
BTG3
BTG family, member 3
PEBP1
phosphatidylethanolamine binding protein 1
KPNA5
karyopherin alpha 5 (importin alpha 6)
PRNP
prion protein
PPP1R15B
protein phosphatase 1, regulatory (inhibitor)
subunit 15B
C3ORF38
chromosome 3 open reading frame 38
MATR3
matrin 3
CTSF
cathepsin F
GLTSCR2
glioma tumor suppressor candidate region
gene 2; glioma tumor suppressor candidate
region gene 2 pseudogene
GLTSCR1
glioma tumor suppressor candidate region
gene 1
SPOCK2
sparc/osteonectin, cwcv and kazal-like
domains proteoglycan (testican) 2

TNFRSF25
TRA2A
TIPARP
WBSCR22
DNAH1
HECA
CCDC59
SCARF2
MOAP1
CCDC66
FAM107B
SH3GLB2
SAFB
MSI2
ENO3
PIK3R5
PLCD1
YES1
DUS3L
DTX1
L3MBTL3
MAP1A
DTX3
TUBGCP2
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tumor necrosis factor receptor superfamily,
member 25
transformer 2 alpha homolog (Drosophila)
TCDD-inducible poly(ADP-ribose)
polymerase
Williams Beuren syndrome chromosome
region 22
dynein, axonemal, heavy chain 1
headcase homolog (Drosophila)
coiled-coil domain containing 59
scavenger receptor class F, member 2
modulator of apoptosis 1
coiled-coil domain containing 66
family with sequence similarity 107, member
B
SH3-domain GRB2-like endophilin B2
scaffold attachment factor B
musashi homolog 2 (Drosophila)
enolase 3 (beta, muscle)
phosphoinositide-3-kinase, regulatory subunit
5
phospholipase C, delta 1
v-yes-1 Yamaguchi sarcoma viral oncogene
homolog 1
dihydrouridine synthase 3-like (S. cerevisiae)
deltex homolog 1 (Drosophila)
l(3)mbt-like 3 (Drosophila)
microtubule-associated protein 1A
deltex homolog 3 (Drosophila)
tubulin, gamma complex associated protein 2

CCDC69
RALGDS
GPS2
ATXN7L2
CCDC77
TOX
TDP1
ANXA11

coiled-coil domain containing 69
ral guanine nucleotide dissociation stimulator
G protein pathway suppressor 2
ataxin 7-like 2
coiled-coil domain containing 77
thymocyte selection-associated high mobility
group box
tyrosyl-DNA phosphodiesterase 1
annexin A11

PSPC1
SLC5A6
DUS4L
RNF41
IGFBP5
NKX3-1
HLA-DMA

paraspeckle component 1; paraspeckle protein
1 pseudogene
solute carrier family 5 (sodium-dependent
vitamin transporter), member 6
dihydrouridine synthase 4-like (S. cerevisiae)
ring finger protein 41
insulin-like growth factor binding protein 5
NK3 homeobox 1
major histocompatibility complex, class II,
DM alpha

Table 23. Genes that are significantly expressed in PAH samples; and significantly correlated with ID3 in tissue samples (573
genes) from the significant gene list provided from GEO PAH datasets.
Gene
Gene Name
ORAOV1
oral cancer overexpressed 1
Symbol
ADIPOR1
adiponectin receptor 1
PDCD7
programmed cell death 7
ZDHHC7
zinc finger, DHHC-type containing 7
ADM
adrenomedullin
ADAMTS7 similar to hCG1991431; similar to
IGFBP5
insulin-like growth factor binding protein
COMPase; ADAM metallopeptidase with
5
thrombospondin type 1 motif, 7
KCNK17
potassium channel, subfamily K, member
LCE3D
late cornified envelope 3D
17
NES
nestin
DCUN1D2
DCN1, defective in cullin neddylation 1,
PCDH10
protocadherin 10
domain containing 2 (S. cerevisiae)
CLPTM1
cleft lip and palate associated
UBP1
upstream binding protein 1 (LBP-1a)
transmembrane protein 1
C19orf25
chromosome 19 open reading frame 25
MCM3AP
minichromosome maintenance complex
ARMCX6
similar to armadillo repeat containing, Xcomponent 3 associated protein
linked 6; armadillo repeat containing, XASB8
ankyrin repeat and SOCS box-containing
linked 6
8
NOTCH4
Notch homolog 4 (Drosophila)
GIMAP6
GTPase, IMAP family member 6
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DALRD3
LOXL3
RHOT2
SORBS2
ARHGEF10
FADS3
POLR2C
LRRC25
GFM1
EXTL3
NSD1
STMN1
TMEM80
MS4A3

ANK1
ETFB
NMUR1
FOXA2
FHOD1
SEMA4G

DALR anticodon binding domain
containing 3
lysyl oxidase-like 3
ras homolog gene family, member T2
sorbin and SH3 domain containing 2
Rho guanine nucleotide exchange factor
(GEF) 10
fatty acid desaturase 3
polymerase (RNA) II (DNA directed)
polypeptide C, 33kDa
leucine rich repeat containing 25
G elongation factor, mitochondrial 1
exostoses (multiple)-like 3
nuclear receptor binding SET domain
protein 1
stathmin 1
transmembrane protein 80
membrane-spanning 4-domains,
subfamily A, member 3 (hematopoietic
cell-specific)
ankyrin 1, erythrocytic
electron-transfer-flavoprotein, beta
polypeptide
neuromedin U receptor 1
forkhead box A2
formin homology 2 domain containing 1
sema domain, immunoglobulin domain
(Ig), transmembrane domain (TM) and
short cytoplasmic domain, (semaphorin)
4G

HIST1H1E
PAOX
IDH3B
DNAL4
PRRG1
RASSF3
PKP4
SNX1
AMPH
USP21
COL4A3
LUC7L
DUT
CWF19L1
IL2
ZNF503
ARHGAP6
TNFSF10
IER2
B3GALNT1

MRPL45
IDH2
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histone cluster 1, H1e
polyamine oxidase (exo-N4-amino)
isocitrate dehydrogenase 3 (NAD+) beta
dynein, axonemal, light chain 4
proline rich Gla (G-carboxyglutamic
acid) 1
Ras association (RalGDS/AF-6) domain
family member 3
plakophilin 4
sorting nexin 1
amphiphysin
ubiquitin specific peptidase 21
collagen, type IV, alpha 3 (Goodpasture
antigen)
LUC7-like (S. cerevisiae)
deoxyuridine triphosphatase
CWF19-like 1, cell cycle control (S.
pombe)
interleukin 2
zinc finger protein 503
Rho GTPase activating protein 6
tumor necrosis factor (ligand)
superfamily, member 10
immediate early response 2
beta-1,3-Nacetylgalactosaminyltransferase 1
(globoside blood group)
mitochondrial ribosomal protein L45
isocitrate dehydrogenase 2 (NADP+),
mitochondrial

AFF2
ZFP37
SOX13
RGL2
GUCY1B3
CSF3R
SSU72
MAPKAP1
PARVB
GNAI1

RAC1

AKR7A3
NOTCH1
FBXO17
OTOS
TBX4
MRE11A
ZNF117
PAXIP1

AF4/FMR2 family, member 2
zinc finger protein 37 homolog (mouse)
SRY (sex determining region Y)-box 13
ral guanine nucleotide dissociation
stimulator-like 2
guanylate cyclase 1, soluble, beta 3
colony stimulating factor 3 receptor
(granulocyte)
SSU72 RNA polymerase II CTD
phosphatase homolog (S. cerevisiae)
mitogen-activated protein kinase
associated protein 1
parvin, beta
guanine nucleotide binding protein (G
protein), alpha inhibiting activity
polypeptide 1
ras-related C3 botulinum toxin substrate
1 (rho family, small GTP binding protein
Rac1)
aldo-keto reductase family 7, member A3
(aflatoxin aldehyde reductase)
Notch homolog 1, translocationassociated (Drosophila)
F-box protein 17
otospiralin
T-box 4
MRE11 meiotic recombination 11
homolog A (S. cerevisiae)
zinc finger protein 117
PAX interacting (with transcriptionactivation domain) protein 1

EFNA4
FGF12
DCAKD
TRAF3IP3
STAT5B
HEXA
FAM127B
REM1
NKD1
NRG2
STAB1
DAP
ACSS2
FKBP8
RNASE3
RABEP1
CDH24
CLK2
AHNAK
LDOC1
GNL3
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ephrin-A4
fibroblast growth factor 12
dephospho-CoA kinase domain
containing
TRAF3 interacting protein 3
signal transducer and activator of
transcription 5B
hexosaminidase A (alpha polypeptide)
family with sequence similarity 127,
member B
RAS (RAD and GEM)-like GTP-binding
1
naked cuticle homolog 1 (Drosophila)
neuregulin 2
stabilin 1
death-associated protein
acyl-CoA synthetase short-chain family
member 2
FK506 binding protein 8, 38kDa
ribonuclease, RNase A family, 3
(eosinophil cationic protein)
rabaptin, RAB GTPase binding effector
protein 1
cadherin-like 24
CDC-like kinase 2
AHNAK nucleoprotein
leucine zipper, down-regulated in cancer
1
guanine nucleotide binding protein-like 3
(nucleolar)

ANGPT1
EIF2B1
ZNF687
USP5
GABBR1
DLGAP3
CSRP1
PRKCDBP
EXTL2
RFC4
FBXW4
FOXK1
TMEM98
GPRC5C
BCL9L
ADCY6
RERE
SLC25A23
AGER

angiopoietin 1
eukaryotic translation initiation factor
2B, subunit 1 alpha, 26kDa
zinc finger protein 687
ubiquitin specific peptidase 5
(isopeptidase T)
gamma-aminobutyric acid (GABA) B
receptor, 1
discs, large (Drosophila) homologassociated protein 3
cysteine and glycine-rich protein 1
protein kinase C, delta binding protein
exostoses (multiple)-like 2
replication factor C (activator 1) 4,
37kDa
F-box and WD repeat domain containing
4
forkhead box K1
similar to transmembrane protein 98;
transmembrane protein 98
G protein-coupled receptor, family C,
group 5, member C
B-cell CLL/lymphoma 9-like
adenylate cyclase 6
arginine-glutamic acid dipeptide (RE)
repeats
solute carrier family 25 (mitochondrial
carrier; phosphate carrier), member 23
advanced glycosylation end productspecific receptor

CTTNBP2N CTTNBP2 N-terminal like
L
MRGPRF
MAS-related GPR, member F
AKT1
v-akt murine thymoma viral oncogene
homolog 1
TSKS
testis-specific serine kinase substrate
ADCY4
adenylate cyclase 4
TTLL7
tubulin tyrosine ligase-like family,
member 7
TAF1C
TATA box binding protein (TBP)associated factor, RNA polymerase I, C,
110kDa
EHBP1
EH domain binding protein 1
CAMK1
calcium/calmodulin-dependent protein
kinase I
MAN2A2
mannosidase, alpha, class 2A, member 2
PIGO
phosphatidylinositol glycan anchor
biosynthesis, class O
RNF43
ring finger protein 43
TNRC6C
trinucleotide repeat containing 6C
TLCD1
TLC domain containing 1
ZCCHC9
zinc finger, CCHC domain containing 9
ATP5G3
ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit C3
(subunit 9)
TMCO3
transmembrane and coiled-coil domains 3
PTDSS1
phosphatidylserine synthase 1
XYLT2
xylosyltransferase II
AGGF1
angiogenic factor with G patch and FHA
domains 1
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RAVER1
CDT1
SLC35A5
TRIM32
EPDR1
RSPO2
PPCDC
NEK3
NEDD4
AGTR1
LDLRAP1
ZNF429
ZNF672
POLE
IMPA2
ZNF781
GNPDA1
CDKN1C
FCN3
TFAP4
MAGEH1

ribonucleoprotein, PTB-binding 1
chromatin licensing and DNA replication
factor 1
solute carrier family 35, member A5
tripartite motif-containing 32
ependymin related protein 1 (zebrafish)
R-spondin 2 homolog (Xenopus laevis)
phosphopantothenoylcysteine
decarboxylase
NIMA (never in mitosis gene a)-related
kinase 3
neural precursor cell expressed,
developmentally down-regulated 4
angiotensin II receptor, type 1
low density lipoprotein receptor adaptor
protein 1
zinc finger protein 429
zinc finger protein 672; hypothetical
LOC100130262
polymerase (DNA directed), epsilon
inositol(myo)-1(or 4)-monophosphatase 2
zinc finger protein 781
glucosamine-6-phosphate deaminase 1
cyclin-dependent kinase inhibitor 1C
(p57, Kip2)
ficolin (collagen/fibrinogen domain
containing) 3 (Hakata antigen)
transcription factor AP-4 (activating
enhancer binding protein 4)
melanoma antigen family H, 1

TINAGL1
ELOVL5

NFYB
VPS26B
UBE2Q1
PECR
SMG6
HIST1H4L
HIST1H4D
SCAMP2
STX6
LOXL4
GNPAT
ATP5B

PEX16
CDC25B
GNS
METTL4
IGF2R
DCN
GANAB
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tubulointerstitial nephritis antigen-like 1
ELOVL family member 5, elongation of
long chain fatty acids (FEN1/Elo2,
SUR4/Elo3-like, yeast)
nuclear transcription factor Y, beta
vacuolar protein sorting 26 homolog B
(S. pombe)
ubiquitin-conjugating enzyme E2Q
family member 1
peroxisomal trans-2-enoyl-CoA reductase
Smg-6 homolog, nonsense mediated
mRNA decay factor (C. elegans)
histone cluster 1, H4l
histone cluster 1, H4d
secretory carrier membrane protein 2
syntaxin 6
lysyl oxidase-like 4
glyceronephosphate O-acyltransferase
ATP synthase, H+ transporting,
mitochondrial F1 complex, beta
polypeptide
peroxisomal biogenesis factor 16
cell division cycle 25 homolog B (S.
pombe)
glucosamine (N-acetyl)-6-sulfatase
methyltransferase like 4
insulin-like growth factor 2 receptor
decorin
glucosidase, alpha; neutral AB

AP2M1
CCL26
DNAJC15
GPS2
SCAMP1
ADRA1B
MMRN1
PCTP
OBFC1
MRPS18A
MRPS14
TUBAL3
TXN2
MUS81
STX10
SF3B1
COG1
SLC44A1
METAP1
EVC
DOCK6
GPR161
TK2
TCEAL4

adaptor-related protein complex 2, mu 1
subunit
chemokine (C-C motif) ligand 26
DnaJ (Hsp40) homolog, subfamily C,
member 15
G protein pathway suppressor 2
secretory carrier membrane protein 1
adrenergic, alpha-1B-, receptor
multimerin 1
phosphatidylcholine transfer protein
oligonucleotide/oligosaccharide-binding
fold containing 1
mitochondrial ribosomal protein S18A
mitochondrial ribosomal protein S14
tubulin, alpha-like 3
thioredoxin 2
MUS81 endonuclease homolog (S.
cerevisiae)
syntaxin 10
splicing factor 3b, subunit 1, 155kDa
component of oligomeric golgi complex
1
solute carrier family 44, member 1
methionyl aminopeptidase 1
Ellis van Creveld syndrome
dedicator of cytokinesis 6
G protein-coupled receptor 161
thymidine kinase 2, mitochondrial
transcription elongation factor A (SII)like 4

RAB40C
DUSP7
SLCO4C1
NSUN5
PARS2
C6orf106
TUSC2
OPN3
CYP4F12

TSPAN7
ZFP2
EPAS1
ACTN4
STRN4
VPS41
IRF2
SCN1B
SEC14L3
TPM1
SEMA3F
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RAB40C, member RAS oncogene family
dual specificity phosphatase 7
solute carrier organic anion transporter
family, member 4C1
NOL1/NOP2/Sun domain family,
member 5
prolyl-tRNA synthetase 2, mitochondrial
(putative)
chromosome 6 open reading frame 106
tumor suppressor candidate 2
opsin 3
similar to cytochrome P450, family 4,
subfamily F, polypeptide 12; cytochrome
P450, family 4, subfamily F, polypeptide
12
tetraspanin 7
zinc finger protein 2 homolog (mouse)
endothelial PAS domain protein 1
actinin, alpha 4
striatin, calmodulin binding protein 4
vacuolar protein sorting 41 homolog (S.
cerevisiae)
interferon regulatory factor 2
sodium channel, voltage-gated, type I,
beta
SEC14-like 3 (S. cerevisiae)
tropomyosin 1 (alpha)
sema domain, immunoglobulin domain
(Ig), short basic domain, secreted,
(semaphorin) 3F

VEGFB
ZMAT2
TMEM11
FMO2
VAMP2
SEMA6C

PTPRB
TMLHE
TEX261
TRIM44
PHF2
GGT6
ATP6V1E1
RBP1
ZNF311
CEP63
FASTKD3
IRS2
TRIB2
DSCR3
DNASE1L1
RBM5
ZNF512

vascular endothelial growth factor B
zinc finger, matrin type 2
transmembrane protein 11
flavin containing monooxygenase 2 (nonfunctional)
vesicle-associated membrane protein 2
(synaptobrevin 2)
sema domain, transmembrane domain
(TM), and cytoplasmic domain,
(semaphorin) 6C
protein tyrosine phosphatase, receptor
type, B
trimethyllysine hydroxylase, epsilon
testis expressed 261
tripartite motif-containing 44
PHD finger protein 2
gamma-glutamyltransferase 6
ATPase, H+ transporting, lysosomal
31kDa, V1 subunit E1
retinol binding protein 1, cellular
zinc finger protein 311
centrosomal protein 63kDa
FAST kinase domains 3
insulin receptor substrate 2
tribbles homolog 2 (Drosophila)
Down syndrome critical region gene 3
deoxyribonuclease I-like 1
RNA binding motif protein 5
zinc finger protein 512

MAP3K11
DDX41
MORC3
VPS52
TMUB2
APEX1
MMACHC

COPS5
MED12
ZFHX4
BANF1
LZIC
DYSF
TTC13
NFKBIL1
ANKRD49
CHD8
CSN3
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mitogen-activated protein kinase kinase
kinase 11
DEAD (Asp-Glu-Ala-Asp) box
polypeptide 41
MORC family CW-type zinc finger 3
vacuolar protein sorting 52 homolog (S.
cerevisiae)
transmembrane and ubiquitin-like
domain containing 2
APEX nuclease (multifunctional DNA
repair enzyme) 1
methylmalonic aciduria (cobalamin
deficiency) cblC type, with
homocystinuria
COP9 constitutive photomorphogenic
homolog subunit 5 (Arabidopsis)
mediator complex subunit 12
zinc finger homeobox 4
similar to barrier-to-autointegration
factor; barrier to autointegration factor 1
leucine zipper and CTNNBIP1 domain
containing
dysferlin, limb girdle muscular dystrophy
2B (autosomal recessive)
tetratricopeptide repeat domain 13
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor-like 1
ankyrin repeat domain 49
chromodomain helicase DNA binding
protein 8
casein kappa

RALA
SPPL2B
CASKIN1
RSRC1
GPAA1
CAMKK2
CEP68
IL17RE
GMEB2
ZFP64
PLEKHA6
CPT1A
ZW10
NKTR
LASP1
GJB1
PPP1R3C
CXXC4
TOP2B
RBM23
RETSAT
SPTBN1

v-ral simian leukemia viral oncogene
homolog A (ras related)
signal peptide peptidase-like 2B
CASK interacting protein 1
arginine/serine-rich coiled-coil 1
glycosylphosphatidylinositol anchor
attachment protein 1 homolog (yeast)
calcium/calmodulin-dependent protein
kinase kinase 2, beta
centrosomal protein 68kDa
interleukin 17 receptor E
glucocorticoid modulatory element
binding protein 2
zinc finger protein 64 homolog (mouse)
pleckstrin homology domain containing,
family A member 6
carnitine palmitoyltransferase 1A (liver)
ZW10, kinetochore associated, homolog
(Drosophila)
natural killer-tumor recognition sequence
LIM and SH3 protein 1
gap junction protein, beta 1, 32kDa
protein phosphatase 1, regulatory
(inhibitor) subunit 3C
CXXC finger 4
topoisomerase (DNA) II beta 180kDa
RNA binding motif protein 23
retinol saturase (all-trans-retinol 13,14reductase)
spectrin, beta, non-erythrocytic 1

DFFB
DMPK
GAB3
TTC9C
INPP5A
THYN1
RIMS3
PHB
DECR2
CANX
ARHGAP9
LRRC28
BSDC1
STK38
SIRT5
PDE5A
SRP14
SLC12A4

LHPP
EPRS
NAT2
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DNA fragmentation factor, 40kDa, beta
polypeptide (caspase-activated DNase)
dystrophia myotonica-protein kinase
GRB2-associated binding protein 3
tetratricopeptide repeat domain 9C
inositol polyphosphate-5-phosphatase,
40kDa
thymocyte nuclear protein 1
regulating synaptic membrane exocytosis
3
prohibitin
2,4-dienoyl CoA reductase 2,
peroxisomal
calnexin
Rho GTPase activating protein 9
leucine rich repeat containing 28
BSD domain containing 1
serine/threonine kinase 38
sirtuin (silent mating type information
regulation 2 homolog) 5 (S. cerevisiae)
phosphodiesterase 5A, cGMP-specific
signal recognition particle 14kDa
solute carrier family 12
(potassium/chloride transporters),
member 4
phospholysine phosphohistidine
inorganic pyrophosphate phosphatase
glutamyl-prolyl-tRNA synthetase
N-acetyltransferase 2 (arylamine Nacetyltransferase)

DHX16
ALG6

TMEM109
CENPB
USP46
NOTUM
TCF12
SPINT2
SHPRH
OSGEPL1
ATP10D
ALDH1L2
TTC23
KRT10
ID3
SH3KBP1
SLC26A6
DLL4
MRPL46
BFAR
SERINC3
CRNKL1
ST5

DEAH (Asp-Glu-Ala-His) box
polypeptide 16
asparagine-linked glycosylation 6, alpha1,3-glucosyltransferase homolog (S.
cerevisiae)
transmembrane protein 109
centromere protein B, 80kDa
ubiquitin specific peptidase 46
notum pectinacetylesterase homolog
(Drosophila)
transcription factor 12
serine peptidase inhibitor, Kunitz type, 2
SNF2 histone linker PHD RING helicase
O-sialoglycoprotein endopeptidase-like 1
ATPase, class V, type 10D
aldehyde dehydrogenase 1 family,
member L2
tetratricopeptide repeat domain 23
keratin 10
inhibitor of DNA binding 3, dominant
negative helix-loop-helix protein
SH3-domain kinase binding protein 1
solute carrier family 26, member 6
delta-like 4 (Drosophila)
mitochondrial ribosomal protein L46
bifunctional apoptosis regulator
serine incorporator 3
crooked neck pre-mRNA splicing factorlike 1 (Drosophila)
suppression of tumorigenicity 5

LCMT2
ARHGEF2
SCRN2
CA4
BPGM
HAAO
SLC7A9
TCF19
PPM1M
WDR20
HECW2
HIC2
PCSK7

RPL8
SH3BGRL
GAPVD1
SLC5A5
SLC43A1
ADAMTS2
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leucine carboxyl methyltransferase 2
Rho/Rac guanine nucleotide exchange
factor (GEF) 2
secernin 2
carbonic anhydrase IV
2,3-bisphosphoglycerate mutase
3-hydroxyanthranilate 3,4-dioxygenase
solute carrier family 7 (cationic amino
acid transporter, y+ system), member 9
transcription factor 19
protein phosphatase 1M (PP2C domain
containing)
WD repeat domain 20
HECT, C2 and WW domain containing
E3 ubiquitin protein ligase 2
hypermethylated in cancer 2
proprotein convertase subtilisin/kexin
type 7 pseudogene; proprotein convertase
subtilisin/kexin type 7
ribosomal protein L8; ribosomal protein
L8 pseudogene 2
SH3 domain binding glutamic acid-rich
protein like
GTPase activating protein and VPS9
domains 1
solute carrier family 5 (sodium iodide
symporter), member 5
solute carrier family 43, member 1
ADAM metallopeptidase with
thrombospondin type 1 motif, 2

NGRN
CHRNB2

neugrin, neurite outgrowth associated
cholinergic receptor, nicotinic, beta 2
(neuronal)
CARD10
caspase recruitment domain family,
member 10
IKBKE
inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase epsilon
ZNF211
zinc finger protein 211
CTDSP2
similar to hCG2013701; CTD (carboxyterminal domain, RNA polymerase II,
polypeptide A) small phosphatase 2
SMOC1
SPARC related modular calcium binding
1
TMEM9
transmembrane protein 9
COG2
component of oligomeric golgi complex
2
PLCD3
phospholipase C, delta 3
CDYL
chromodomain protein, Y-like
ZNF630
zinc finger protein 630
STARD3NL STARD3 N-terminal like
TFEB
transcription factor EB
ATP11C
ATPase, class VI, type 11C
BBS1
Bardet-Biedl syndrome 1
SAE1
SUMO1 activating enzyme subunit 1
ACACB
acetyl-Coenzyme A carboxylase beta
FIS1
fission 1 (mitochondrial outer membrane)
homolog (S. cerevisiae)
OLFM4
olfactomedin 4
NR3C1
nuclear receptor subfamily 3, group C,
member 1 (glucocorticoid receptor)

ALS2CL
FGD5
CASP2
CCDC8
GATA2
CPNE2
PSRC1
KCTD15
IL22RA1
CARD8
C11orf49
PECAM1
MSC
CECR6
CYP4V2
NDRG4
SF3B2
RREB1
PKN1
TTYH3
PTPN9
ILVBL
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ALS2 C-terminal like
FYVE, RhoGEF and PH domain
containing 5
caspase 2, apoptosis-related cysteine
peptidase
coiled-coil domain containing 8
GATA binding protein 2
copine II
proline/serine-rich coiled-coil 1
potassium channel tetramerisation
domain containing 15
interleukin 22 receptor, alpha 1
caspase recruitment domain family,
member 8
chromosome 11 open reading frame 49
platelet/endothelial cell adhesion
molecule
musculin (activated B-cell factor-1)
cat eye syndrome chromosome region,
candidate 6
cytochrome P450, family 4, subfamily V,
polypeptide 2
NDRG family member 4
splicing factor 3b, subunit 2, 145kDa
ras responsive element binding protein 1
protein kinase N1
tweety homolog 3 (Drosophila)
protein tyrosine phosphatase, nonreceptor type 9
ilvB (bacterial acetolactate synthase)-like

RPA2
COPS6
NIF3L1
SYT17
TMEM69
SYPL1
EMP1
SAMM50
CCT7
TM7SF2
GJA5
CYBRD1
ARHGAP4
TDRD10
GPR107
ASF1A
HARS2
VPS37D
GSTA4
PHACTR2
TSSC1
DNAJB12

replication protein A2, 32kDa
COP9 constitutive photomorphogenic
homolog subunit 6 (Arabidopsis)
NIF3 NGG1 interacting factor 3-like 1
(S. pombe)
synaptotagmin XVII; synaptotagmin VII
transmembrane protein 69
synaptophysin-like 1
epithelial membrane protein 1
sorting and assembly machinery
component 50 homolog (S. cerevisiae)
chaperonin containing TCP1, subunit 7
(eta)
transmembrane 7 superfamily member 2
gap junction protein, alpha 5, 40kDa
cytochrome b reductase 1
Rho GTPase activating protein 4
tudor domain containing 10
G protein-coupled receptor 107
ASF1 anti-silencing function 1 homolog
A (S. cerevisiae)
histidyl-tRNA synthetase 2
vacuolar protein sorting 37 homolog D
(S. cerevisiae)
glutathione S-transferase alpha 4
phosphatase and actin regulator 2
tumor suppressing subtransferable
candidate 1
DnaJ (Hsp40) homolog, subfamily B,
member 12

NRGN
DRD4
MAP3K13
CYP2R1
DIXDC1
NOSTRIN
LRMP
ACOX3
TXNDC11
ZNF333
ARHGAP1
LHFP
GTF2E1
RASGRP2
LBH
PTPN6
CIDEB
ARHGEF6
LTK
DNAJC4
UGDH
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neurogranin (protein kinase C substrate,
RC3)
dopamine receptor D4
mitogen-activated protein kinase kinase
kinase 13
cytochrome P450, family 2, subfamily R,
polypeptide 1
DIX domain containing 1
nitric oxide synthase trafficker
lymphoid-restricted membrane protein
acyl-Coenzyme A oxidase 3, pristanoyl
thioredoxin domain containing 11
zinc finger protein 333
Rho GTPase activating protein 1
lipoma HMGIC fusion partner
general transcription factor IIE,
polypeptide 1, alpha 56kDa
RAS guanyl releasing protein 2 (calcium
and DAG-regulated)
limb bud and heart development homolog
(mouse)
protein tyrosine phosphatase, nonreceptor type 6
cell death-inducing DFFA-like effector b
Rac/Cdc42 guanine nucleotide exchange
factor (GEF) 6
leukocyte receptor tyrosine kinase
DnaJ (Hsp40) homolog, subfamily C,
member 4
UDP-glucose dehydrogenase

RASSF1
HYAL1
HES7
LETMD1
STON2
SCARF1
MANEA
TOB2
C1orf116
COG4
PPIE
RCBTB1

C10orf10
RHBDF1
CPS1
ABLIM3
RAPGEF1
FADS2
EXOC4
SLC4A2

Ras association (RalGDS/AF-6) domain
family member 1
hyaluronoglucosaminidase 1
hairy and enhancer of split 7 (Drosophila)
LETM1 domain containing 1
stonin 2
scavenger receptor class F, member 1
mannosidase, endo-alpha
transducer of ERBB2, 2
chromosome 1 open reading frame 116
component of oligomeric golgi complex
4
peptidylprolyl isomerase E (cyclophilin
E)
regulator of chromosome condensation
(RCC1) and BTB (POZ) domain
containing protein 1
chromosome 10 open reading frame 10
rhomboid 5 homolog 1 (Drosophila)
carbamoyl-phosphate synthetase 1,
mitochondrial
actin binding LIM protein family,
member 3
Rap guanine nucleotide exchange factor
(GEF) 1
fatty acid desaturase 2
exocyst complex component 4
solute carrier family 4, anion exchanger,
member 2 (erythrocyte membrane protein
band 3-like 1)

TNRC6B
RGL1
BTG3
PURA
2-Mar
PTGIS
COPS7A
KCNJ10
MPPE1
H1FX
TMCO6
SLC16A11
ZNF76
AVPI1
ZNF609
FIGNL1
TRAF7
DVL3
MAN2C1
ADAT1
FOXF2
RAB26
OR8B8
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trinucleotide repeat containing 6B
ral guanine nucleotide dissociation
stimulator-like 1
BTG family, member 3
purine-rich element binding protein A
membrane-associated ring finger
(C3HC4) 2
prostaglandin I2 (prostacyclin) synthase
COP9 constitutive photomorphogenic
homolog subunit 7A (Arabidopsis)
potassium inwardly-rectifying channel,
subfamily J, member 10
metallophosphoesterase 1
H1 histone family, member X
transmembrane and coiled-coil domains 6
solute carrier family 16, member 11
(monocarboxylic acid transporter 11)
zinc finger protein 76 (expressed in
testis)
arginine vasopressin-induced 1
zinc finger protein 609
fidgetin-like 1
TNF receptor-associated factor 7
dishevelled, dsh homolog 3 (Drosophila)
mannosidase, alpha, class 2C, member 1
adenosine deaminase, tRNA-specific 1
forkhead box F2
RAB26, member RAS oncogene family
olfactory receptor, family 8, subfamily B,
member 8

CTNS
RXRB
PEX11A
SNTA1

NISCH
ATOH8
PRMT2
CD1D
GRTP1
RNF146
JAG2
LAMA5
DCTN1
MMP2

ZSWIM1
ZFYVE19
PTPRM
SLC35D2
SLCO2A1
ATG16L2
SS18L2

cystinosis, nephropathic
retinoid X receptor, beta
peroxisomal biogenesis factor 11 alpha
syntrophin, alpha 1 (dystrophinassociated protein A1, 59kDa, acidic
component)
nischarin
atonal homolog 8 (Drosophila)
protein arginine methyltransferase 2
CD1d molecule
growth hormone regulated TBC protein 1
ring finger protein 146
jagged 2
laminin, alpha 5
dynactin 1 (p150, glued homolog,
Drosophila)
matrix metallopeptidase 2 (gelatinase A,
72kDa gelatinase, 72kDa type IV
collagenase)
zinc finger, SWIM-type containing 1
zinc finger, FYVE domain containing 19
protein tyrosine phosphatase, receptor
type, M
solute carrier family 35, member D2
solute carrier organic anion transporter
family, member 2A1
ATG16 autophagy related 16-like 2 (S.
cerevisiae)
synovial sarcoma translocation gene on
chromosome 18-like 2

ESD
NPM2
PIGC
ANGEL1
SFXN3
USP19
CCNB1IP1
SDS
PRKCH
C11orf71
PODXL
ARRDC1
HDAC1
CX3CR1
TSPAN10
NEK8
SDHB
RB1
MVD
ASH2L
CXXC1
INPP5B
WDR45
MYH9
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esterase D/formylglutathione hydrolase
nucleophosmin/nucleoplasmin, 2
phosphatidylinositol glycan anchor
biosynthesis, class C
angel homolog 1 (Drosophila)
sideroflexin 3
ubiquitin specific peptidase 19
cyclin B1 interacting protein 1
serine dehydratase
protein kinase C, eta
chromosome 11 open reading frame 71
podocalyxin-like
arrestin domain containing 1
histone deacetylase 1
chemokine (C-X3-C motif) receptor 1
tetraspanin 10
NIMA (never in mitosis gene a)- related
kinase 8
succinate dehydrogenase complex,
subunit B, iron sulfur (Ip)
retinoblastoma 1
mevalonate (diphospho) decarboxylase
ash2 (absent, small, or homeotic)-like
(Drosophila)
CXXC finger 1 (PHD domain)
inositol polyphosphate-5-phosphatase,
75kDa
WD repeat domain 45
myosin, heavy chain 9, non-muscle

HPS3
JAM3
PPP2R5A
ZFAND2B
CHMP2A
ETV5
PDE9A
GLO1
TEX264
SYNCRIP
PHKB
CYFIP1
CCS
ZBTB4
HLF
DPF2
AES
EIF4B

TACC3
SDF4
ZCCHC3
NR2F1

Hermansky-Pudlak syndrome 3
junctional adhesion molecule 3
protein phosphatase 2, regulatory subunit
B', alpha isoform
zinc finger, AN1-type domain 2B
chromatin modifying protein 2A
ets variant 5
phosphodiesterase 9A
glyoxalase I
testis expressed 264
synaptotagmin binding, cytoplasmic
RNA interacting protein
phosphorylase kinase, beta
cytoplasmic FMR1 interacting protein 1
copper chaperone for superoxide
dismutase
zinc finger and BTB domain containing 4
hepatic leukemia factor
D4, zinc and double PHD fingers family
2
amino-terminal enhancer of split
similar to eukaryotic translation initiation
factor 4H; eukaryotic translation
initiation factor 4B
transforming, acidic coiled-coil
containing protein 3
stromal cell derived factor 4
zinc finger, CCHC domain containing 3
nuclear receptor subfamily 2, group F,
member 1

RAVER2
CRYZL1
PTGDR
DDX21
ADARB1
PAX4
CDC37
PUM2
LSS
CNNM3
SPSB3
MGAT1
RACGAP1

GOT2

PDE7A
PON3
DNASE1L2
TIMP3
TMEM42

149

ribonucleoprotein, PTB-binding 2
crystallin, zeta (quinone reductase)-like 1
prostaglandin D2 receptor (DP)
DEAD (Asp-Glu-Ala-Asp) box
polypeptide 21
adenosine deaminase, RNA-specific, B1
(RED1 homolog rat)
paired box 4
cell division cycle 37 homolog (S.
cerevisiae)
pumilio homolog 2 (Drosophila)
lanosterol synthase (2,3-oxidosqualenelanosterol cyclase)
cyclin M3
splA/ryanodine receptor domain and
SOCS box containing 3
mannosyl (alpha-1,3-)-glycoprotein beta1,2-N-acetylglucosaminyltransferase
Rac GTPase activating protein 1
pseudogene; Rac GTPase activating
protein 1
glutamic-oxaloacetic transaminase 2,
mitochondrial (aspartate
aminotransferase 2)
phosphodiesterase 7A
paraoxonase 3
deoxyribonuclease I-like 2
TIMP metallopeptidase inhibitor 3
transmembrane protein 42

CACNA1E
LRP6

calcium channel, voltage-dependent, R
type, alpha 1E subunit
low density lipoprotein receptor-related
protein 6

FARP1

UROD

FERM, RhoGEF (ARHGEF) and
pleckstrin domain protein 1
(chondrocyte-derived)
uroporphyrinogen decarboxylase

Table 24. Common genes between (significantly expressed genes in PAH and ID3 correlated, blood samples), and
((significantly expressed genes in PAH and ID3 correlated, tissue) (28 genes) from the significant gene list provided from
GEO PAH datasets
Gene
Gene Name
SPTBN1
spectrin, beta, non-erythrocytic 1
Symbol
EIF4B
similar to eukaryotic translation initiation
MRPL46
mitochondrial ribosomal protein L46
factor 4H; eukaryotic translation initiation
factor 4B
HIC2
hypermethylated in cancer 2
GPS2
G protein pathway suppressor 2
PTDSS1
phosphatidylserine synthase 1
H1FX
H1 histone family, member X
BCL9L
B-cell CLL/lymphoma 9-like
VEGFB
vascular endothelial growth factor B
TXNDC11 thioredoxin domain containing 11
PRKCH
protein kinase C, eta
IER2
immediate early response 2
VAMP2
vesicle-associated membrane protein 2
HARS2
histidyl-tRNA synthetase 2, mitochondrial
(synaptobrevin 2)
(putative); D-tyrosyl-tRNA deacylase 1
DMPK
dystrophia myotonica-protein kinase
homolog (S. cerevisiae)
SRP14
signal recognition particle 14kDa
NGRN
neugrin, neurite outgrowth associated
(homologous Alu RNA binding protein)
C6orf106
chromosome 6 open reading frame 106
pseudogene 1; signal recognition particle
SAE1
SUMO1 activating enzyme subunit 1
14kDa (homologous Alu RNA binding
GLO1
glyoxalase I
protein)
KRT10
keratin 10
BTG3
BTG family, member 3
ID3
inhibitor of DNA binding 3, dominant
IGFBP5
insulin-like growth factor binding protein
negative helix-loop-helix protein
5
GMEB2
glucocorticoid modulatory element
POLR2C
polymerase (RNA) II (DNA directed)
binding protein 2
polypeptide C, 33kDa
LAMA5
laminin, alpha 5
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WDR20

WD repeat domain 20
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Blood Results: (GeneOntology, pantherdb.org)
For blood sample analysis, we imported the significant gene list including 701
genes into the panther database. However, some genes had different matched IDs, and the
database included both IDs. Thus, 735 gene IDs were included. To further evaluate the
gene list, we performed different comprehensive functions analysis including biological
process, cellular component, Molecular function, GO biological process, GO cellular
component, GO molecular function, pathways, and protein class. In biological process,
different functions were involved with the significant gene list provided from GEO PAH
datasets including cellular process, metabolic process, localization, developmental process,
cellular component organization or biogenesis, response to stimulus, biological regulation,
multicellular organismal process, immune system process, reproduction, biological
adhesion, locomotion, cell killing (Figure 8). Cellular process and molecular process
reported the most number of genes involved with 333 and 301 genes, respectively.
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Figure 8 Biological process functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Blood samples) from panther database gene
ontology analysis.
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In cellular component, the functional analysis: cell junction, membrane,
macromolecular complex, extracellular matrix, cell part, organelle, and extracellular region
were involved with the significant gene list provided from GEO PAH datasets; however,
cell part and organelle had the highest number of genes involved with 192 and 134 genes,
respectively (Figure 9).
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Figure 9 Cellular component functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Blood samples) from panther database gene
ontology analysis.
In GO molecular function analysis, rRNA binding, structural constituent of
ribosome, RNA binding, nucleic acid binding, DNA binding, enzyme binding, heterocyclic
compound binding, organic cyclic compound binding, protein binding, binding, molecular
function, G-protein coupled receptor activity were involved with the significant gene list
provided from GEO PAH datasets (Figure 10). Moreover, molecular function, binding, and
protein binding were the most functions with number of genes involved 684, 632, and 531
genes, respectively. Interestingly, molecular functions with small number of genes
associated had higher fold enrichment.
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Figure 10 GO Molecular functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Blood samples) from panther database gene
ontology analysis.
Pathways analysis reported 95 pathways to be involved in our significant gene list
provided from GEO PAH datasets (Figure 11). Gonadotropin-releasing hormone receptor
pathway, inflammation mediated by chemokine and cytokine signaling pathway, apoptosis
signaling pathway, Wnt signaling pathway, Huntington disease, and CCKR signaling map
represented the highest number of genes involved among all pathways with 17, 16, 12, 11,
11, and 10 genes, respectively.
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Figure 11 Pathways functional analysis involved with the significant gene list provided
from GEO PAH datasets – (Blood samples) from panther database gene ontology
analysis.
Protein class reported that ribosomal protein, RNA binding protein, transcription
factor, and nucleic acid binding were involved with the significant gene list provided from
GEO PAH datasets (Figure 12). Number of genes reported in each class were 25, 74, 93,
and 151, respectively. Although, ribosomal protein, the class with small number of genes
associated, showed the highest fold enrichment.
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Figure 1. Protein Class functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Blood samples) from panther database gene
ontology analysis.
String (Functional Enrichments)
String database predict protein-protein interactions and provide functional
enrichments for biological process, molecular function, cellular component and KEGG
pathways associated with the significant gene list provided from GEO PAH datasets. For
biological process, 180 GO terms were observed to have set of genes involved. Cellular
process, metabolic process, organic substance metabolic process, primary metabolic
process, and cellular metabolic process had the highest number of genes in their pathways,
with 429, 370, 366, 365, and 357 genes, respectively (supplement 3).
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Figure 2. GO Molecular functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Blood samples) from STING functional enrichment
database.
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GO of molecular function observed 9 pathways to be involved including poly(A)
RNA binding, nucleic acid binding, RNA binding, heterocyclic compound binding, organic
cyclic compound binding, DNA binding, binding, structural constituent of ribosome, and
enzyme binding to be involved with the significant gene list provided from GEO PAH
datasets (Figure 13). Organic cyclic compound binding, heterocyclic compound binding,
and nucleic acid binding reported the largest number of genes involved with 244, 243, and
200 respectively (Supplement 4 for full gene list). Cellular component showed that 43 GO
pathways to be involved with the significant gene list provided from GEO PAH datasets
(supplement 5). KEGG pathways showed that 8 pathways to be associated with the
significant gene list provided from GEO PAH datasets including Ribosome, HTLV-I
infection, RNA degradation, Purine metabolism, RNA polymerase, MAPK signaling
pathway, Pathways in cancer, and HIF-1 signaling pathway. Of these pathways, HTLV-I
infection and Pathways in cancer reported 25 and 24 genes to be involved, respectively
(Figure 14).
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Figure 3. Pathways description analysis involved with the significant gene list provided
from GEO PAH datasets – (Blood samples) from STING functional enrichment database.
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An interaction network map was generated based on protein-protein interaction
data provided by the STRING database. It concludes functional interactions between each
of the 701 core genes and generated the network map which represent the interactions of
these genes and their protein products (Figure 15). Another network map was generated
using the significant gene list provided from GEO PAH datasets, however, it represent the
highest confidence level of interaction between these genes and their protein products
(Figure 16).

Figure 4. An interaction network map was generated based on protein-protein
interaction data using the significant gene list provided from GEO PAH datasets –
(Blood samples) from STING functional enrichment database.
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Figure 5. An interaction network map was generated based on the highest confidence
level of protein-protein interaction involved with the significant gene list provided from
GEO PAH datasets – (Blood samples) from STRING functional enrichment database.
Tissue Samples Results:
For tissue sample analysis, we imported the significant gene list provided from
GEO PAH datasets including 573 genes into the database. However, some genes had
different matched IDs, and the database included both IDs. Thus, 602 gene IDs were
included. To further evaluate the gene list, we performed different comprehensive
functions analysis including biological process, cellular component, molecular function,
GO biological process, GO cellular component, GO molecular function, pathways, and
protein class. In biological process, different functions were involved with the significant
gene list provided from GEO PAH datasets including cellular component organization or
biogenesis, cellular process, localization, reproduction, biological regulation, response to
stimulus, developmental process, multicellular organismal process, biological adhesion,
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locomotion, metabolic process, and immune system process (Figure 17). Cellular process
and metabolic process reported the most number of genes involved with 303 and 258 genes,
respectively.
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Figure 6. Biological process functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Tissue samples) from panther database gene
ontology analysis.
In cellular component, synapse, cell junction, membrane, macromolecular
complex, extracellular matrix, cell part, organelle, and extracellular region were involved
with the significant gene list provided from GEO PAH datasets; however, cell part and
organelle had the highest number of genes involved with 163 and 90 genes, respectively
(Figure 18). In GO biological process, small molecule metabolic process, cellular
metabolic process, single-organism cellular process, organic substance metabolic process,
metabolic process, primary metabolic process, cellular process, single-organism process,
biological process, detection of stimulus involved in sensory perception, and sensory
perception of chemical stimulus were involved with the significant gene list provided from
GEO PAH datasets. Moreover, cellular process and single-organism process were the most
functions with number of genes involved 510 and 433 genes, respectively. Small molecule
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metabolic process, cellular metabolic process reported the highest fold enrichment among
other biological process with 1.69 and 1.28 fold enrichment, respectively (Figure 18).
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Figure 7. Cellular component functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Tissue samples) from panther database gene
ontology analysis.
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Figure 8. GO Biological Process functional analysis involved with the significant gene
list provided from GEO PAH datasets – (Tissue samples) from panther database gene
ontology analysis.
In GO of cellular component functional analysis, cytosol, intracellular organelle
part, organelle part, cytoplasmic part, cytoplasm, intracellular membrane-bounded
organelle, intracellular, intracellular organelle, intracellular part, membrane-bounded
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organelle, organelle, cell part, cell, and cellular component were involved with the
significant gene list provided from GEO PAH datasets (Figure 20). Moreover, cell and cell
part, intracellular, and intracellular part represented the highest number of gene involved
with 543, 500, and 486 genes, respectively. Cytosol and intracellular organelle part were
the highest in fold enrichment with 1.32 and 1.3, respectively.
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Figure 20. GO of Cellular component functional analysis involved with the significant
gene list provided from GEO PAH datasets – (Tissue samples) from panther database
gene ontology analysis.
In GO molecular functional analysis, cation binding, metal ion binding, protein
binding, catalytic activity, binding, and molecular function were involved with the
significant gene list provided from GEO PAH datasets (Figure 21). Moreover, protein
binding and catalytic activity represented the highest number of genes involved with 417
and 220 genes, respectively. Cation binding and metal ion binding were the highest in fold
enrichment with 1.37 and 1.36, respectively. In molecular function, translation regulator
activity, binding, receptor activity, structural molecule activity, signal transducer activity,
catalytic activity, antioxidant activity, and transporter activity were involved with the
significant gene list provided from GEO PAH datasets (Figure 22). Molecular function of
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binding and catalytic activity reported 194 and 190 genes to be involved, respectively.
Pathway analysis reported 90 pathways to be involved in the significant gene list provided
from GEO PAH datasets (Figure 23). Gonadotropin-releasing hormone receptor pathway,
Angiogenesis, Wnt signaling pathway, inflammation mediated by chemokine and cytokine
signaling pathway, and EGF receptor signaling pathway represented the highest number of
genes involved among all pathways with 13, 11, 10, 10, and 7 genes, respectively.
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Figure 21. GO of Molecular functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Tissue samples) from panther database gene
ontology analysis.
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Figure 22. Molecular functional analysis involved with the significant gene list provided
from GEO PAH datasets – (Tissue samples) from panther database gene ontology
analysis.
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Figure 23 Pathway functional analysis involved with the significant gene list provided
from GEO PAH datasets – (Tissue samples) from panther database gene ontology
analysis.
Protein class analysis reported 20 protein class to be involved with the significant
gene list provided from GEO PAH datasets (Figure 24). Nucleic acid binding, enzyme
modulator, hydrolase, transferase, and transcription factor represented the highest number
of genes involved with 91, 54, 51, 46, and 45 genes respectively.
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Figure 9. Protein Class functional analysis involved with the significant gene list
provided from GEO PAH datasets – (Tissue samples) from panther database gene
ontology analysis.
Analyzing tissue samples using STRING database for biological process reported
23 pathways to be involved in the significant gene list provided from GEO PAH datasets
(Figure 25). GO Cellular process, single-organism cellular process, single-organism
process, and metabolic process showed the highest number of gene with 367, 313, 310, and
295 genes, respectively. GO of Enrichment component showed 16 components to be
involved with the significant gene list provided from GEO PAH datasets (Figure 26). Cell
part, intracellular part, and organelle represented the highest number of genes involved
with 429, 395, and 367 genes, respectively. GO of molecular function observed 8 pathways
to be involved including binding, ion binding, catalytic activity, protein binding, cation
binding, metal ion binding, transition metal ion binding, and phosphoric ester hydrolase
activity. Binding, ion binding, and catalytic activity reported the largest number of genes
involved with 320, 205, and 180, respectively (Figure 27) (Supplement attached for full
gene list).
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Figure 25. Biological process reported 23 pathways involved with the significant gene
list provided from GEO PAH datasets – (Blood samples) from STING functional
enrichment database.
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Figure 26. GO of Enrichment component reported 16 components to be involved with the
significant gene list provided from GEO PAH datasets – (Blood samples) from STING
functional enrichment database.
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Figure 27. GO of molecular function observed 8 pathways to be with the significant gene
list provided from GEO PAH datasets – (Blood samples) from STING functional
enrichment database.
An interaction network map was generated based on protein-protein interaction
data provided by the STRING database. It concludes functional interactions between each
of the 573 core genes and generated the network map which represent the interactions of
with the significant gene list provided from GEO PAH datasets and their protein products
(Figure 28). Another network map was generated; however, it represents the highest
confidence level of interaction between these genes and their protein products (Figure 29).
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Figure 28. An interaction network map was generated based on protein-protein
interaction data provided of the significant gene list provided from GEO PAH datasets –
(Blood samples) from STING functional enrichment database.

Figure 29. An interaction network map for Tissue samples was generated based on the
highest confidence level of protein-protein interaction.

168

We searched through panther web-tool gene ontology for pathways associated with
blood samples and tissue samples, and compared these pathways from STRING database.
Common pathways were selected for further analysis. Also, we searched the literature for
PAH associated pathways and genes associated with PAH. We searched through all
pathways, and pathways with 3< genes involved were included, and common genes were
included in a separate gene list.
29 genes found to be common in blood samples, and 18 genes in tissue samples
(Table 28 and Table 29). This gene list was imported into Bene software to find out and
validate the association between these genes with PAH in blood and tissue samples in a
structure of BN which represent the best score in association between variables. The best
structure of BN of tissue samples including genes associated with PAH in Figure 30.
Table 25 Genes associated with PAH; and PAH pathways from Gene Ontology,
STRING, and literature (Blood Samples) (29 genes)
Gene Symbol
Gene Name
ATF4
activating transcription factor 4(ATF4)
AXIN2
axin 2(AXIN2)
BAX
BCL2 associated X, apoptosis regulator(BAX)
CD3E
CD3e molecule(CD3E)
CREM
cAMP responsive element modulator(CREM)
ATF2
activating transcription factor 2(ATF2)
CREBBP
CREB binding protein(CREBBP)
FKBP11
FK506 binding protein 11(FKBP11)
SNIP1
Smad nuclear interacting protein 1(SNIP1)
BAG3
BCL2 associated athanogene 3(BAG3)
BAG4
BCL2 associated athanogene 4(BAG4)
FOS
Fos proto-oncogene, AP-1 transcription factor subunit(FOS)
JUND
JunD proto-oncogene, AP-1 transcription factor subunit(JUND)
SMAD7
SMAD family member 7(SMAD7)
LTB
lymphotoxin beta(LTB)
EIF2A
eukaryotic translation initiation factor 2A(EIF2A)
GADD45B
growth arrest and DNA damage inducible beta(GADD45B)
MAPK6
mitogen-activated protein kinase 6(MAPK6)
PRKCH
protein kinase C eta(PRKCH)
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PPP3CC
DCP1A
EXOC2
RELA
RELB
RALGDS
SUMO3
TGFB3
RRAS2
PIK3R5

protein phosphatase 3 catalytic subunit gamma(PPP3CC)
decapping mRNA 1A(DCP1A)
exocyst complex component 2(EXOC2)
RELA proto-oncogene, NF-kB subunit(RELA)
RELB proto-oncogene, NF-kB subunit(RELB)
ral guanine nucleotide dissociation stimulator(RALGDS)
small ubiquitin-like modifier 3(SUMO3)
transforming growth factor beta 3(TGFB3)
related RAS viral (r-ras) oncogene homolog 2(RRAS2)
phosphoinositide-3-kinase regulatory subunit 5(PIK3R5)

Table 26 Genes associated with PAH and PAH pathways from Gene Ontology, STRING,
and literature (Tissue Samples) (18 genes)
Gene
Gene Name
Symbol
TNFSF10

tumor necrosis factor superfamily member 10(TNFSF10)

AES

amino-terminal enhancer of split(AES)

AKT1

AKT serine/threonine kinase 1(AKT1)

ARHGAP Rho GTPase activating protein 1(ARHGAP1)
1
AP2M1

adaptor related protein complex 2 mu 1 subunit(AP2M1)

DVL3

dishevelled segment polarity protein 3(DVL3)

HDAC1

histone deacetylase 1(HDAC1)

IGF2R

insulin like growth factor 2 receptor(IGF2R)

PCDH10

protocadherin 10(PCDH10)

LRP6

LDL receptor related protein 6(LRP6)

PRKCH

protein kinase C eta(PRKCH)

PPP2R5A

protein phosphatase 2 regulatory subunit B'alpha(PPP2R5A)

CDH24

cadherin 24(CDH24)

RALA

RAS like proto-oncogene A(RALA)

RGL2

ral guanine nucleotide dissociation stimulator like 2(RGL2)
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RAC1

ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding
protein Rac1)(RAC1)

NKD1

naked cuticle homolog 1(NKD1)

RGL1

ral guanine nucleotide dissociation stimulator like 1(RGL1)

Figure 30. The best structure of BN of tissue samples including genes associated with
PAH using Bene software (20 variables)

We searched the Comparative Toxicogenomics Database (http://ctdbase.org/) for
association between the identified PAH and ID3 target genes and PCBs associated genes.
We used the gene list of PAH and ID3 target genes (701 genes) in blood samples and PCBs
associated genes curated from CTD (648). The common genes in blood sample analysis
were 34 genes (Table 27). We used the gene list of PAH and ID3 target genes (573 genes)
in tissue samples and PCBs associated genes curated from CTD (648). The common genes
in tissue sample analysis were 19 genes (Table 27).
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Table 27 Common (34) genes between PAH and ID3 target genes (701 genes) in blood
samples and PCBs associated genes (648). Common (19) genes between PAH and ID3
target genes (573 genes) in tissue samples and PCBs associated genes (648) using CTD
database.
Common (34) genes between PAH and ID3
target genes (701 genes) in blood samples and
PCBs associated genes (648)
ALDH5A1, BTG1, CDKN1B, CIRBP, CLK1,
COL12A1, CTSK, DNAJB9, DUSP1, EBP,
EMP2, ENC1, FOS, HSP90AB1, ID3, IL6,
ILF2, LNX2, MASTL, MCM6, MMP3,
NECAP1, PEBP1, PFKFB3, PLEKHB1,
PRC1,
PRNP,
PTGER4,
RAD23B,
RNASEH1, SAFB, TNFRSF25, TSEN54,
YPEL5

Common (19) genes between PAH and ID3
target genes (573 genes) in tissue samples and
PCBs associated genes (648)
AKT1, ARHGEF10, CASP2, CDT1, CLK2,
CSF3R, HIST1H4L, ID3, IL2, MAN2C1,
NR3C1, POLE, RACGAP1, NF146, SMG6,
STMN1, TACC3, TIMP3, UROD

Figure 31 Common (34) genes between PAH and ID3 target genes (701 genes) in blood
samples and PCBs associated genes (648).

Figure 32 Common (19) genes between PAH and ID3 target genes (573 genes) in tissue
samples and PCBs associated genes (648).
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We used the gene list of PAH-associated genes; and genes associated with PAH
pathways in literature and we found 5 genes to be common among different pathways
including VEGFB, PRKCH, VAMP2, POLR2C, and LAMA5. Then, we used the
expression data we have for VEGFB, PRKCH, VAMP2, POLR2C, LAMA5, location, and
PAH; and we run it into Genie software to see how these genes are expressed in the data
and what would be the relationship between them. We run the analysis many times and
each we changed the status of one of the variables. For genes (low, normal, and high
expression), location (blood and tissue), and PAH (control and Disease) (Figure 33-37).
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A

B

C

Figure 33 Genie software analysis: A) Original expression of genes, PAH, and location variables using our meta-analyzed
microarray datasets. B) We overexpressed PAH variable to see the effect on its parent variable. C) We knockdown PAH
variable to be all control sample expression.
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C

B
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Figure 34 Genie software analysis: A) Normal expression of VAMP2 gene and its effect on other variable using our metaanalyzed microarray datasets. B) We overexpressed VAMP2 variable to see the effect on other variables. C) We knockdown
VAMP2 variable to see the effect on other variables.

A

B

C

Figure 35 Genie software analysis: A) Normal expression of POLR2C gene and its effect on other variable using our metaanalyzed microarray datasets. B) We overexpressed POLR2C variable to see the effect on other variables. C) We knockdown
POLR2C variable to see the effect on other variables
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B

C

Figure 36 Genie software analysis: A) Normal expression of VEGFB gene and its effect on other variable using our metaanalyzed microarray datasets. B) We overexpressed VEGFB variable to see the effect on other variables. C) We knockdown
VEGFB variable to see the effect on other variables.
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B

C

Figure 37 Genie software analysis: A) Normal expression of PRKCH gene and its effect on other variable using our metaanalyzed microarray datasets. B) We overexpressed PRKCH variable to see the effect on other variables. C) We knockdown
PRKCH variable to see the effect on other variables
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DISCUSSION
Our meta-analysis of PAH microarray datasets published in GEO would be the first
meta-analysis on PAH microarray expression data. We identified the key gene network
that significantly associated with PAH and different biological material including blood
and tissues. We used those genes involved in pathways associated with PAH using different
sources including literature, PANTHER gene Ontology, and STRING web tools. All
pathways that had more than 3 genes involved were used, and genes were combined
together.
Many pathways and genes are known to be associated with PAH. ACVRL1, ALK1,
BMPR1B, BMPR2, CAV1, CBLN2, EIF2AK4, ENG, KCNA5, KCNK3, SMAD9, TBX,
TBX, CYP1B1, ACE, 5-HTT, PGIS, MMP2, MMP9, Bax, TGFBR2, VIP, ET1, and
angiopoietin 1. While using STRING database, many pathways showed an association with
PAH through gene association, and the most significant pathways were Apoptosis
signaling pathway, p53 pathway, Ras Pathway, T cell activation, TGF-beta signaling
pathway, VEGF signaling pathway, Wnt signaling pathway.
In blood sample analysis using STRING database, apoptosis signaling pathway
reported that ATF2, EIF2A, FOS, PRKCH, RELA, RELB, LTB, BAX, ATF4, BAG4,
BAG3, and CREM to be associated with PAH. p53 pathway reported that PIK3R5,
CREBBP, GADD45B, BAX, and SUMO3 to be associated with PAH. Moreover, Ras
Pathway reported that ATF2, RRAS2, RALGDS, and EXOC2 to be associated with PAH.
T cell activation reported that CD3, FOS, PPP3CC, and CD3E to be associated with PAH.
TGF-beta signaling pathway reported ATF2, RRAS2, CREBBP, TGFB3, SMAD7,
DCP1A, JUND, SNIP1, and FKBP11 to be associated with PAH. VEGF signaling pathway
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reported PRKCH, MAPK6, and RRAS2 to be associated with PAH. Wnt signaling pathway
reported that ATF2, RRAS2, CREBBP, TGFB3, SMAD7, DCP1A, JUND, SNIP1,
FKBP11, AXIN2, and PRKCH to be associated with PAH.
In tissue sample analysis using STRING database, Wnt signaling pathway reported
that AES AP2M1, CDH24, DVL3, HDAC1, LRP6, NKD1, PCDH10, PPP2R5A, and
PRKCH to be associated with PAH. Ras Pathway reported that RAC1, RGL2, AKT1,
RALA, and RGL1 to be associated with PAH. Apoptosis signaling pathway reported that
PRKCH, IGF2R, TNFSF10, and AKT1 to be associated with PAH. VEGF signaling
pathway reported that RAC1, PRKCH, AKT1, and ARHGAP1 to be associated with PAH.
p53 pathway and T cell activation reported that HDAC1 and AKT1; RAC1 and AKT1 to
be associated with PAH, respectively.
PRKCH is a gene that encodes the η isozyme of protein kinase C (PKCη) and it is
known to play a significant role in signal transduction that control T-cell activation
(Teixeira et al., 2008). PRKCH showed significant association with rheumatoid arthritis as
it was expressed in lower levels than normal control. Our results showed that Low
expression of PRKCH resulted in higher probability of PAH, and high expression of
PRKCH decreases the probability of PAH (Figure 34 B and C).
VEGF reported to be increased in lung tissue with PAH and VEGFB is another
isoform of it (Malenfant et al., 2013). VEGFB controls many non-angiogenic functions
such as facilitating fatty acid transport in EC and preventing angiotension 2 (which increase
cardiac diastolic dysfunction) (Voelkel & Gomez-Arroyo, 2014). Low expression of
VEGFB was found in the right ventricle of SuHx rats (Al-Husseini et al., 2015). Our results
showed that knock-down VEGFB is significantly associated with decrease the expression
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of VAMP2, POLR2C, and PRKCH. Whereas, over expression of VEGFB, cases increase
in expression of same genes. However, it causes decrease in probability of PAH status
comparing with normal and low expression of VEGFB. In summary, our meta-analysis
showed that different expression in VAMP2, LAMA5, POLR2C, VEGFB, and PRKCH
are the most significantly associated genes with PAH and PAH regulated pathways.
Although, these genes suggested to be highly influencing the pathogenesis of PAH.
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CHAPTER 6
OVERALL CONCLUSIONS
The main goal of this dissertation was to study the molecular determinant of PAH
and to evaluate the exposure to EDC (PCB) and their association with the risk of PAH in
a representative NHANES 1999-2004 data of the U.S population. Molecular level
interactions that are associated with PAH were studied by meta-analyzing 6 microarray
gene expression datasets of PAH from GEO. The resulted gene list was used to determine
gene ontology and PAH-associated pathways using Panther and string database. Combined
results from our meta-analysis, Panther and String databases were used to determine the
plausible markov blanket genes network using Bayesian network analysis.
Meta-analysis of gene expression microarray datasets from GEO resulted in 10,716
genes to be common in all PAH studied in blood and tissue samples. ID3 correlated genes
were matched with 701 and 573 genes from blood and tissue samples, respectively. GO
pathway analysis showed that Gonadotropin-releasing hormone receptor pathway,
inflammation mediated by chemokine and cytokine signaling pathway, and apoptosis
signaling pathway had the highest number of gene involved from blood samples. However,
Gonadotropin-releasing hormone receptor pathway, Angiogenesis, and Wnt signaling
pathway had the highest number of genes involved from tissue samples. Common genes in
pathways associated with PAH from gene ontology databases resulted in 29 genes and 18
genes common for blood and tissue samples, respectively. These genes were matched with
literature PAH pathway associated genes and resulted in 5 genes to be common among
different pathways including VEGFB, PRKCH, VAMP2, POLR2C, and LAMA5.

185

Supported with information that females have higher risk of PAH, we evaluated
PCBs serum concentrations and their association with risk of PAH using NHANES 19992004 survey data. All 6 PCBs (74, 99, 118, 138, 153, and 180) concentration were higher
in people at risk of PAH than people not at risk of PAH in the U.S. population > 20 years
old. Also, higher risk of PAH was reported in the sum of dioxin-like PCBs (PCB 74 and
118), and non-dioxin-like PCBs (PCB 118, 138, 153, and 180) concentration in the U.S.
population > 20 years old. All confounders (gender, age, BMI, annual family income,
educational level, smoking, and alcohol use) were associated with the higher risk of PAH
except older age groups. Different LOD of PCBs (> LOD, > 50%, 50-75%, and >75%)
were significantly higher in people at risk of PAH except PCB 180.
Overall, we are representing genes (VEGFB, PRKCH, VAMP2, POLR2C, and
LAMA5) that were associated with PAH risk factors using bioinformatics and geneontology. Also, we provide plausible gene network pathway that could lead to PAH.
Additionally, we evaluated different PCBs serum concentrations and their association with
the risk of PAH in the U.S population.
LIMITATIONS
Risk of PAH variable that was created using PAH associated risk factors remains a
limitation in our study. Also, small number of people at risk of PAH in NHANES 19992004 data, resulted in decreasing the significance risk of PAH and exposure to PCBs
results.
Future Studies
Even though our results showed association between PCBs and risk of PAH,
epidemiologic studies need to be conducted to report the association between exposure to
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EDCs and development of PAH. Multiple pathways associated with PAH, its related
estrogen toxicity, and at the same time continuous exposure to EDCs, support the needs to
conduct epidemiological studies. Lastly, RNA sequence studies need to update findings of
such deep level analysis and its association of development of PAH; and further validate
by what mechanism estrogen would increase risk of females.
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